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Chapter 1 
Introduction 
 
A woman in the United States in her lifetime has a 1 in 3 chance of being 
diagnosed with cancer1.  Of those diagnosed, the greatest percentage will have 
breast cancer1.  Focused research and public health efforts over the last 40 
years since the signing into law of the National Cancer Act have contributed to 
dramatic increases in 5-year survival rates for all cancers from 50% in 1975 to 
nearly 70% in 2010, and for breast cancer from 75% to over 90%1.  However, the 
greatest strides have come from the successful treatment of the early stages of 
cancer.  This is evidenced by the 99% 5-year survival rate for breast cancers 
defined as localized disease compared to the tragic 25% 5-year survival rate for 
those that have disease spread to other organs1. 
 
This spread of cancer from its initiating site to propagate in other organs is called 
metastasis, and it is this stage of the disease that is most feared by clinicians and 
patients alike as it is responsible for over 90% of cancer deaths2,3.  Yet despite 
the clinical challenges metastasis poses, it is still a biological program and may 
be parsed into its constitutive subroutines, each to be interrogated and inspected 
for an obscured fault in the process that might be exploited by a new therapy, 
potentially adding to the oncologist’s options for metastatic disease treatment.  In 
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this work, I investigate the metastatic process at various levels looking for such 
exploitable subtleties by asking the following questions and answering them in 
the subsequent chapters.  They are: 
 
Chapter 2: What are genetic molecular drivers that allow certain cancer 
cells to metastasize? 
  
Chapter 3: What are environmental cues to tumor cells that trigger 
metastasis? 
  
Chapter 4: Can we harness physical property differences to isolate cancer 
cells in patients once they do metastasize? 
  
Chapter 5: Is there an overall mechanical phenotype of the most 
aggressive tumor cells that are successful in metastasis? 
 
The biological program of metastasis that tumor cells undergo is termed the 
metastatic cascade4,5.  In this metaphor, cascade conjures up images of rushing 
waterfalls pouring en masse from one level to the next, but cancer cells are not 
as homogenous as the water molecules in a river.  Tumors are comprised of a 
heterogeneous population and not every cell in a primary tumor has the intrinsic 
capability to metastasize.  This was definitively shown by Isaiah Fidler in 19776.  
In that work, he divided a murine melanoma cell line into two halves, injecting 
portions of one half into a series of mice and using the other half to generate 
clonal populations from individual cells6.  If every cell in the original population 
was capable of forming metastases, then all mice injected with the clonal 
populations should have similar numbers of metastases as those mice injected 
with the parental cell line mixture.  What he observed instead was that the clonal 
populations had a broad range of metastases some with fewer than the parental 
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line and some with many times more6.  This was not an artifact brought about by 
the cloning procedure as re-cloning two of the original moderately metastatic 
subclones maintained a similar burden of metastasis6.  This conclusively 
demonstrated that not all cells within a cell line are equal in their capability to 
metastasize.  The group later showed similar results with a human melanoma 
cell line7.  Another group then expanded these observations and was able to 
track the expansion of a clonal population in vivo rather than artificially pre-select 
populations in vitro8.  They transfected plasmid DNA and used the random 
insertion location as a unique identifier for clones.  After injecting mice with this 
heterogeneous population of transfected cells, they isolated and analyzed the 
metastatic lesions determining that each lesion was formed by one clone from 
the original population8.  That is, each metastasis had cells with only one 
insertion site.  Primary tumor heterogeneity and the metastatic capability of only 
select cells from the original tumor has held true to the present day with 
researchers now using modern deep-sequencing techniques on primary and 
metastatic tumor samples from patients directly rather than from mouse 
models9,10.  What these studies show is that in order to stop the lethal process of 
metastasis, preventing a tumor from growing in size is not enough.  We must 
understand the characteristics of the metastatic cells specifically and what factors 
allow them to metastasize and the others cells not. 
 
The challenge in studying the metastatic population of cells, however, lies in their 
rarity.  Only few cells at every step in the metastatic process are able to meet the 
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varied and differing criteria required of them to successfully metastasize11-19.  In 
seminal work as a PhD student, Fidler demonstrated only 1.5% of cells injected 
into the tail veins of mice survived 24 hours and 0.5% survived 72 hours16.  
Lower percentages were seen by other groups analyzing later time points in 
experimental mouse models of metastasis with only 0.1% of tail vein injected 
cells dividing after 11 days in one study17 and just 0.02% of injected cells growing 
into metastatic tumors in another15.  An important consideration to these works is 
the artificial nature of the experimental setup.  Cancer cells were injected directly 
into the circulation of mice and not shed from primary tumors.  However, 
sobering studies in humans quantified just how unlikely it is for metastasis to 
occur in a clinical setting as well11,12.  Weiss’s group collected blood from the 
renal vein in patients undergoing nephrectomy for renal carcinoma12.  Ostensibly, 
the renal vein would contain all cancer cells shed into the circulation by the 
primary renal tumor.  One patient had a 10 cm primary tumor that shed 7,309 
tumor emboli per 1 mL of collected blood yet had no detectable metastases after 
surgery over 2 years later12.  Given a renal blood flow of about 500 mL per 
minute12, this patient’s tumor was releasing countless cancer cells every day into 
her circulation prior to resection and none were able to successfully grow.  Tarin 
et. al. in a more dramatic example with a prospective study followed patients with 
peritoneovenous shunts to relive their chronic ascites generated from incurable 
abdominal tumors11.  Multiple patients released tens of millions of viable cancer 
cells as measured by a clonogenicity assay from their ascites directly into their 
jugular vein every 24 hours, yet about half of the 15 patients autopsied after 
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death had no metastases to other organs – including one patient who survived 
27 months after the shunt was placed11.  Certainly other patients did develop 
lethal metastases in each study, but they were only from very rare cells of the 
heterogeneous population – estimated to be <0.01% of those that even leave the 
primary tumor11,12,15,16,20,21 – that ultimately flourished at distant sites and killed 
the patients. 
 
Beginning with first principles, naturally, in order to form metastases one must 
first have a primary tumor.  The biological processes that govern tumor initiation 
and growth and the heritable and environmental factors that may predispose to 
cancer formation are worthy of intense study themselves22-24, but they are 
beyond the scope of this work.  However, the Appendix details the study of a rare 
auto-immune breast disease that shares a striking geographic overlap with a 
particularly aggressive form of breast cancer.  Much more investigation is 
warranted in order to definitively establish or refute this relationship, but I 
hypothesize this rare disease might prepare the necessary breast environment 
for a specific type of aggressive breast cancer to take hold. 
 
Once a primary tumor has formed though, the series of steps a cancer cell must 
traverse in order to form a metastasis are: acquiring motion, invading into local 
tissue, entering the lymphatics or blood vessels, surviving in circulation, leaving 
the vasculature, and finally proliferating in the new location2,13,19-21,24-30.  Because 
of the rarity of the cells that can successfully navigate this process and the 
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inefficiency at each step, metastasis should not be thought of as a cascading, 
progressive waterfall of cancer cells, but rather a series of sieves each 
presenting an obstacle only tumors cells with certain traits can bypass and move 
on to the next step. 
 
Acquiring the capability to migrate and invade the normal surrounding 
parenchyma represents the first metastatic sieve separating cancer cells from 
normal cells31.  This change is the transition of a lesion from a benign adenoma 
to a carcinoma.  E-cadherin, the main adhesion molecule of epithelia, is 
frequently lost during this transition in many cancers and was first shown as a 
necessary step in a transgenic mouse model of pancreatic ß-cell 
carcinogenesis32.  In this model, E-cadherin was expressed in the non-invasive 
adenoma stage in all samples, but in over 200 spontaneous ß-cell carcinomas it 
was lost32.  This mouse model of spontaneous cancer was then crossed with 
another model that had E-cadherin expression driven by the insulin promoter to 
maintain E-cadherin expression.  The tumor incidence in the double transgenics 
dropped from 26% to 8% and, notably, all carcinomas that did arise in the double 
transgenics had lost the expression of E-cadherin – even the transgene 
expression – demonstrating the strong negative selective pressure against this 
common epithelial adhesion marker as a necessary step in the formation of ß-
tumors32.  After cancer cells lose normal adhesion proteins, they must gain the 
ability to migrate.  Erik Sahai’s group demonstrated the role of transforming 
growth factor ß (TGF-ß) in inducing this motility switch in breast cancer33.  Using 
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intravital imaging and a fluorescent reporter of TGF-ß activity, they saw 
heterogeneity in TGF-ß signaling throughout the tumor with its activity coinciding 
with just the 5% of cells that were motile33.  This work further demonstrated the 
inefficiency of the metastatic process as 95% of the primary tumor cells were 
non-motile33.  Also important in bypassing this first metastatic sieve and 
progressing to an invasive carcinoma is the role of the normal stromal cells and 
basement membrane surrounding a lesion34.  In a breast cancer model of ductal 
carcinoma in situ (DCIS), the loss of myoepithelial cells and a degradation of the 
basement membrane was required for the transition from DCIS to invasive 
carcinoma35.  Furthermore, co-injection of myoepithelial cells could suppress the 
conversion35.  Taken together, these studies accurately portray the first challenge 
of the metastatic series of sieves in that would-be metastatic cells must lose 
cellular adhesion proteins and gain motility and normal stromal cells act in 
regulating this step. 
 
The next sieve, intravasation, involves cancer cells moving between endothelial 
cell junctions, or transcellularly through the endothelial cells themselves36, and 
entering the lumina of lymphatic or blood capillaries20,21  Condeelis and Segall’s 
group was able to directly visualize this process in vivo37,38.  Using fluorescently 
labeled metastatic and non-metastatic cell rat mammary adenocarcinoma cell 
lines and time lapse in vivo imaging, they followed cancer cells as they moved 
through the tumor and intravasated into capillaries.  Upon reaching the capillary, 
the non-metastatic cell line fragmented apart as it could not withstand the 
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geometric rigors of squeezing through the endothelium37.  In a separate study, 
the same group showed a necessary role for perivascular macrophages, a 
component of the normal stroma, aiding in the intravasation step38.  Furthermore, 
the vessels cancer cells use to intravasate are not pre-existing but are newly 
formed with the growth of the lesion.  The growing tumor induces 
lymphangiogenesis by secreting vascular endothelial growth factor (VEGF), 
specifically VEGF-C and VEGF-D21,39-43.  Seminal studies demonstrated a role 
for VEGF in breast and other cancers by overexpressing it in various cell lines41-
43.  The tumors grown from cell lines overexpressing VEGF had increased growth 
of new lymphatic vessels coupled with increased cancer metastasis through 
these newly formed vessels41-43.  Later work showed this newly formed tumor 
vasculature was weakened and “leaky” as compared to mature vessels in normal 
tissues due to secreted signals from the tumor, a characteristic which further 
facilitated intravasation44,45. 
 
Once in the circulation, cancer cells are called circulating tumor cells (CTCs) and 
must survive the inhospitable circulatory system plagued with hemodynamic 
shear forces and immune-mediated killing20,21,26,46.  CTCs must ultimately 
physically lodge or, via cell surface receptors, attach to the endothelium in a 
distant organ.  In one of the earliest CTC studies, Zeidman watched as CTCs 
lodged in or passed through the mesenteric capillaries of anesthetized rabbits47.  
He injected suspensions of cancer cells into the mesenteric artery and filmed the 
arterio-capillary junction as the cancer cells either deformed in shape and 
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squeezed through the constriction or maintained their rigid shape and arrested at 
the junction47.  Arresting was not merely a function of cancer cell size as some 
large cells never arrested being pliable enough to circulate and other smaller 
more rigid cells arrested immediately47.  Further research demonstrated a role for 
platelets and fibrin forming emboli with the tumor cells leading to their arrest in 
vessels48,49 and more recently activated integrin on a cancer cell’s surface was 
shown to promote metastasis by interacting with platelets and causing the arrest 
of cancer cells in the vasculature50.  Of note, only a subpopulation of the breast 
cancer cell line used in the study expressed activated integrin50.  Once arrested 
in a blood vessel, the cancer cell either migrates across the endothelial cell 
barrier or, as some studies have shown21,51,52, simply multiplies and grows large 
enough to rupture the vessel.  In conjunction with the intravasation studies, this 
body of work suggests a metastatic cell must have a precise biomechanical 
phenotype in order to be deformable enough to squeeze into a blood vessel but 
not so pliable that it never arrests in circulation.  It must also display the proper 
integrin signal to interact with platelets to form a tumor embolus. 
 
In the final stage of metastasis, a cancer cell must overcome the last metastatic 
sieve and proliferate in its new location.  While some metastases grow 
intravascularly and rupture the vessel, many extravasate and remain dormant53-
56.  Judah Folkman pioneered the concept of primary tumors requiring new 
vasculature to grow beyond a diffusion limited size57,58 and his group also later 
demonstrated a need for angiogenesis at metastatic sites for proliferation53,54.  In 
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their later work, the Folkman group showed that systemic suppression of 
angiogenesis maintained stable-sized micrometastases54.  His group determined 
these stable metastases proliferated just as rapidly as growing metastases, but 
without sufficient nutrients to support a larger population, their growth was 
balanced by a higher degree of apoptosis54.  Another group – using a chronic 
cranial window in mice and fluorescently labeled cancer cells – imaged in real-
time as cells arrested, extravasated, and moved to a perivascular position and 
remained dormant in the mouse brain56.  This nutrient-rich perivascular position 
was essential for survival as cells that migrated too far away perished56.  Ann 
Chambers’s group similarly investigated metastatic dormancy using a 
nanoparticle dye to track individual cells of highly metastatic and lowly metastatic 
mammary carcinoma cell lines55.  They found that only 0.006% of cells in the 
highly metastatic population formed metastases corroborating the rarity of 
successful metastatic cells; and, interestingly, in the lowly metastatic cell line 
they found that a significant portion of these cells were able to successfully 
extravasate but remained quiescent afterwards neither dividing or dying55.  These 
lowly metastatic cells had all the capabilities required to get to the final site of a 
metastasis, but yet failed at the last step and were unable to ultimately grow.  
Taken together, these studies demonstrate the true inefficiency of the metastatic 
series of sieves.  Even if a cancer cell is successful in gaining motility and 
intravasating, survives the circulation and arrests, is able to extravasate and 
remains close enough to a vessel to receive nutrients, a cancer cell must still 
 11 
 
finally receive the proper signals and be in the right microenvironment to flourish, 
otherwise it will lay dormant. 
 
Imbued with the knowledge of the metastatic journey of a cancer cell through 
often fibrotic tissues, squeezing into blood vessels in the small spaces between 
other cells, being pumped around the body in the circulation, and crawling back 
out again in a distant organ, it is easy to come to see how very physical and 
mechanical in nature the process is59-61.  As was exampled above, a non-
metastatic cell line while able to bypass the first metastatic sieve becoming an 
invasive carcinoma could not withstand the geometric constraints of intravasation 
or the circulatory shear forces and was immediately fragmented after entering the 
capillary lumen37.  Another study demonstrated that a cancer cell could be too 
flexible and not arrest in a blood vessel to form a metastasis47.  However 
traversing the metastatic series of sieves is not just a one-way interaction of the 
cancer cells moving through their environment.  In fact, there is increasing 
evidence that physical environmental itself signals to cancer cells and can dictate 
cellular behavior and alter tumor characteristics59-63.  Valerie Weaver’s group first 
demonstrated a role for substrate stiffness in altering a breast cancer cell’s 
intracellular signaling64.  In in vitro work in 2D and 2D cultures, they modified the 
stiffness of mixed collagen and basement membrane gels and investigated the 
activity of known mechanotransducers.  They found that by increasing the 
stiffness of the substrate, much as a tumor is stiffer than its surrounding tissue, 
integrin adhesions linked this mechanical input to intracellular signaling pathways 
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that enhance growth and promote malignant transformation64.  Other groups 
demonstrated more global changes such as increased histone acetylation in 
cancer cells grown in suspension versus adherent cultures65 and altered 
chromosomal nuclear localization with a corresponding change in gene 
expression in response to differently shaped nanopillars generating different 
forces on the cytoskeleton66.  More recent studies by the Weaver group proved 
that mechanical inputs not only change cell signaling or gene expression in vitro, 
but that tumor rheology can have a functional effect in vivo67.  They used a 
transgenic mouse model of breast cancer and fibroblasts expressing different 
levels of lysyl oxidase, an enzyme that initiates the crosslinking of collagen and 
increases stiffness of the extracellular matrix, to test the importance of this matrix 
remodeling and stiffening.  They showed that fibroblasts in the mammary fat pad 
expressing high amounts of lysyl oxidase lead to tissue stiffening which promoted 
tumor growth via increased signaling by focal adhesion kinase and 
phosphatidylinositol-3-kinase67.  Inhibition of lysyl oxidase reversed this effect67.  
They further showed the tumor promotion was not due to any secreted factor but 
due to changes in rheology alone67.  Therefore, given the bi-directional nature of 
the environmental physical inputs to cancer cells and metastatic cells’ 
biomechanically guided traversing of the metastatic process, in order to study the 
metastatic series of sieves effectively one requires both the capability to precisely 
control physical attributes of a cell’s surroundings and the understanding of 
cancer biology.  The engineering field of microfluidics affords just this opportunity 
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to marry precision engineering on a micrometer scale with testing clinically 
relevant questions of metastasis. 
 
Microfluidics deals with the manipulation of fluids on the very small scale – 
typically microliter volumes in channels 1 µm to 1000 µm68,69.  The laws of 
physics at this size scale allow for precision in controlling multiple variables on 
the cellular level68-71.  The main disadvantage of in vivo studies of metastases is 
that this tight regulation is not possible70,71.  Over the last decade, there has been 
a dramatic rise in the use of microfluidic engineered devices for applications in 
cancer68,69,72,73.  They have been particularly useful in cancer metastasis 
research in two main areas: as advanced cell migration assays and as tools to 
separate and collect cancer cells from the circulation68,69.  For harvesting 
circulating tumor cells, they afford a larger surface to volume ratio increasing the 
likelihood of capturing these exceedingly rare cells68.  Mehmet Toner’s group has 
proved microfluidic technology’s utility for capturing CTCs in two seminal 
studies74,75.  The used a microfluidic chip, termed the CTC-chip, which had 
78,000 microposts coated with anti-epithelial-cell-adhesion-molecule antibody to 
capture CTCs74.  They captured CTCs from 112 of 113 patients by processing 
their samples of whole blood directly through the CTC-chip and were able to 
further manipulate the captured cells for RNA extraction for RT-PCR analysis, 
which is an important investigative capability the other immunomagnetic-bead 
purification assays lack74.  A later improvement in the design facilitated greater 
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cancer cell-micropost interaction under gentler flow that allowed for the discovery 
of clusters of cancer cells and leukocytes circulating together in patients75. 
 
Microfluidic techniques’ primary advantages in chemotactic assays are the 
capability to generate defined and complex concentration gradients of various 
factors, direct visualization of migrating cells, and the ability to engineer specific 
structures to mimic the tumor environment68-71,76.  Shuichi Takayama’s group 
used these advantages to engineer a device to study the role of chemokine 
receptors in the CTC adhesion and extravasation step in the metastatic series of 
sieves77.  They created a monolayer of endothelial cells at the base of a channel 
and flowed breast cancer cells over their vasculature mimic calculating the 
percent that successfully arrested77.  Importantly, the design of the device 
allowed for different stimulation of endothelial cells in upstream and downstream 
positions serving as an internal control for itself.  Because of this ingenuity, they 
discovered the importance of the chemokine receptor, CXCR4, expressed by the 
endothelial cells themselves – and not just by the cancer cells as was previously 
known – in the adhesion and arrest of CTCs77.  David Beebe’s group in studying 
the DCIS to carcinoma transition in breast cancer used the precise patterning 
and localization of cells afforded by microfluidics to show that the transition to 
invasive cancer in this model was not just dependent on secreted factors, but 
also on physical cell-cell interaction between fibroblasts and the DCIS cell line78.  
They were able to separate the cells by small, defined distances that allowed for 
soluble factor diffusion but did not allow for cell-cell contact.  At these ranges, 
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they saw an intermediate and incomplete transition to invasive cancer78.  Only 
when the fibroblasts and DCIS cell line were positioned closely enough to 
physically interact did the transition to carcinoma complete78.  Melody Swartz’s 
group utilized the advantages provided by microfluidics to investigate the effects 
of interstitial fluid flow in the tumor microenvironment on cancer cell migration 
and invasion in 3D79.  They found yet another example of tumor heterogeneity 
and that the breast cancer cells studied contained a subpopulation that was 
intrinsically stimulated to migrate in the direction of the fluid flow, i.e. towards the 
draining lymphatic vessels79.  This observation could only be made in a 
microfluidic device allowing for the control of specific, slow flow rates and live cell 
imaging. 
 
Because of the mechanical nature of the journey of a tumor cell through the 
metastatic series of sieves and for the aforementioned advantages of using 
microfluidics to study steps in this process, I utilized both microfluidic migration 
devices (Chapters 2 and 3) and circulating tumor cell capture devices (Chapter 4) 
in my study of metastasis (Fig. 1.1).  In Chapter 2, cancer cells are challenged 
with a geometrically confining migration space which mimics the constraints of a 
lymphatic capillary and the early metastatic sieve intravasation.  After migration, 
cells are recaptured and analyzed for genetic differences.  In Chapter 3, the 
effects of secreted factors from normal immune cells in the tumor 
microenvironment are tested for their stimulation of cancer cell migration to 
bypass metastatic sieves.  In Chapter 4, the adhesive property of cancer cells as 
 16 
 
they differ from normal blood cells is leveraged as a novel paradigm for 
circulating tumor cell capture.  Lastly, Chapter 5 presents work which represents 
a departure from the typical utility of microfluidics and using specifically designed 
microfluidic assays accomplishes a multiparametric cellular phenotyping of the 
most aggressive subpopulation of cancer cells’ biomechanical properties, which 
may confer the capability to effectively traverse the metastatic series of sieves. 
  
 17 
 
Figure 1.1. The metastatic series of sieves. An outline of the metastatic series 
of sieves and the steps studied by each of the subsequent chapters.  
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Chapter 2 
Single-cell Migration Chip for Chemotaxis-Based Microfluidic 
Selection of Heterogeneous Cell Populations 
 
This chapter has been  previously been published in *Chen YC, *Allen SG, 
Ingram P, Buckanovich R, Merajver SD, Yoon E (2015) Single-cell migration chip 
for chemotaxis-based microfluidic selection of heterogeneous cell populations. 
Scientific Reports, 5, Article number: 9980. 
 
Chapter Summary 
The first two metastatic sieves a tumor cell must overcome are tumor cell 
migration toward and intravasation into capillaries, yet not all cancer cells are 
imbued with the same capability to do so. This heterogeneity within a tumor and 
the rarity of the successfully metastatic cells is a fundamental property of cancer. 
Tools to help us understand what molecular characteristics allow a certain 
subpopulation of cells to spread from the primary tumor and bypass the 
metastatic sieves are thus critical for overcoming metastasis. Conventional in 
vitro migration platforms treat populations in aggregate, which leads to a masking 
of intrinsic differences among cells. Some migration assays reported recently 
have single-cell resolution, but these platforms do not provide for selective 
retrieval of the distinct migrating and non-migrating cell populations for further 
analysis. Thus, to study the intrinsic differences in cells responsible for 
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chemotactic heterogeneity, we developed a single-cell migration platform so that 
individual cells’ migration behavior can be studied and the heterogeneous 
population sorted based upon chemotactic phenotype. Furthermore, after 
migration, the highly chemotactic and non-chemotactic cells were retrieved and 
proved viable for later molecular analysis of their differences. Moreover, we 
modified the migration channel to resemble lymphatic capillaries to better 
understand how certain cancer cells are able to move through geometrically 
confining spaces. 
 
Introduction 
Cell migration is an essential process in angiogenesis, cancer metastasis, wound 
healing, inflammation, and embryogenesis. In particular, significant attention has 
been paid to the migration of cancer cells since cancer metastases account for 
more than 90% of cancer-related mortality.1,2 Cancer metastases result from a 
multi-step process with significant attrition of viable cells at each stage in the 
metastatic series of sieves. One such rate-limiting step is the chemotactic 
migration and intravasation of tumor cells from the tumor stroma to a capillary 
bed or lymphatic vessels.1-4 The study of the intravasation step has been 
hampered though by the lack of accessible in vitro techniques. Additionally, the 
regulation of certain metastasis-related genes also modulates the occurrence 
and burden of metastases. Although several genes have been discovered and 
may be potential targets for therapeutics,5-7 the study of these metastasis-related 
genes still largely depends on xenograft or tail-vein injection mouse models, 
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which focus on global differences in large cell populations and require 
considerable time and expense thereby precluding their adaptation or input into 
personalized therapy.2,4,8 Furthermore, single-cell resolution of mechanical 
differences and direct visualization are also at present impractical in xenograft-
based experiments in which typically only metastatic growth endpoints are 
assessed rather than the interceding steps. Hence, there is a need to develop in 
vitro devices which can realistically emulate critical steps of the metastatic sieves 
– especially the confining geometry of intravasation into and migration through 
blood and lymphatic capillaries – and allow for the direct visualization of the 
process as well as allowing for the separation and further characterization of cells 
with differing chemotactic properties.2,3 
 
Popular long-standing approaches for studying cell motility and invasion in vitro 
such as wound healing and transwell assays have significant limitations.9,10 
Wound healing assays present challenges both in the reproducibility of the 
scratch and in the inability to discern and separate the more motile from the less 
motile cells within a population.11 Transwell assays provide quantitative binary 
motility results in large cell populations, but imaging of the actual migration 
process of the individual cells is not possible. These fundamental limitations 
preclude the use of these assays to understand in detail the migration of cancer 
cells under conditions that more closely mimic the series of metastatic sieves. 
Realizing these limitations and taking advantage of modern microfabrication 
technologies, a number of studies have employed microfluidic channels to study 
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cell migration more effectively.12-16 In some studies, different channel cross-
sectional sizes and geometries have been used to study the effects of geometry 
on cell migration,15,17-20 while in others the migration channel was filled with 
hydrogel or extra-cellular matrix components in order to simulate the cancer 
invasion process through stroma.21,22 In yet other approaches, two or more cell 
types were co-cultured in microfluidic channels to approximate the cellular 
diversity in the tissue micro-environment.23-25 However, these previous 
microfluidic approaches that study collective migration behaviors lack the 
concurrent capabilities to trace in detail a single cell’s behavior, capture migrating 
cells, and investigate cell population heterogeneity with regards to chemotaxis. 
Furthermore, the geometry-based studies were not on the biological scale of pre-
lymphatics and lymphatic capillaries.15,26-28 
 
Cellular heterogeneity is a key characteristic of cancer and cancer cell 
populations are diverse within a tumor mass.1,29,30 Due to genetic differences as 
well as differing epigenetic and metabolic regulation, subgroups of cancer cells in 
a tumor have distinct growth advantages as the conditions change and thus 
diverse phenotypes with differing migration and metastatic capability evolve in a 
tumor mass over time.30,31 As researchers have begun to recognize the 
importance of cellular heterogeneity contributing to metastasis, several studies 
have reported on techniques to study the migration behavior of individual cancer 
cells.32-37 These prior platforms have a low capture efficiency, typically loading 
many cells yet only investigating a small portion. This inefficiency proves critically 
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unfavorable for applications that use rare samples such as primary tumor 
analysis. More importantly, these platforms, as with other microfluidic migration 
devices, do not allow for the retrieval of cells after the migration assay. This re-
harvesting of the cells after the migration assay for further downstream analysis 
is of the utmost importance for an understanding of the fundamental causes of 
increased chemotaxis in some cells within a population that is otherwise the 
same. Although recently one study has demonstrated the separation of a cancer 
cell line population based on chemotactic phenotype, it did not enrich for 
increased chemotaxis in the selected subpopulation as compared to the parent 
population and required the loading of thousands of cells.16 
 
Therefore, to overcome these and other limitations, we designed a single-cell 
migration platform that allows for the post-migration collection and analysis of 
differing chemotactic subpopulations of cells and that can be modified to 
geometrically mimic the tight spaces in the pre-lymphatic and lymphatic 
capillaries that a cancer cell must navigate on its way to metastasize.3,26,28 Our 
platform incorporates a single-cell capture scheme which positions one cell at the 
entrance of each migration channel, so the chemotactic behavior of each 
individual cell can be specifically traced and delineated over time. Using this cell 
positioning technique, assays are performed by monitoring 20 captured cells in 
each device, making the platform favorable for future use with primary tumor 
samples and other rare cells in contrast to prior devices. Importantly, after the 
migration assays, the highly chemotactic cells can be retrieved for further 
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downstream molecular and phenotypic analysis in comparison to the non-
chemotactic subpopulation. 
 
We show that the highly chemotactic subpopulation of MDA-MB-231 breast 
cancer cells selected through the migration assay maintain this migratory 
phenotype after harvesting and reintroduction to the migration assay. 
Furthermore, the chemotactic cells have a more mesenchymal morphology 
compared to the non-chemotactic residual cells and also express significantly 
greater amounts of the mitogen activator of protein kinase (MAPK) isoform p38γ 
and Ras-homology (Rho) GTPase isoform RhoC, both critical modulators of 
mesenchymal motility in MDA-MB-231 cells.38 Lastly, using our lymphatic 
capillary in vitro mimic, we corroborate our prior in vivo results that showed p38γ 
was necessary for contralateral lymph node metastasis.38 We customized the 
migration channels in our device to include choke points on the geometric scale 
of the constricting lymphatic capillary dimensions in vivo in order to allow our 
study ex vivo of the capillary intravasation step of cancer metastasis to the lymph 
nodes.26 Using p38γ shRNA knockdown and scrambled vector control breast 
cancer cells in our newly developed lymphatic-mimetic device, we show that the 
knockdown p38γ cells are unable to effectively traverse choke points at the 
critical size of 6 μm x 10 μm, which is the size of lymphatic vessels in vivo.26 Our 
present device can thus be used to directly visualize one of the critical steps of 
the metastatic series of sieves in order to reveal further insights into what 
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molecular underpinnings allow certain cancer cells within a heterogeneous tumor 
to intravasate into capillaries and subsequently metastasize. 
 
Results 
Design of the single-cell capture scheme 
The microfluidic device consists of single-cell capture sites and migration 
channels. Fig. 2.1 (A) shows a schematic diagram of the described chip and 
fabrication processes. To achieve single-cell resolution, cells are loaded by 
gravity flow and hydrodynamically captured at each capture site (Fig. 2.1(B)). We 
incorporated the capture area directly adjacent to the entrance of the narrow 
migration channel, an innovative feature as compared to other devices.39-41 As 
shown in Fig. 2.1 (C), two paths are created: a shorter central path and a longer 
serpentine path. The flow rate of each path is inversely proportional to its 
hydrodynamic resistance. A long serpentine structure increases the 
hydrodynamic resistance (RS), so the serpentine flow resistance is larger than 
that of the central path. Therefore, the serpentine flow (QS) is less than the 
central flow (QC), and cells will more likely follow the central path. As the opening 
of the central path is slightly smaller (height: 20 μm, width: 10 μm) than the size 
of cancer cells (e.g., SKOV3 cells has an average diameter of 14.1 μm, SD ±3.2 
μm) and funnel-shaped, the captured cell consistently plugs the gap and blocks 
the flow through the central path (cell valving). Thus, the remainder of the cells 
travel through the serpentine path and are subsequently captured in the 
downstream capture sites (Fig. 2.S1). 
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In order to optimize the length of the serpentine path and achieve a high cell 
capture rate, we simulated the pressure and velocity field for various channel 
geometries. Fig. 2.S2 shows the simulation of the pressure and flow velocity 
under varying serpentine lengths ranging from 200 μm to 800 μm. Ideally, the 
larger the hydrodynamic resistance of the serpentine path is (RS, which is 
proportional to the serpentine length) the higher the capture rate. However, when 
the serpentine length is longer than 800 μm, the hydrodynamic resistance of the 
serpentine path (RS) becomes so large that the flow velocity drops significantly. 
In this case, cells may get stuck along the serpentine path resulting in clogging. 
As a result, there is a large standard deviation of capture rates observed in chips 
with very long serpentine lengths (Fig. 2.1 (D)). A similar problem arises under 
gravity flow when many more than 20 migration channels are incorporated (data 
not shown). To further optimize the cell capture rate in this asymmetric capturing 
design, the media volume in the right inlet during loading (80 μL) is slightly less 
than that in the left inlet (100 μL). The resulting weak gravity flow rightward into 
the migration channel guides the cells closer to the capture site to increase the 
capture probability. From simulations, the optimal serpentine length was 
determined to be 600 μm, to achieve high capture rates of over 94% (capturing 
nearly exactly one cell per each migration channel) (Fig. 2.1 (D)). A video 
demonstrating the cell capturing process can be found at 
https://youtu.be/_2TGZMbfnLE. 
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The stiffness of the cells of interest is also critical for optimal cell capture. More 
elastic cells yield higher capture rates since they deform more easily and plug the 
central path, sealing the capture site better than stiffer cells do. Based on the 
particular cancer cell types used in the experiments, the geometry of serpentine 
lengths and path openings were modified to improve capture efficiency, as 
described in more detail in the supplementary methods. Extensive studies were 
performed on various cell types including SKOV3, A2780DK, C2C12, MDA-MB-
231, and PC3 cell lines, and we have achieved capture rates greater than 85% in 
all the tested cell types (Table 2.1). These experimental data demonstrate that 
the proposed single-cell capture mechanism is reliable and robust for a broad 
spectrum of cell types, and thus amenable to the study of individual cancer cells’ 
migration. 
 
Chemical gradient generation 
The migration of cancer cells can be driven by chemotaxis whereby differences 
in the concentration of growth factors or other chemokines can induce tumor cells 
to intravasate into the circulatory system.42-44 To model this in vivo condition, the 
migration channels in our device (width: 40 μm, height: 10 μm, length: 1 mm) are 
designed to specifically study the movement of cells with a concentration 
gradient profile generated by diffusion.45 To generate this chemical concentration 
profile, serum-free culture media with chemoattractant is pipetted into the right 
inlet and serum-free culture media is pipetted into the left inlet. Due to the nature 
of diffusion, the concentration of the chemoattractant in the migration channels 
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increases linearly along the channel from left to right, as simulated in Fig. 2.S3. 
The generated chemical profile projected in the simulation was confirmed 
experimentally using a fluorescent dye (Fluorescein 5(6)-isothiocyanate, F3651, 
Sigma-Aldrich). The fluorescent intensity was measured and plotted in Fig. 2.1 
(E). The measured fluorescent concentration profile agrees with simulation 
results (COMSOL 3.5), verifying that concentration profiles can be successfully 
generated. Additional simulations were performed to investigate whether a 
migrating cell in the channel would affect the gradient profile. A pseudo-cell (10 
μm width by 10 μm height and 40 μm length) was added to the model to simulate 
a potentially blocked channel. However, since the channel cross-section (40 μm 
by 10 μm) is much larger than that of a cell (10 μm by 10 μm), the gradient was 
only minimally changed (<2% difference), as shown in Fig. 2.S4. 
 
Single-cell migration assay 
Cancer metastases are caused by a multi-step process which begins with the 
escape of tumor cells from the primary tumor through the basement membrane 
and the subsequent intravasation of cancer cells into capillary vessels under the 
influence of chemoattractants and cellular signals generated by cell-cell 
junctions.2,42 In order to validate the utility of the fabricated migration chip as an 
in vitro model of migration, we investigated the chemotaxis of SKOV3 ovarian 
cancer cells toward a higher concentration of hepatocyte growth factor (HGF), 
which is a well-known chemoattractant across many cell types.46 
 
 33 
 
Fig. 2.2 illustrates the single-cell migration tests in the platform. After cell loading 
utilizing gravity-driven flow, all the captured SKOV3 cells were positioned at the 
capture sites along the left side, as shown in Fig. 2.2 (A). The captured cells 
attached to the substrate within three hours and chemotaxis was monitored over 
24 hours at single-cell resolution, as shown in Fig. 2.2 (B). After cell loading, 
media in the right inlet was replaced with serum-free media supplemented with 
50 ng/mL HGF, which induces SKOV3 cell migration.47 Serum-free media without 
HGF was pipetted into the left inlet, creating a linear concentration gradient of 
HGF along the migration channel. After 24 hours, we observed that more cells 
migrated to the right side when exposed to the HGF concentration gradient, while 
under the control conditions (applying serum-free culture media to both inlets) the 
cells did not show any directional migration (Fig. 2.2 (A)). This increase in 
chemotaxis was dependent on HGF concentration and is plotted in Fig. 2.2 (C). 
These data demonstrate that our platform is suitable for studies relying on single-
cell chemotaxis as a read-out. 
 
Selective subpopulation harvesting for downstream cellular heterogeneity 
analysis  
Cellular heterogeneity is a key characteristic of cancer. Subpopulations or even 
single cells in a primary tumor or within a cancer cell line may have their own 
distinct phenotype due to genomic mutations or differential genetic and 
epigenetic regulation.1,29-31 In our single-cell migration platform, we can not only 
monitor the movement of each cell but also selectively harvest the highly 
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chemotactic and the non-chemotactic subpopulations for downstream analysis 
after the migration assay. This additional capability grants the opportunity to 
analyze the intrinsic differences within cell populations which contribute to the 
observed heterogeneity in motility. 
 
Although MDA-MB-231 is an aggressive breast cancer cell line, some cells within 
this line exhibit yet a greater chemotactic potential than others in that we observe 
not all cells migrate equally toward a chemoattractant stimulant (data not shown). 
To understand the differences even within a traditionally presumed 
“homogenous” cell line that could lead to this phenotypic dissimilarity, we sought 
to collect and further characterize the highly chemotactic MDA-MB-231 
population in comparison to the cancer cells that remained on the cell-loading 
side of the device and were not stimulated by the gradient to directionally 
migrate. After a migration assay using 10% fetal bovine serum as the 
chemoattractant, both highly chemotactic and non-chemotactic MDA-MB-231 
cells were retrieved as illustrated in Fig. 2.3 (A-E). Fig. 2.3 (B) shows a highly 
chemotactic MDA-MB-231 cell, which had migrated all the way to the serpentine 
channel on the right side of the device within 24 hours. To selectively harvest 
these cell populations, we must use a different protocol than for cell seeding. For 
cell loading at the start of a migration experiment, we utilize only gravity-driven 
flow by adding 100 μL of cell-containing media into the inlets with no liquid in the 
outlets to achieve a pressure difference of around 50-100 Pa. For cell retrieval, 
trypsin is flowed from the outlets to the inlets, detaching and directing 
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chemotactic cells to the right inlet and the non-chemotactic cells to left inlet. 
Additionally, we apply a negative pressure of about 1,000 Pa via pipet bulb on 
the inlet reservoirs as trypsin flows from the outlet reservoirs. This pressure 
gradient generates a flow rate strong enough to overcome the slight diameter 
difference between a cell (~13 μm) and the central path capture site (20 μm x 10 
μm) so that the cells deform and flow through the capture channel and toward the 
collecting inlets, without incurring damage. After 5 minutes of trypsinization under 
negative pressure, the target cell populations were detached, retrieved from the 
inlet, and then re-plated into 60 mm petri dishes for recovery and propagation 
(Fig. 2.3 (C, D, E)). After 12 hours of recovery, scanning electron microscope 
images of the retrieved cells revealed that the highly chemotactic cells were more 
elongated with a distinct mesenchymal morphology whereas the non-chemotactic 
cells were rounded with an epithelial-like morphology (Fig. 2.3 (F,G)).48-50 
 
In order to evaluate the two populations further, we allowed the harvested cells to 
grow in tissue culture for 4 days after retrieval. The collected cells grew into 
distinct colonies each containing about 30-40 cells as shown in Fig. 2.4 (A, B, D). 
We found that the harvested highly chemotactic cells maintained their 
mesenchymal morphology, even after forming a colony over 4 days, while in 
comparison, the non-chemotactic cells remained tightly clustered and epithelial in 
appearance (Fig. 2.4 (A, B)). In the chemotactic colonies, all daughter cells were 
also spread over a larger area than those in colonies formed by non-chemotactic 
cells. There was a significant difference in the colony radius between the two 
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groups (Fig. 2.4 (C)), with no observed difference in the proliferation rate (Fig. 2.4 
(D)). The cells of a chemotactic colony also had significantly greater aspect ratios 
than cells in a non-chemotactic colony, indicating maintenance of the 
mesenchymal and epithelial morphologies, respectively (Fig. 2.4 (E)). 
 
To examine whether the difference in chemotaxis was maintained after cell 
retrieval and culture, single-cell migration assays were performed on the 
daughter cells from the chemotactic and non-chemotactic clusters. Despite only 
having a limited (<1,000) number of descendant cells from the even smaller 
number of harvested chemotactic and non-chemotactic cells, our single-cell 
migration chip could efficiently handle such limited quantities due to a high 
capture efficiency. The progeny of the highly chemotactic cells remained 
significantly more migratory than those of either the harvested non-chemotactic 
cells or the non-migration-sorted bulk population (Fig. 2.4 (F)), while no 
significant difference was observed between the descendants of the non-
chemotactic cells and unsorted MDA-MB-231 cells. These results demonstrate 
that the distinct characteristics of sorted cells are maintained after the harvesting 
and limited propagation process, allowing further studies on the differences 
between these highly chemotactic and non-chemotactic cells to be reliably 
interpreted. 
 
Taking advantage of this fact and to further ascertain what molecular differences 
between these two populations within the same cell line might account for their 
 37 
 
different migration behavior, we harvested the chemotactic and non-chemotactic 
populations from a separate set of migration devices and cultured them for 4 
days as before. We then isolated RNA from the chemotactic and non-
chemotactic cells as well as from bulk MDA-MB-231 cells plated in the similar 
numbers to the quantity harvested from the migration devices. We performed RT-
qPCR on samples from 3 separate chemotaxis-sorting experiments and found 
that the chemotactic cells expressed significantly higher amounts of RhoC 
GTPase and p38γ mRNA as compared to the non-chemotactic cell population 
that remained on the cell-loading side of the device (Fig. 2.4 (G)). Both of these 
proteins have been shown in previous studies to be important mediators of 
cancer cell motility and higher expression correlated with advanced cancer stage 
and worse prognosis.38,51-54 
 
Customized migration channel for mimicking lymphatic capillary geometry 
Capillary intravasation is a critical step in the metastasis of cancer to the lymph 
nodes,3 yet limited devices at present allow for the ideal in vitro study of this 
process.15 To address this gap, we designed a device with migration channels 
with a series of choke points in order to mimic the geometric constraints of 
lymphatic capillaries within our migration chip.26 
 
In previous work, we studied mitogen activator of protein kinase (MAPK) family 
member, p38γ, which has a known role as a motility regulator in aggressive 
breast cancer cells.38 In that study, MDA-MB-231 breast cancer cells transfected 
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with shRNA targeting the p38γ isoform, p38γ knockdown (GKD) cells, had a 
rounded morphology and decreased or eliminated mesenchymal migration. 
These cells were more epithelial and had dysfunctional actin cytoskeleton cycling 
leading to ineffective random walk in 2-dimensional migration when compared to 
cells transfected with a scrambled shRNA control plasmid (SCR).38 Importantly, 
these results had been modeled previously by us in silico and, for the p38γ 
knock-down cells, the endpoint of decreased lymph metastases have been 
observed in vivo. Now, we wished to test whether our newly developed device in 
our present work would reliably approximate lymphatic invasion as a rapid and 
convenient in vitro mimic. Thus, to characterize the migration capability of MDA-
MB-231 breast cancer cells in a 3D geometric model of lymphatic capillaries, we 
altered our single-cell migration chip to contain multiple migration resistance 
choke points (Fig. 2.5 (A,B)) and successfully demonstrated the capability of 
tracing single cells in this lymphatic capillary invasion assay (Fig. 2.5 (C,D)). The 
size variation of the migration channels and choke points are illustrated in Fig. 
2.5 (B) and represent the continuum of mechanical stresses a cancer cell would 
encounter in vivo, with the narrowest choke point corresponding to the average 
diameter of lymphatic vessels draining to axillary lymph nodes.26-28 
 
The qualitative effects of p38γ knockdown on migration through choke points can 
be seen in Fig. 2.5 (C). Fig. 2.5 (C) shows the representative morphologies of the 
scrambled vector (SCR) cells and p38γ knockdown (GKD) cells within the 
narrowest choke point channels (6 µm x 10 µm). F-actin fibers are labeled with 
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red fluorescence protein (RFP) and stably transfected cells are labeled with 
green fluoresecence protein (GFP) through their respective expressing plasmids. 
SCR cells are able to form long pseudopodia that can reach past the choke point 
in a mesenchymal-like manner to form an attachment beyond the narrowing; 
thus, these cells are successful in migrating through the lymphatic-capillary 
mimics by contraction of their stress fibers in the typical “rubber band-like” 
fashion (Fig. 2.5 (C)).  In contrast, the GKD cells ineffectively cycle their 
cytoskeleton in a basket-weave configuration, as demonstrated previously,38 and 
thus are only able to squeeze into the narrow channel but can travel no further, 
with the actin evenly distributed around the periphery of the cell (Fig. 2.5 (C)). 
 
To quantify this observation further, we measured the cell migration distance (as 
a function of “passed choke points” or relative distance in the channels) for 
multiple choke point geometries, as plotted in Fig. 2.5 (D). We observed that 
SCR and GKD cells have equivalent chemotactic potential in response to a 
serum gradient when the migration channel is wide (30 µm x 10 µm) and without 
choke points, but the number of traversed choke points of GKD cells significantly 
diminishes when the migration is obstructed by the narrowest choke points (6 µm 
x 10 µm). To verify the decreased migration efficiency of p38γ knockdown cells, 
the migration velocity of MDA-MB-231 cells in the narrowest choke point 
channels was measured and shown in Fig. S5. While the variation is large, the 
migration velocity of SCR cells is almost double that of GKD cells. This result 
supports the hypothesis that the motility of GKD cells is decreased due to 
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unproductive actin cytoskeletal cycling as previously reported,38 but also allows, 
for the first time, direct visualization of what might be happening in vivo at the 
critical intravasation step for lymph node metastases that caused the GKD cells 
to have decreased contralateral lymph node metastases in mice.38 
 
Discussion 
Many microfluidic devices for cell migration have been reported in recent 
years.14-16,25,32-37,40,41 Although multiple approaches have been designed to 
exploit the advantages of microfluidics (small volumes and precise micro-
environment control), most assays still measure an average behavior over large 
numbers of cells with an underlying implicit assumption that all cells are 
essentially identical. However, as cellular heterogeneity is increasingly 
recognized as a key aspect of the evolution of cancers and of the genesis of 
inherent resistance to treatment and recurrence,29 there is a need to leverage 
microfluidics for the study of tumor heterogeneity. In this work, we have 
developed, characterized, and tested a tool that has the capability to select highly 
chemotactic cells for study and to enable their recovery for further 
characterization of this subpopulation’s differences from its non-chemotactic 
counterpart population. Given that only certain cells within a tumor are the key 
metastases-initiating cells,1,2 we anticipate that this tool has the potential to 
greatly advance our detailed molecular studies of the multiple cellular 
subpopulations comprising a primary or a metastatic tumor. Understanding 
specific differences that lead some cancer cells to successfully bypass the 
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metastatic sieves and leave the primary tumor and seed metastases is of great 
benefit to develop and test anti-metastatic strategies. Here, we demonstrated 
single-cell migration and investigation of the individual chemotactic profile of 
each cell rather than their average aggregate behavior. Moreover, following the 
assays, cell populations of different chemotactic potential extremes were 
selectively retrieved for further downstream analysis to better query the inherent 
differences in these subpopulations. 
 
The presented migration device reliably positions exactly one cell next to the 
migration channel, granting the advantages of using a small number of cells and 
allowing for easy tracing of single-cell migration behavior. We incorporated a 
hydrodynamic scheme within the migration channel that, through optimization, 
achieved near an 85% capture rate in 5 different mammalian cell lines. In order 
to achieve this high single cell capture efficiency, precise control of the 
hydrodynamic resistances was necessitated not just for the individual channel 
subsections (serpentine channel vs. central channel) but also across the whole 
migration device. When more than 20 migration channels (and thus 20+ 
serpentine channels and 20+ central channels) were incorporated, the gravity-
driven flow rate with the volumes used for cell seeding was too slow and cell 
clogging occurred. However, even with just 20 migration channels, the assays 
can be performed on the limited inputs of cells as demonstrated by our post-
assay recovery and re-assessment of migration properties of less than 1,000 
cells. In addition, a chemoattractant gradient can be reliably generated in the 
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narrow migration channels with a limited effect on the concentration profile by a 
migrating cell. 
 
Using the described platform, we have successfully demonstrated three single-
cell migration assays: tracing SKOV3 cell chemotaxis induced by HGF, 
determining molecular differences between the highly chemotactic and non-
chemotactic populations of MDA-MB-231 breast cancer cells, and studying a 
metastasis-related gene (p38γ) by evaluating its effect on cancer cell migration 
through channels mimicking the geometric constraints of lymphatic capillary 
intravasation. Our prior work revealed the differences between GKD and SCR 
cells in their actin cytoskeleton oscillations and random-walk migration via 
computer modeling and demonstrated reduced lymphatic metastases in vivo in 
mice.38 With our newly developed single-cell migration chip, we are able to 
directly visualize how the GKD cells are mechanically less capable of lymphatic 
intravasation. This experiment demonstrated the potential of the proposed single-
cell platform for studying models of cell migration in vitro in devices that can 
geometrically mimic critical steps in the metastatic process and the ability to 
discern cellular motility differences as a result of specifically induced or native 
signaling characteristics.  Furthermore, evaluation of the motility and indirect 
metastatic potential of certain cell fractions in vitro has the potential to enable 
targeting specific cell subpopulations in vivo so as to eliminate them preferentially 
before they may have a chance to metastasize. 
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Our platform also provides a method for chemotactic-based selection. Highly 
chemotactic and non-chemotactic cells were selectively retrieved after the 
migration assay for further propagation and analysis. While a previously reported 
device also allows for the chemotactic selection of cells,16 this device suffers from 
the necessity of loading thousands of cells precluding its potential use with small 
tumor biopsy samples. Utilizing our device and with loading only hundreds of 
cells, we demonstrate that the distinct characteristics of migration-sorted cells are 
maintained after harvesting and limited expansion in tissue culture. This allows 
for reliable interpretation of further downstream studies to distinguish the 
differences between the highly chemotactic and non-chemotactic cell populations 
within a given “homogenous” sample.  Thus, the present platform provides the 
capability to correlate the migration phenotype of the highly chemotactic cells 
with a molecular signature of gene expression within this subpopulation. 
Although a recent study demonstrated poor correlation between the speed of 
mother and daughter cells in the immediate 6 hours after cell division, this was 
for cells from the entire spectrum of migration speeds.14 In our work, we select for 
the highly chemotactic subpopulation and show that for these cells this migration 
and mesenchymal morphology phenotype is heritable, at least over limited 
generations. Furthermore, this same population of cells also expresses greater 
amounts of mRNA of two known migration and metastasis-associated genes, 
RhoC and p38γ, than the non-chemotactic subpopulation does.38,51-54 Therefore, 
our present device has the capability of selecting cancer cells based upon their 
chemotactic phenotype and then enabling the harvest and assessment of what 
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molecular underpinnings might be responsible for the difference in chemotaxis. 
We believe our study sets the stage for the investigation of motility heterogeneity 
and metastatic potential within cancers on a broader scale and can yield new 
insights as to the mechanical and molecular basis of why certain tumor cells in a 
patient are able to metastasize. 
 
Materials and Methods 
Device Fabrication and Assembly 
The migration devices were formed from a single layer of PDMS 
(polydimethlysiloxane), which was fabricated on a silicon substrate by standard 
soft lithography, and a glass slide. Three masks were used to fabricate the 
multiple heights for the serpentine channel region (40 µm height), the capture 
gap (20 µm height), and the migration channel (10 µm height). Channel widths 
were 40 µm unless otherwise stated (choke points and central path). The PDMS 
layer was bonded to the glass slide after activated by oxygen plasma treatment 
(80 Watts, 60 seconds) to form a complete fluidic channel. Before cell loading, 
collagen (Collagen Type 1, 354236, BD Biosciences) solution (1.45mL Collagen, 
0.1mL acetic acid in 50mL DI Water) was flowed through the device for one hour 
to coat collagen on the substrate to enhance cell adhesion. Devices were then 
rinsed with PBS (Gibco 10082) for one hour to remove the residual collagen 
solution before use. 
 
Cell Culture 
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SKOV3 (ovarian cancer) and A2780DK (ovarian cancer) cells were obtained from 
Dr. Ronald Buckanovich’s lab (University of Michigan, MI, USA) and cultured in 
RPMI (Gibco 11875) with 10% FBS (Gibco 10082) and 1% 
penicillin/streptomycin (Gibco 15140). PC3 (prostate cancer) cells were obtained 
from Dr. Ken Pienta’s lab (University of Michigan, now at Johns Hopkins 
University) and cultured in DMEM (Gibco 11965) with 10% FBS and 1% 
penicillin/streptomycin. MDA-MB-231 (breast cancer) cells were cultured in RPMI 
with 10% FBS and 1% penicillin/streptomycin. Cells were cultured at 5% CO2. 
The p38γ knockdown MDA-MB-231 (GKD) cells were stably transfected in the 
Merajver lab with short hairpin RNA (shRNA) targeting p38γ and the scrambled 
vector (SCR) cells were transfected with a scrambled hairpin RNA as previously 
reported.45 
 
Single-cell Migration Assay 
Cells were harvested from culture plates with 0.05% Trypsin/EDTA (Gibco 
25200) and centrifuged at 1000 rpm for 5 min. To improve the imaging quality, 
cells were stained by green fluorescent (Invitrogen, Cell tracker Green C2925) 
dye. Then, the cells were re-suspended in culture media to a concentration of 
1x105 cells/ml. 100 µL of this cell solution was pipetted into the left inlet, and 80 
µL of media only was pipetted into the right inlet. After 10 minutes, the cell 
solution in the left inlet was replaced with 100 µL serum-free culture media, and 
100 µL serum-free media with the indicated chemoattractant was applied to the 
other inlet to induce chemotactic migration. Then, the entire chip was put into a 
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cell culture incubator. Migration distance was measured based on the final cell 
position after 24 hours of incubation without media replenishment. Only the 
migration channels having single cells were counted. The velocity of cells was 
measured by imaging cell positions every 30 minutes. Results presented 
represent means ± standard deviations. A two-tailed student t-test (unpaired) 
was used to measure significance. 
 
Selective Subpopulation Retrieval 
We selectively harvested the chemotactic and non-chemotactic cells after a 24 
hour migration assay. The cells that remained in the left side (loading side) were 
considered non-chemotactic cells, while the cells that had migrated the entire 1 
mm migration channel to the right side (chemoattractant side) within 24 hours 
were considered highly chemotactic cells (Fig. 2.3(A)). To avoid possible 
contamination, both the inlets and outlet were washed carefully with trypsin 
before cell harvesting. 100 µL of PBS was pipetted into the outlet and left for 5 
minutes to wash away any residual serum or debris in the channel. Trypsin was 
then pipetted into each outlet and flowed from the outlet to the inlet for 5 minutes. 
In this manner, the highly motile cells were trypsinized and directed to the right 
inlet, while the non-motile cells were directed to the left inlet. A slight negative 
pressure (~1,000 Pa) was also applied to each collecting inlet to prevent cell 
capture by the central paths since with this increased flow rate the cells 
overcame the slight difference in diameter and deformed and flowed through the 
central path. The detached cells were pipetted into a 60 mm petri dish or 96-well 
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plate for recovery and propagation. As cells plated at an ultralow density (~ tens 
of cells) have poor viability, we cultured these cells in MDA-MB-231 conditioned 
media. Conditioned media was obtained by culturing 3 mL of RPMI 
supplemented with 10% FBS on a 80% confluent layer of MDA-MB-231 in a 60 
mm dish for one day prior to harvesting. Three consecutive 10-minute, 2,000 rpm 
centrifuging processes removing and re-centrifuging the media supernatant were 
performed to remove possible cellular contamination from the conditioned media 
once it was removed from the cell conditioning plate. The triple-centrifuged 
conditioned media was further plated alone and cultured in an incubator as a 
control to verify that no residual MDA-MB-231 cells were introduced into our 
chemotactic and non-chemotactic cultures. 
 
RNA Isolation and RT-qPCR 
After selective subpopulation retrieval, the harvested chemotactic and non-
chemotactic cells were plated into 96-well plates for 4 days of culture. MDA-MB-
231 cells that had not been migration-sorted were plated in equal densities to the 
chemotactic and non-chemotactic populations and used as bulk control. 
Biological replicates were harvested from 3 separate migration sortings each 
comprising at least 10 devices. RNA was extracted using the Single Cell RNA 
Isolation Kit (Norgen Biotek Corp, Cat. 51800) according to the manufacturer’s 
standard protocol. RNA was eluted in 9 µL. The cDNA was prepared using the 
Reverse Transcription System (Promega, Cat. A3500) according to the standard 
protocol using Oligo(dT) primers and the entirety of the harvested RNA (~7 µL) 
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was used in each 20 µL cDNA reaction. The reaction was incubated at 42C for 
45 minutes then inactivated at 95C for 5 minutes before storing at -20C until 
use. Template dilutions of the 20 µL cDNA reactions were made by mixing 10 µL 
of cDNA with 10 µL of RNase/DNase free water. Qiagen QuantiTect SYBR 
Green PCR Kit (Cat. 204143) was used for the qRT-PCR reaction according to 
the standard manufacturer’s hot-start protocol. Primers were purchased from 
Integrated DNA Technologies: RPL22 (Hs.PT.51.607028), RPL30 
(Hs.PT.51.3119226), RhoC (Hs.PT.56a.39081600), and p38γ 
(Hs.PT.58.45504579). Primers were diluted into 500 µL of TE buffer (20x). Each 
20 µL reaction well contained 10 µL of mastermix, 8 µL of water, 1 µL of the 1:2 
diluted cDNA, and 1 µL of 20x primer. Triplicate technical replicates were 
performed on each gene for each of the triplicate biological replicates. The 
reaction was run on a StepOnePlus Real-Time PCR System (Applied 
Biosystems) with melt curve analysis for specificity of products. Results were 
analyzed with REST 2009 software using both RPL22 and RPL30 for 
normalization and with 5,000 iterations.55 
 
Statistical Analysis  
Two-tailed, unpaired student’s t-tests were used for all comparisons with a 
significance level of 0.05 considered statistically significant. For RT-qPCR 
results, REST 2009 analysis software was used to assess significance using 
both RPL22 and RPL30 for normalization and with 5,000 iterations.55 Results are 
presented as mean ± SD. 
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Figure 2.1. Proposed microfluidic chip for single-cell migration. (A) 3D 
schematic drawing of the chip. The cells are loaded in the left side, and the 
chemoattractant induces the migration through the migration channels toward the 
right. (B) Enlarged 3D schematic drawing of one cell capture site. (C) Schematic 
of the cell capture principle. (D) SKOV3 cell capture rate with different serpentine 
lengths (N= 4 devices). The optimal length determined from these experiments 
was 600 μm. (E) Concentration gradient of chemicals in the migration channel. 
The red line indicates the simulation result by COMSOL 3.5. The blue line is the 
measurement of the fluorescent dye intensity in the migration channel. 
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Figure 2.2. Single-cell migration assay using HGF as a chemoattractant for 
SKOV3 cells. (A) The images of the single-cell migration assay. The upper two 
images illustrate the single-cell distribution after cell loading (cells were loaded 
from the left channel). All captured cells are aligned along the left side of the 
migration channels. The lower two images illustrate the cell distribution after 24 
hours without a chemoattractant (lower left, control) and with 50ng/mL of HGF in 
serum-free media added to the right inlet (lower right, stimulated). Compared to 
the control, the HGF induced cells to migrate further to the right. (B) The process 
of cell migration. First, a cell is captured by the hydrodynamic force from the cell 
solution. After 4-6 hours the cell attaches to the substrate and then it begins to 
move into the migration channel. (C) Result of the chemoattractant assays. The 
graph illustrates the relative ratio of migrated cells (all the way to the opposite 
side) and migrating cells (within the channel) vs. HGF concentration. The result 
confirms that the HGF is a strong chemoattractant for the SKOV3 cells. Data 
points represent means ± standard deviations (N= 4 devices), ** refers to P < 
0.01 compared to the no HGF control. 
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Figure 2.3. Selective retrieval and downstream analysis of the highly 
chemotactic cells. (A) The schematics for cell retrieval. (B) A representative 
highly chemotactic cell, which has migrated completely through the migration 
channel within 24 hours. (scale bar: 50 µm) (C) After 3 minutes of trypsinization, 
the cell became rounded in morphology. (scale bar: 50 µm) (D) After 5 minutes of 
trypsinization, the cell was successfully detached and flowed to the right inlet. 
(scale bar: 50 µm) (E) All detached cells were transferred to a 60mm petri-dish or 
96-well plate. (scale bar: 50 µm) (F) Scanning electron microscope image of a 
non-chemotactic cell exhibiting epithelial morphology 12 hours after retrieval. 
(scale bar: 10 µm) (G) Scanning electron microscope image of a highly 
chemotactic cell exhibiting mesenchymal morphology 12 hours after retrieval. 
(scale bar: 10 µm) 
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Figure 2.4 Characterization of the highly chemotactic subpopulation. (A) 
The colony formed by a single chemotactic cell after 4 days. The cells in the 
colony maintained an elongated (mesenchymal-like) shape and spread over a 
wide area. (scale bar: 100 µm) (B) The colony formed by a single non-
chemotactic cell after 4 days. The cells were epithelial in morphology and tightly 
clustered. (scale bar: 100 µm) (C) The comparison of the colony radius between 
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the highly chemotactic and non-chemotactic cell colonies. The colonies formed 
by chemotactic cells have a significantly larger radius (N = 8 colonies), ** refers 
to P < 0.01. (D) The comparison of the number of cells per colony between the 
highly chemotactic and non-chemotactic cell colonies. No significant difference 
was observed. (N = 8 colonies) (E) The descendant cells from chemotactic cells 
exhibit a significantly higher aspect ratio 4 days after retrieval, indicating 
persistence of the mesenchymal-like morphology (N = 8 colonies), ** refers to P 
< 0.01. (F) The migration distance of repeated single-cell migration assays. 
Descendants of highly chemotactic cells persisted to be more migratory than the 
descendants of non-chemotactic cells and the unsorted bulk MDA-MB-231 cells 
(N = 5 devices), * refers to P < 0.05. (G) The chemotactic cells exhibited a higher 
expression of mRNA as analyzed by qRT-PCR of the migration and metastasis-
associated genes RhoC and p38γ as compared to non-chemotactic cells; * refers 
to P < 0.05, and ** refers to P < 0.01, respectively. 
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Figure 2.5. Customized migration channels for mimicking lymphatic 
capillary geometry. (A) Photomicrograph of the fabricated device. (B) Size 
variation of migration channels. The length of choke point is 100 μm, and the 
width of choke point varies from 6 μm (narrowest) to 30 μm (no choke point). (C) 
Qualitative observation of migration behavior of MDA-MB-231 cells in the 6 µm x 
10 µm choke point. The scrambled control (SCR) cells can form a stable and 
long stress fiber to migrate through the choke point, while the p38γ knockdown 
(GKD) cells can only squeeze into the choke point. F-actin is labeled by RFP and 
GFP is expressed by the targeted or scrambled shRNA plasmid. (D) Single-cell 
migration assay on different channel geometries. The motilities of both cells are 
similar in the straight channels, but the SCR MDA-MB-231 cells are far more 
motile in narrower choke point channels. Data points represent means ± 
standard deviations (N = 8 devices), ** refers to P < 0.01. 
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 Cell Type 
Capture 
Rate 
Skov3 
Ovarian 
cancer 
93.8±6.4 % 
A2780DK 
Ovarian 
cancer 
88.6±10.2 % 
C2C12 
Mouse 
muscle 
myoblast 
92.2±4.5 % 
MDA-MB-231 
Breast 
cancer 
91.5±7.2 % 
PC3 
Prostate 
cancer 
85.1±9.7 % 
 
Table 2.1. Capture rates of five cell lines. (N = 4 devices)
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Supplemental Figures 
 
Figure 2.S1. Simulations of flow velocity before and after capturing one cell 
by COMSOL 4.3. (A) Before cell capture, simulation of flow velocity shows that 
the higher flow rate through the central path, so the cells will more likely follow 
the central path. (B) After capturing one cell, the captured cell plugs the gap and 
blocks the flow through the central path. Thus, the rest of the cells will travel 
through the serpentine path and will be subsequently captured in the 
downstream capture sites. 
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Figure 2.S2. Simulations of flow velocity and pressure on different 
serpentine lengths ranging from 200 µm to 800 µm by COMSOL 4.3. (A) 
Simulations of pressure distribution illustrates that the quick transition in the 
capture site leads to a high capture probability of single cells at the site. (B) 
Simulations of flow velocity indicates that when the serpentine structure is short, 
the flow rate through serpentine path becomes higher, which means that the cell 
is less likely to be driven to the capture gap. 
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Figure 2.S3. Simulations of chemical concentration gradient generated in 
the device by COMSOL 3.5. (A) The simulation of the whole chip demonstrates 
that the chemical concentration is uniform from the upstream to the downstream 
channels since the diffusion is relatively slow. (B) Enlarged view of the first few 
channels. The simulated concentration profile shows the linear chemical gradient 
is formed in the migration channel. Concentrations are shown in color scale with 
red being 1 M chemokine and blue being 0 M chemokine. 
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Figure 2.S4. Simulations of chemical concentration profile with and without 
cell migrating in the migration channel. (A) The simulation of the chemical 
concentration profile with and without cell migrating in the migration channel. The 
cell was emulated by adding a pseudo-cell (10 μm width by 10 μm height and 40 
μm length) on the bottom of the channel to block diffusion. The cell was placed at 
the center (500 μm from the left) (B) The concentration profile in the channel. (C) 
Enlarged concentration profile in the channel from the 400 μm to 600 μm 
position. Since the channel cross-section (10 μm by 40 μm) is much larger than 
cell, the concentration is altered by less than 2%. 
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Figure 2.S5. The migration velocity of MDA-MB-231 cells in the 6 µm x 10 
µm choke points. The scrambled control (SCR) cells can migrate more 
efficiently than the p38γ knockdown (GKD) cells through the choke point.  
  
 61 
 
References 
1. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. 
Cell 144, 646-674, (2011). 
2. Steeg, P. S. Tumor metastasis: mechanistic insights and clinical 
challenges. Nat Med 12, 895-904, (2006). 
3. Nathanson, S. D. Insights into the mechanisms of lymph node metastasis. 
Cancer 98, 413-423, (2003). 
4. Sethi, N. & Kang, Y. Unravelling the complexity of metastasis - molecular 
understanding and targeted therapies. Nat Rev Cancer 11, 735-748, (2011). 
5. Yoshida, B. A., Sokoloff, M. M., Welch, D. R. & Rinker-Schaeffer, C. W. 
Metastasis-suppressor genes: a review and perspective on an emerging field. J 
Natl Cancer Inst 92, 1717-1730, (2000). 
6. Gobeil, S., Zhu, X., Doillon, C. J. & Green, M. R. A genome-wide shRNA 
screen identifies GAS1 as a novel melanoma metastasis suppressor gene. 
Genes Dev 22, 2932-2940, (2008). 
7. Shoushtari, A. N., Szmulewitz, R. Z. & Rinker-Schaeffer, C. W. 
Metastasis-suppressor genes in clinical practice: lost in translation? Nat Rev Clin 
Oncol 8, 333-342, (2011). 
8. Steeg, P. S. Metastasis suppressors alter the signal transduction of 
cancer cells. Nat Rev Cancer 3, 55-63, (2003). 
9. Rodriguez, L. G., Wu, X. & Guan, J. L. Wound-healing assay. Methods 
Mol Biol 294, 23-29, (2005). 
10. Chen, H. C. Boyden chamber assay. Methods Mol Biol 294, 15-22, (2005). 
11. Xie, Y. et al. A microchip-based model wound with multiple types of cells. 
Lab Chip 11, 2819-2822, (2011). 
12. Irimia, D., Charras, G., Agrawal, N., Mitchison, T. & Toner, M. Polar 
stimulation and constrained cell migration in microfluidic channels. Lab Chip 7, 
1783-1790, (2007). 
13. Shin, M. K., Kim, S. K. & Jung, H. Integration of intra- and extravasation in 
one cell-based microfluidic chip for the study of cancer metastasis. Lab Chip 11, 
3880-3887, (2011). 
14. Yan, J. & Irimia, D. Stochastic variations of migration speed between cells 
in clonal populations. Technology (Singap World Sci) 2, 185-188, (2014). 
15. Desai, S. P., Bhatia, S. N., Toner, M. & Irimia, D. Mitochondrial localization 
and the persistent migration of epithelial cancer cells. Biophys J 104, 2077-2088, 
(2013). 
16. Bajpai, S., Mitchell, M. J., King, M. R. & Reinhart-King, C. A. A microfluidic 
device to select for cells based on chemotactic phenotype. Technology (Singap 
World Sci) 2, 101-105, (2014). 
17. Irimia, D. & Toner, M. Spontaneous migration of cancer cells under 
conditions of mechanical confinement. Integr Biol (Camb) 1, 506-512, (2009). 
18. Mak, M., Reinhart-King, C. A. & Erickson, D. Microfabricated physical 
spatial gradients for investigating cell migration and invasion dynamics. PLoS 
One 6, e20825, (2011). 
 62 
 
19. Gallego-Perez, D. et al. Microfabricated mimics of in vivo structural cues 
for the study of guided tumor cell migration. Lab Chip 12, 4424-4432, (2012). 
20. Ko, Y. G., Co, C. C. & Ho, C. C. Gradient-free directional cell migration in 
continuous microchannels. Soft Matter 9, 2467-2474, (2013). 
21. Chung, S. et al. Cell migration into scaffolds under co-culture conditions in 
a microfluidic platform. Lab Chip 9, 269-275, (2009). 
22. De Cock, L. J. et al. Engineered 3D microporous gelatin scaffolds to study 
cell migration. Chem Commun (Camb) 48, 3512-3514, (2012). 
23. Chaw, K. C., Manimaran, M., Tay, E. H. & Swaminathan, S. Multi-step 
microfluidic device for studying cancer metastasis. Lab Chip 7, 1041-1047, 
(2007). 
24. Kaji, H., Yokoi, T., Kawashima, T. & Nishizawa, M. Controlled cocultures 
of HeLa cells and human umbilical vein endothelial cells on detachable 
substrates. Lab Chip 9, 427-432, (2009). 
25. Jeon, J. S., Zervantonakis, I. K., Chung, S., Kamm, R. D. & Charest, J. L. 
In vitro model of tumor cell extravasation. PLoS One 8, e56910, (2013). 
26. Culligan, K. et al. A detailed appraisal of mesocolic lymphangiology - an 
immunohistochemical and stereological analysis. J Anat 225, 463-472, (2014). 
27. Zhong, S. Q., Xu, Y. D., Zhang, Y. F., Hai, L. S. & Tang, F. C. Three-
dimensional structure of lymphatics in rabbit stomach. World J Gastroenterol 4, 
550-552, (1998). 
28. Nakayama, A., Ogawa, A., Fukuta, Y. & Kudo, K. Relation between 
lymphatic vessel diameter and clinicopathologic parameters in squamous cell 
carcinomas of the oral region. Cancer 86, 200-206, (1999). 
29. Altschuler, S. J. & Wu, L. F. Cellular heterogeneity: do differences make a 
difference? Cell 141, 559-563, (2010). 
30. Magee, J. A., Piskounova, E. & Morrison, S. J. Cancer stem cells: impact, 
heterogeneity, and uncertainty. Cancer Cell 21, 283-296, (2012). 
31. Negrini, S., Gorgoulis, V. G. & Halazonetis, T. D. Genomic instability--an 
evolving hallmark of cancer. Nat Rev Mol Cell Biol 11, 220-228, (2010). 
32. Hong, S., Pan, Q. & Lee, L. P. Single-cell level co-culture platform for 
intercellular communication. Integr Biol (Camb) 4, 374-380, (2012). 
33. Zheng, C. et al. Live cell imaging analysis of the epigenetic regulation of 
the human endothelial cell migration at single-cell resolution. Lab Chip 12, 3063-
3072, (2012). 
34. Kraning-Rush, C. M., Carey, S. P., Lampi, M. C. & Reinhart-King, C. A. 
Microfabricated collagen tracks facilitate single cell metastatic invasion in 3D. 
Integr Biol (Camb) 5, 606-616, (2013). 
35. Mak, M. & Erickson, D. Mechanical decision trees for investigating and 
modulating single-cell cancer invasion dynamics. Lab Chip 14, 964-971, (2014). 
36. Pushkarsky, I. et al. Automated single-cell motility analysis on a chip using 
lensfree microscopy. Sci Rep 4, 4717, (2014). 
37. Stroka, K. M. et al. Water permeation drives tumor cell migration in 
confined microenvironments. Cell 157, 611-623, (2014). 
 63 
 
38. Rosenthal, D. T. et al. p38gamma promotes breast cancer cell motility and 
metastasis through regulation of RhoC GTPase, cytoskeletal architecture, and a 
novel leading edge behavior. Cancer Res 71, 6338-6349, (2011). 
39. Frimat, J. P. et al. A microfluidic array with cellular valving for single cell 
co-culture. Lab Chip 11, 231-237, (2011). 
40. Tan, W. H. & Takeuchi, S. A trap-and-release integrated microfluidic 
system for dynamic microarray applications. Proc Natl Acad Sci U S A 104, 
1146-1151, (2007). 
41. Chen, Y. C. et al. Paired single cell co-culture microenvironments isolated 
by two-phase flow with continuous nutrient renewal. Lab Chip 14, 2941-2947, 
(2014). 
42. Joyce, J. A. & Pollard, J. W. Microenvironmental regulation of metastasis. 
Nat Rev Cancer 9, 239-252, (2009). 
43. Kakinuma, T. & Hwang, S. T. Chemokines, chemokine receptors, and 
cancer metastasis. J Leukoc Biol 79, 639-651, (2006). 
44. Koizumi, K., Hojo, S., Akashi, T., Yasumoto, K. & Saiki, I. Chemokine 
receptors in cancer metastasis and cancer cell-derived chemokines in host 
immune response. Cancer Sci 98, 1652-1658, (2007). 
45. Walker, G. M. et al. Effects of flow and diffusion on chemotaxis studies in 
a microfabricated gradient generator. Lab Chip 5, 611-618, (2005). 
46. Scarpino, S. et al. Hepatocyte growth factor (HGF) stimulates tumour 
invasiveness in papillary carcinoma of the thyroid. J Pathol 189, 570-575, (1999). 
47. Wei, W., Kong, B., Yang, Q. & Qu, X. Hepatocyte growth factor enhances 
ovarian cancer cell invasion through downregulation of thrombospondin-1. 
Cancer Biol Ther 9, 79-87, (2010). 
48. Yang, J. & Weinberg, R. A. Epithelial-mesenchymal transition: at the 
crossroads of development and tumor metastasis. Dev Cell 14, 818-829, (2008). 
49. Kalluri, R. & Weinberg, R. A. The basics of epithelial-mesenchymal 
transition. J Clin Invest 119, 1420-1428, (2009). 
50. Nieto, M. A. The ins and outs of the epithelial to mesenchymal transition in 
health and disease. Annu Rev Cell Dev Biol 27, 347-376, (2011). 
51. Rosenthal, D. T. et al. RhoC impacts the metastatic potential and 
abundance of breast cancer stem cells. PLoS One 7, e40979, (2012). 
52. Kleer, C. G. et al. RhoC-GTPase is a novel tissue biomarker associated 
with biologically aggressive carcinomas of the breast. Breast Cancer Res Treat 
93, 101-110, (2005). 
53. Qi, X. et al. p38gamma mitogen-activated protein kinase integrates 
signaling crosstalk between Ras and estrogen receptor to increase breast cancer 
invasion. Cancer Res 66, 7540-7547, (2006). 
54. Lehman, H. L. et al. Regulation of inflammatory breast cancer cell invasion 
through Akt1/PKBalpha phosphorylation of RhoC GTPase. Mol Cancer Res 10, 
1306-1318, (2012). 
55. Pfaffl, M. W., Horgan, G. W. & Dempfle, L. Relative expression software 
tool (REST) for group-wise comparison and statistical analysis of relative 
expression results in real-time PCR. Nucleic Acids Res 30, e36, (2002). 
 
 64 
 
Chapter 3 
Macrophages Enhance Migration in Inflammatory Breast Cancer 
Cells via RhoC GTPase Signaling 
 
Chapter Summary 
In addition to discerning genetic molecular drivers of metastasis as in Chapter 2, 
it is equally important to characterize environmental cues that may stimulate 
potential metastatic cells and trigger them to bypass a metastatic sieve.  A tumor 
does not grow in isolation; it is surrounded by non-cancerous stroma and also an 
infiltration of immune cells.  Some of these immune cells are macrophages, 
termed tumor-associated macrophages, and have been shown to have a pro-
tumorigenic and pro-metastatic effect.  In this work, we study the effect of 
macrophage-conditioned media on inflammatory breast cancer.  This is a rare 
and very aggressive subset of breast cancer nearly metastatic from its inception.  
We demonstrate that inflammatory breast cancer cells are hyper-responsive to 
macrophage-conditioned media, which stimulates an extreme migratory 
phenotype.  We found that interleukins -6, -8, and -10 within the macrophage 
media are sufficient to induce this effect individually and that a Ras-homology 
GTPase is necessary for the extreme migration. 
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Introduction 
Inflammatory breast cancer (IBC) is a rare and very aggressive form of breast 
cancer with the poorest prognosis1-4.  IBC is characterized by a rapid onset – 
within 6 months by definition – of symptoms comprising breast erythema, edema 
which may cause a peau d’orange appearance of the overlying skin, and 
occasional ulceration1-3.  A definitive diagnosis of IBC is made with these clinical 
symptoms and timeline coupled with pathologic confirmation of invasive 
carcinoma3.  Although IBC has a low incidence (about 2% in the United 
States1,2,4), it is the most lethal form of breast cancer with a median survival of 3 
years compared to >10 years for other non-inflammatory breast cancers4-6.  A 
key characteristic of inflammatory breast cancer distinguishing it from non-
inflammatory breast cancers (nIBC) is IBC’s propensity for near immediate 
metastasis.  About two-thirds of IBC patients present with lymph node 
involvement and one-third of patients already have distant metastasis at initial 
diagnosis1,2,5,6.  The survival curves for metastatic nIBC and non-metastatic IBC 
are nearly identical the first five years post diagnosis, further highlighting IBC’s 
characteristic lethality and rapid metastasis7. 
 
Many genetic profiling studies have been conducted to try and discern the 
specific differences between IBC and nIBC that drive the dramatic disparity in 
mortality8-12.  However, the overarching conclusion of these studies is that no 
tumor molecular signature can be considered conclusive to adequately 
distinguish IBC and nIBC2,8.  The 5 molecular subtypes of nIBC  (luminal A, 
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luminal B, basal-like, HER2-enriched, and normal-like) are also represented in 
IBC and IBC patients have a poor prognosis regardless of the subtype5,6,10,13,14.   
A recent study determined that initial findings in differential gene expression 
between IBC and nIBC was in fact due to a difference in proportion of the 5 
subtypes (IBC has fewer Luminal A and greater HER2-enriched cancers); when 
they directly compared subtypes, all IBC vs. nIBC expression differences 
disappeared10.  Yet another study looked at histologic features in nIBC that can 
predict patient outcomes and found the markers had no such predictive effect in 
IBC leading the authors to conclude that IBC has a distinct biological behavior15.  
One of the few proteins that is continuously found to be differentially expressed 
between IBC and nIBC is the Ras homology GTPase isoform, RhoC16-19.  Rho 
proteins are involved in the actin cytoskeleton turnover and are important for cell 
motility20-22.  Rho GTPases also signal to a variety of downstream effectors to 
influence cell survival and proliferation20,21.  While it is not a wholly specific 
marker for IBC as it is expressed in some late stage nIBCs due to its general 
importance in cancer cell migration23,24, RhoC is overexpressed in over 90% of 
IBC cancers and has been shown to be a driver of IBC metastasis18,19,25-27. 
 
The focus on tumor-intrinsic features such as gene expression and the recent 
finding of a stromal gene signature associated with IBC have yielded helpful, but 
limited, explanatory power for the particularly aggressive nature of IBC28.  Thus, 
we hypothesized that perhaps a tumor-extrinsic factor might further explain the 
differences in behavior of IBC and nIBC.  Knowing the importance of the immune 
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components in the tumor microenvironment, we sought to determine if tumor-
associated macrophages (TAMs) could promote IBC’s extreme metastatic 
nature.  TAMs have been shown to have a wide range of pro-tumor effects in 
many cancers including supporting angiogenesis, promotion of tumor cell 
invasion and migration, suppressing antitumor responses, and even promoting 
metastasis29-32. 
 
In this work, we show that the IBC cell lines SUM149 and SUM190 are hyper-
responsive to macrophage-conditioned media as compared to the normal-like 
MCF10A breast cell line and the aggressive nIBC MDA-MB-231 breast cancer 
cell line.  We further interrogate the enhanced IBC migratory phenotype to 
macrophage-conditioned media using a microfluidic migration device that allows 
for individual cell positional information yielding insights into the specific 
migration pattern.  We determined that interleukins -6, -8, and -10 within the 
macrophage-conditioned media are sufficient to stimulate this enhanced IBC 
migration.  Furthermore, we found that the known metastatic oncogene, RhoC 
GTPase, is necessary for the enhanced migration response and for the 
macrophage-conditioned media activation of the mitogen-activated protein kinase 
(MAPK) cascade. 
 
Results 
Macrophage-conditioned media enhances IBC migration 
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The normal-like MCF10A, aggressive non-inflammatory breast cancer MDA-MB-
231, and inflammatory breast cancer SUM190 and SUM149 cell lines were 
evaluated for their migration potential to serum and macrophage-conditioned 
media (MCM) in transwell migration chambers.  MCM was generated from 
phorbol 12-myristate 13-acetate (PMA) differentiated U937 cells as described in 
the methods section.  MCF10A and MDA-MB-231 cells did not migrate more than 
the negative control (serum free media in the top and bottom chambers, SFM – 
SFM) when exposed to MCM in the bottom chamber (SFM – MCM) or both 
chambers (MCM – MCM) (columns 1, 2 and 3) (Fig. 3.1 A,B).  The two cell lines 
had similar migration toward a serum gradient in the presence or absence of 
MCM (columns 4 and 5) (Fig. 3.1 A, B).  In contrast, the IBC cell line, SUM190, 
was more motile merely in the presence of MCM without a concentration gradient 
(column 2) and MCM induced an eight-fold greater increase in migration over the 
10% serum gradient positive control (column 5) (Fig. 3.1 C).  SUM149 cells also 
were more responsive to the MCM than were MCF10A or MDA-MB-231 cells.  
SUM149 cells had significantly enhanced migration toward an MCM gradient and 
were more motile in the presence of MCM stimulation over SFM negative control 
(columns 2 and 3) (Fig. 3.1 D).  Representative transwell migration membranes 
for each cell line and condition are shown in Figure 3.S1. 
 
Given that the IBC cell lines were more responsive to the MCM than the non-IBC 
cell lines, we next sought to understand if a certain subpopulation of the IBC cells 
was responsible for this behavior.  In order to facilitate the tracking of individual 
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cell migration paths, we utilized a microfluidic migration device with a series of 
horizontal migration channels that allowed us to determine single cell positional 
information throughout the migration experiment (Fig. 3.S2).  In these devices, a 
passive diffusion concentration gradient can be generated from the left side of 
the device to the right side by loading the experimental media into the left and 
right reservoirs, respectively (Fig. 3.S2 B), much like the top and bottom 
chambers of a transwell assay.  Cells are loaded down the left side of the device 
and then attracted to migrate toward the right side where there is a higher 
concentration of soluble factors.  Using the microfluidic devices, we discovered 
that the increase in migration was not due to undirected increased chemomotility 
as might have been suggested by the transwell assays (MCM – MCM not 
different from SFM – SFM), but in fact due to a statistically significant enhanced 
capability of both SUM190 and SUM149 IBC cells to chemotax about twice the 
distance toward the serum gradient in the presence of MCM stimulation (MCM – 
MCM+10% serum greater than SFM – 10% serum) (Fig. 3.2 A, B).  This 
distinction was likely only possible through having migration distance information 
on a per-cell basis rather than the binary output of a transwell assay.  SUM190 
and SUM149 cells also respectively migrated 1.3 and 1.5 times further toward an 
MCM gradient than toward the 10% serum gradient controls demonstrating that 
the MCM could also act as a chemoattractant (Fig. 3.2 A, B).  A closer inspection 
of the distribution of cell migration distances reveals that this effect stems from 
two subpopulations of the IBC cell lines (Fig. 3.2 C, D).  In the SFM – MCM 
conditions, a bimodal distribution of approximately equal percentages of cells is 
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apparent comprising of non-migratory cells (defined as those cells migrating less 
than the SFM – SFM average distance) and extreme migratory cells (defined as 
those cells migrating further than the SFM – 10% serum average distance) (Fig. 
3.2 C, D).  These two groups account for the vast majority, about 80 – 90%, of all 
the IBC cells.  The significantly enhanced chemotaxis in the MCM – MCM+10% 
serum groups is subsequently explained then by the presence of the MCM on the 
left side of the device stimulating all the cells at the starting location which 
prompts the conversion of the non-migratory cell population into extreme 
migratory cells.  In SUM149 cells, the non-migratory cell percentage dropped 
from 40% of the population to 10% and the extreme migrators increased 
proportionately from 50% to 80% when comparing the SFM – MCM and MCM – 
MCM+10% serum conditions (Fig. 3.2 D).  While not as pronounced, a similar 
trend of a decreasing percentage of non-migratory and a proportionate 
increasing percentage of extreme migratory cells was seen in the SUM190 cells 
as well (Fig. 3.2 C).  This led us to conclude that it was not necessarily a specific 
factor in the conditioned media acting as the chemoattractant leading to enhance 
migration in the MCM – MCM+10% serum groups, but that the cytokine milieu 
might serve to “prime” the IBC cells’ cellular machinery in order to become hyper-
responsive to the serum chemoattractant. 
 
Interleukins -6, -8, and -10 are sufficient to enhance IBC migration 
In order to determine what molecular components of the macrophage-
conditioned media were effecting the enhanced migration of the IBC cells, we 
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profiled the MCM and media conditioned by SUM190 and SUM149 cells using a 
bead-based 27-plex ELISA.  The concentrations of selected cytokines are plotted 
in Figure 3.3 A and B with all 27 cytokines shown in Figure 3.S3 A.  The first 
column represents the PMA-differentiated U937 MCM.  The second and fourth 
columns show the basal secretion of cytokines by unstimulated SUM190 and 
SUM149 cells, respectively.  The third and fifth columns represent SUM190 and 
SUM149 cells stimulated with MCM.  In accordance with prior findings33, we 
found that SUM149 cells basally secrete high amounts (77 ng/mL) of interleukin 
(IL) -8.  Interestingly, in the presence of MCM, SUM190 and SUM149 cells were 
both stimulated to produce chemokine C-C motif ligand 5 (CCL5), IL-6, vascular 
endothelial cell growth factor  (VEGF), and chemokine C-C motif ligand 2  
(CCL2) (Fig. 3.3 A, B).  The concentrations of these cytokines increased over the 
levels found in the MCM and the only cellular production source were the IBC 
cells themselves for these conditions. 
 
Cytokines IL-8, tumor necrosis factor α (TNFα), CCL5, IL-6, VEGF, CCL2, and 
IL-10 were selected based on their high concentrations and suspected 
involvement in non-inflammatory breast cancer for transwell migration screening 
of enhanced migration34.  For each cytokine, a no gradient control (equal 
concentrations of the cytokine in the top and bottom chambers: cytokine – 
cytokine) and a serum-spiked condition (cytokine – cytokine+10% serum) 
mimicking the MCM – MCM+10% serum condition were performed.  Cytokines 
were used at similar concentrations as those measured in the MCM.  In SUM190 
 72 
 
cells, although all the tested cytokines trended toward increasing migration, only 
IL-6, IL-8, and IL-10 induced statistically significantly enhanced migration over 
the SFM – 10% serum control (Fig. 3.3 C).  As SUM190 transwell migration was 
a good predictor of the microfluidic migration behavior (Fig. 3.1 and 3.2), these 
three cytokines were further profiled in the microfluidic devices.  IL-6 and IL-10 
stimulation of SUM149 cells also increased their migration over SFM – 10% 
serum control, although the effect was not statistically significant (Fig. 3.S3 B). 
 
All three cytokines tested – IL-6, IL-8, and IL-10 – significantly enhanced 
migration over 10% serum gradient controls across both IBC cell lines in the 
microfluidic migration devices (Fig. 3.3 D, E). While the fold increase in migration 
was moderate at about 1.5 times that of the 10% serum condition for each 
cytokine, it was robust enough that in SUM149 cells the IL6 – IL6+10% serum 
condition there was no statistically significant difference from the MCM – 
MCM+10% serum condition and in SUM190 cells none of the cytokine – 
cytokine+10% serum conditions were statistically different from the MCM – 
MCM+10% serum condition (Fig. 3.3 D, E). 
 
RhoC GTPase is necessary for the IBC extreme migration and MCM activation of 
the MAPK cascade 
Given that RhoC GTPase has been shown to be a key driver of IBC metastasis 
in in vivo models26 and it is differentially expressed between IBC and nIBC 
tumors across studies16,17,19, we hypothesized that RhoC might play a role in the 
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enhanced migration response of IBC to the MCM.  In support of this, both IBC 
cell lines, SUM190 and SUM149, had an increase in RhoC expression after 
stimulation with MCM while there was no change in RhoC expression in either 
MCF10A or MDA-MB-231 cell lines (Fig. 3.4 A).  To further test the function of 
RhoC, we generated a CRISPR construct targeting RhoC to knockout the gene 
in both SUM149 (149crRhoC) and SUM190 (190crRhoC) cell lines (Fig. 3.4 B).  
The knockout was specific to RhoC and did not have an effect on the expression 
of the closely related RhoA GTPase (Fig. 3.4 B).  As seen in Figures 3.4 C and 
D, knocking out RhoC specifically and completely abolished the extreme 
migration of the MCM – MCM+10% serum condition in both 149crRhoC and 
190crRhoC cells in the microfluidic migration assay.  Verifying that the CRISPR 
RhoC effect was specific to the MCM enhanced migration and did not simply 
abrogate all migration, the 149crRhoC and 190crRhoC cells were still able to 
migrate to the 10% serum gradient as robustly as wildtype SUM149 and SUM190 
(Fig. 3.S4). 
 
The mitogen-activated protein kinase (MAPK) pathway has previously been 
shown to be important in RhoC signaling and therefore we investigated its role in 
MCM induced IBC cell migration18.  MCM stimulation of wildtype SUM190 and 
SUM149 induces phosphorylation and activation of MEK, MAPK, and p38 (Fig. 
3.5).  In 149crRhoC cells, stimulation with MCM fails to phosphorylate any of 
these proteins in the absence of RhoC (Fig. 3.5).  In 190crRhoC cells, MEK and 
MAPK are still activated in the absence of RhoC while p38 phosphorylation is 
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abrogated (Fig. 3.5).  STAT3 phosphorylation also increases in both SUM190 
and SUM149 cells with stimulation by MCM and its phosphorylation abrogated in 
the absence of RhoC. 
 
Discussion 
Many studies have sought to understand the genetic determinants of the IBC 
phenotype8-10,15.  The research has demonstrated, however, IBC’s genetic 
heterogeneity and molecular subtype similarity to nIBC and has failed to discover 
an IBC-specific genetic profile2,10.  This led us to conjecture that factors extrinsic 
to the cancer cells themselves might explain IBC’s pronounced metastatic 
propensity and tested whether tumor-associated macrophages could be 
contributing to the disease.  A similar view, in accordance with our hypothesis, 
that breast parenchymal biology – altered by breastfeeding, pregnancy, and 
body-mass index – might provide the proper “soil” for IBC to flourish was also 
recently posited7. 
 
In this study, we found that two IBC cell lines, SUM190 and SUM149, were 
hyper-responsive to macrophage-conditioned media as compared to the normal-
like MCF10A and nIBC MDA-MB-231 cell lines.  To analyze this behavior further, 
we designed a microfluidic migration device that allowed us to follow individual 
cells and glean the precise magnitude of their response, something not possible 
with a traditional transwell assay.  We demonstrated that stimulating the IBC cells 
with MCM enhances their migration to a serum gradient double that of the MCM-
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unstimulated cells.  The MCM itself is not the cue for the increased migration per 
se as in the extreme migratory condition there is no gradient to factors in the 
MCM, and the MCM – MCM condition alone did not increase migration over the 
SFM – SFM negative control.  Therefore, we purport that components of the 
macrophage-conditioned media serve to “prime” the IBC cells in order to become 
hyper-responsive and extremely migratory when they do receive the directional 
chemoattractant signal from the serum gradient.  Our microfluidic migration 
devices also allowed us to discern that within SUM190 and SUM149, there exists 
a population of cells that are intrinsic extreme migrators to an MCM gradient.  
Upon stimulation with MCM on both sides of the device, thus removing this 
gradient, and superimposing a serum gradient (MCM – MCM+10% serum), many 
of the previous would-be non-migratory cells were converted to extreme 
migratory cells. 
 
When we profiled the secreted factors in the macrophage-conditioned media and 
screened them for increasing the IBC migration potential, we found that 
interleukins -6, -8, and -10 alone were sufficient to recapitulate the enhanced 
migration effect.  When exposed to a non-gradient condition for these cytokines 
superimposed with a serum gradient (cytokine – cytokine+10% serum), both 
SUM190 and SUM149 had significantly increased migration over the serum 
gradient control alone (SFM – 10% serum).  While significant, this increase in 
migration was more modest compared to the doubling of migration seen with the 
total MCM.  Likely this is due a mixture of cytokines found in the MCM acting in 
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concert to induce the extreme migration effect.  However, the combinatorics of 
27+ factors found in the MCM precluded experimentation.  Our finding that these 
three cytokines – IL-6, IL-8, and IL-10 – might contribute to IBC’s metastatic 
phenotype is in agreement with another study that showed in a canine model of 
IBC tissue homogenate levels of IL-6, IL-8, and IL-10 were significantly higher 
than in canine nIBC35.  Furthermore, in nIBC, patient serum levels of IL-6, IL-8, 
and IL-10 all increase with increasing stage supporting their association with 
invasion and metastasis34,36. 
 
Our results are also in keeping with other recent studies that profiled the effect of 
macrophages on inflammatory breast cancer37-39.  One group studied the 
epithelial-mesenchymal transition in IBC cell lines and found IL-6 to be one 
essential driver of the transition as measured by qRT-PCR of a standard gene 
panel37.  A second group in a series of experiments investigated the effect of 
conditioned media from undifferentiated U937 cells on SUM149 and later isolated 
CD14+ leukocytes directly from the draining blood vessels supplying IBC and 
nIBC tumors during surgery38,39.  This patient-based study showed that not only 
do IBC patients have greater staining in tumor sections for CD14+ monocytes, 
but that IL-8 and IL-10 were among the cytokines significantly differently 
expressed between IBC and nIBC macrophages38. 
 
We now add to this nascent body of work investigating the role of the 
microenvironment on IBC our own results utilizing two IBC cell lines and yield 
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insights into how the macrophage-secreted cytokines may be functioning.  
Rather than acting as bona fide chemoattractants themselves, we propose that 
the macrophage-conditioned media – and in it IL-6, IL-8, and IL-10 – “prime” the 
IBC cells to have a magnified migration response by increasing the expression of 
RhoC.  Furthermore, we demonstrated a necessity for RhoC GTPase for the 
MCM-induced enhanced migration in both SUM190 and SUM149 and suggest it 
likely mediates the effect by signaling through the MAPK cascade.  Using 
CRISPR RhoC knockouts of the IBC cell lines, the increased migration in the 
MCM – MCM+10% serum condition is completely abrogated and the CRISPR 
cell lines migrate no further than they do to SFM – 10% serum.  MCM also 
increases phosphorylation of components of the MAPK pathway and STAT3 in 
both SUM190 and SUM149 cells.  This pathway activation is completely 
abrogated in SUM149 cells in the absence of RhoC.  In 190crRhoC cells, MAPK 
and MEK remained activated when treated with MCM, but p38 and STAT3 
signaling are abolished.  SUM190 cells have HER-2 overexpression and 
therefore may require minimal signal to initiate signal transduction in this pathway 
accounting for the differential signaling between SUM190 and SUM149 cells40.  
IBC is a heterogeneous disease as demonstrated by the difference in signaling 
between SUM190 and SUM149 cells. Yet while the precise patterns of 
phosphorylation and activation might differ between the two cell lines, the two 
IBC cell lines share the commonality of enhanced migration to macrophage-
secreted cytokines through the common node of RhoC.  Thus, our work reveals 
both a role for the microenvironment in tumor-associated macrophage secreted 
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cytokines and suggests RhoC as a potential target for therapeutic intervention 
aimed at preventing the metastasis of inflammatory breast cancer. 
 
Materials and Methods 
Cell culture 
SUM149 and SUM190 cells were maintained in Ham’s F-12 w/L-glutamine 
(Fisher Scientific) containing 0.5 μg mL-1 Fungizone, 5 μg mL-1 Gentamicin, 100 
units mL-1 penicillin, and 100 μg mL-1 streptomycin (all Invitrogen).  Additionally, 
SUM149 cells were supplemented with 5% fetal bovine serum, 5 μg mL-1 Insulin 
and 1 μg mL-1 Hydrocortisone (Sigma-Aldrich).  SUM190 cells were 
supplemented with 0.1% bovine serum albumin, 5 μg mL-1 Insulin and 1 μg mL-1 
Hydrocortisone (Sigma-Aldrich).  MDA-MB-231 cells were cultured in RPMI with 
10% FBS and 1% penicillin/streptomycin.  SUM149 and SUM190 cells were 
maintained at 37ºC with 10% CO2 and all other cell lines at 37ºC with 5% CO2.  
Fresh 0.25% trypsin-EDTA in phosphate buffered saline (PBS) was used to re-
suspend cells. 
 
CRISPR cell line generation 
SUM149 and SUM190 cell lines were transfected using the Nucleofector II 
system (Lonza) with pSpCas9(BB)-2A-GFP (PX458), which was a gift from Feng 
Zhang (Addgene plasmid # 48138), containing the target sequence 
AGGAAGACTATGATCGACTG against RhoC.  Two days after transfection, 
single cells were sorted for GFP expression into 96 well plates.  Following clonal 
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expansion, genomic DNA was isolated and clones were screened for RhoC 
mutations using SURVEYOR reactions (IDT) with the following primer pair: 
Forward-CTGTCTTTGCTTCATTCTCCCT and Reverse-
CCAGAGCAGTCTTAGAAGCCAT.  Positive clones were sequenced to identify 
specific mutational events and immunoblotted for RhoC and RhoA. 
 
U937 differentiation and macrophage-conditioned media preparation 
U937 cells were differentiated to macrophages as reported previously41,42.  
Briefly, 100 ng/mL of phorbol-12-myris-tate-12-acetate (PMA) (Thermo Fisher, 
BP685) was added to U937 cells in complete growth medium for 24 hours.  
Then, the differentiated U937 cells were rinsed and serum-free media (SFM) 
added and collected after another 24 hours.  This macrophage-conditioned 
media was then centrifuged and concentrated using Amicon Ultra 3K filters (EMD 
Millipore, UFC900324) at 4C and rediluted with fresh SFM. 
 
Transwell migration assay 
Corning Costar Transwell supports (Corning, 3422) were used according the 
manufacturer’s protocol.  After trypsinization and counting, cells were aliquoted 
and resuspended in the appropriate media for the top insert and plated at 25,000 
cells per insert.  After incubation at 37C at either 5% or 10% CO2 for 24 hours, 
the inserts were removed and the top layer wiped with a cotton swab.  Then the 
cells were fixed and stained with crystal violet.  Images were taken at 2X of the 
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entire migration area and the area of purple color extracted from each image and 
used as a surrogate for cell number. 
 
Microfluidic device fabrication and assembly 
The migration devices were formed from a single layer of PDMS 
(polydimethlysiloxane), which was fabricated on a silicon substrate by standard 
soft lithography, and a glass slide. Channel widths were 40 µm and channel 
height was 10 µm. The PDMS layer was bonded to the glass slide after activation 
by oxygen plasma treatment (80 Watts, 60 seconds) to form a complete fluidic 
channel. Before cell loading, collagen I (BD Biosciences, 354236) solution 
(1.45mL collagen, 0.1mL acetic acid in 50mL deionized water) was flowed 
through the device for 18-24 hours in a tissue culture incubator to coat collagen 
on the substrate to enhance cell adhesion. Devices were then rinsed with HBSS 
for approximately one hour to remove the residual collagen solution before use. 
 
Microfluidic migration assay 
After rinsing the collagen coating, 100 µL of cells were loaded into the top left 
reservoir at 400,000 cells per mL and allowed to flow down the left vertical 
channel and align at the entrances to the horizontal migration channels.  
Residual cells were vacuumed and then rinsed away from the top left reservoir 
and complete culture medium added to all four reservoirs in a “no flow” condition 
for 6 hours to allow the cells to adhere to the migration device.  After, the 
complete media was removed and serum-free media flowed over the attached 
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cells for approximately one hour.  Then, the top left and right inlet reservoirs were 
changed to the appropriate media conditions and 0 hour images captured.  The 
device was placed in a tissue culture incubator for 24 hours and the final 
migration images captured.  Cell migration distance was calculated as the 
difference in horizontal position between the 24 hour and 0 hour images. 
 
Measurement of cytokines in conditioned media 
The Bioplex Pro Human Cytokine 27-plex assay (Biorad, M500KCAF0Y) was 
used to measure cytokine concentrations in the specified media per the 
manufacturer’s protocol.  Washing was carried out utilizing a handheld magnetic 
plate holder and plates were read on a Bioplex MAGPIX (Biorad) machine. 
 
Immunoblotting 
Cells were harvested in RIPA buffer (Thermo Scientific) with protease and 
phosphatase inhibitors (Roche Diagnostics).  Immunoblotting was done after 
sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) on 
gradient 4-15% gels (Biorad) at 30 µg protein and transfer to polyvinylidene 
fluoride (PVDF) membranes.  All antibodies besides the secondary horseradish 
peroxidase-conjugated antibody (Santa Cruz Biotechnology) were purchased 
from Cell Signaling Technologies:  phospho-MAPK (Thr202/Tyr204), MAPK, 
phospho-p38 (Thr180/ Tyr182), p38, phospho- MEK (Ser 217/221), MEK, 
phospho- STAT3 (Tyr705 and Ser727), STAT3, RhoC, RhoA, ß-actin.  
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SuperSignal West Pico Luminol/Enchancer Solution was purchased from Thermo 
Scientific. 
 
Statistical Analysis  
Two-tailed, unpaired student’s t-tests were used for all comparisons with a 
significance level of 0.05 considered statistically significant.  In Figures, * refers 
to P < 0.05, ** to P < 0.01, and *** to P < 0.001. 
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Figure 3.1. Inflammatory breast cancer cells are hyper-responsive to 
macrophage conditioned media.  Transwell migration assays of (A) MCF10A, 
(B) MDA-MB-231, (C) SUM190, and (D) SUM149 cells.  MCF10A and MDA-MB-
231 migrated similarly to the SFM – SFM or SFM – 10% serum control conditions 
when exposed to the MCM.  SUM190 migrated 8-fold more when stimulated with 
MCM in conjunction with a serum gradient.  SUM149 was more migratory over 
the SFM – SFM condition when exposed to MCM – MCM or SFM – MCM.  The 
entire transwell membrane was imaged and the area of migrated cells calculated.  
All conditions were normalized to the SFM – 10% serum condition as 100% 
migration.  Error bars represent s.e.m. 
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Figure 3.2. Macrophage conditioned media induces extreme migration in 
inflammatory breast cancer cells.  Microfluidic migration device assays of (A) 
SUM190 and (B) SUM149 cells.  Both SUM190 and SUM149 had a 2-fold 
enhanced migration to the MCM – MCM+10% serum condition over SFM – 10% 
serum positive control.  For (C) and (D), SUM190 and SUM149 cells were 
separated into 3 groups: non-migratory were cells with a migration distance less 
than the SFM – SFM average distance, extreme migratory cells were those with 
a migration distance greater than the SFM – 10% serum average, and 
moderately migratory cells had distances between these averages.  The 
percentage of total cells for each group is plotted.  The MCM – MCM+10% serum 
condition stimulated non-migratory cells to become extreme migratory cells in 
SUM190 and SUM149.  Error bars represent s.e.m. 
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Figure 3.3. IL-6, IL-8, and IL-10 enhance inflammatory breast cancer 
migration.  The concentration of selected cytokines in different media conditions 
is plotted in (A) and (B).  The percent migration relative to the SFM – 10% serum 
condition for each cytokine stimulation conditions of SUM190 transwell migration 
is graphed in (C).  IL-6, IL-8, and IL-10 significantly increased SUM190 transwell 
migration.  In (D) and (E), microfluidic migration to cytokine conditions is plotted 
for SUM190 and SUM149 cells, respectively.  IL-6, IL-8, and IL-10 significantly 
enhanced migration in both cell lines over SFM – 10% serum control.  Error bars 
represent s.e.m. 
  
 86 
 
Figure 3.4. RhoC is necessary for the inflammatory breast cancer migration 
response to macrophage conditioned media.  (A) MCM increased the 
expression of RhoC in SUM190 and SUM149 but not in MCF10A or MDA-MB-
231 cells.  (B) Immunoblotting confirmation of CRISPR knockout of RhoC and not 
of RhoA.  In (C) and (D), microfluidic migration of the SUM190 and SUM149 
CRISPR RhoC knockout cell lines, respectively.  RhoC is necessary for the 
enhanced migration effect as MCM – MCM+10% serum migration is not different 
from SFM – 10% serum control.  Error bars represent s.e.m. 
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Figure 3.5. Macrophage conditioned media activates the MAPK cascade in 
inflammatory breast cancer cells.  Immunoblotting for the indicated phospho-
proteins and total proteins.  RhoC was necessary for the MCM-induced 
phosphorylation of MEK, MAPK, p38, and STAT3 in SUM149 cells and RhoC 
was necessary for the MCM-induced phosphorylation of p38 and STAT3 in 
SUM190 cells.  Immunoblots shown are representative of 3 separate 
experiments. 
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Figure 3.S1. MCF10A, MDA-MB-231, SUM190, and SUM149 transwell 
migration to macrophage-conditioned media.  Representative images of 
transwell membranes used to calculate percent migration for Figure 1.  Cells 
were stained with crystal violet and the area of purple color extracted from each 
image and used as a surrogate for cell number.  The area of each cell line’s SFM 
– 10% serum condition was used to normalize values. 
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Figure 3.S2. Schematic of the microfluidic migration device.  (A) Photograph 
of the microfluidic migration device depicting the 2 inlet (top) and 2 outlet 
(bottom) reservoirs.  The serpentine loading channels can be seen running 
vertically with the horizontal migration channels, too small to be appreciated 
here, running perpendicularly between them.  The device is bonded to a standard 
glass slide.  (B) and (C) are schematics of the migration channels and geometry.  
By loading different media conditions into the left and right inlet reservoirs, a 
diffusion gradient is created along the axis of the horizontal migration channels.  
(D) Photomicrographs of one channel and a migrating cell at the 0 hour and 24 
hour time points.  Migration distance was calculated as the difference between 
the 24 hour and 0 hour locations. 
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Figure 3.S3. Macrophage-conditioned media cytokines.  The concentration of 
all measured 27 cytokines in different media conditions is plotted in (A).  The 
U937 bar represents undifferentiated U937 monocyte conditioned media.  (B) 
The percent migration relative to the SFM – 10% serum condition for each 
cytokine stimulation conditions of SUM149 transwell migration.   
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Figure 3.S4. SUM149, 149crRhoC, SUM190, and 190crRhoC average 
microfluidic migration.  Average microfluidic migration distances for (A) 
SUM190 and 190crRhoC and (B) SUM149 and 149crRhoC cells.  SUM190 and 
190crRhoC cells did not migrate differently to SFM – 10% serum control, but the 
absence of RhoC in 190crRhoC cells completely abrogated the enhanced 
migration response to MCM – MCM+10% serum.  149crRhoC cells migrated 
further to the SFM – 10% serum condition than SUM149 cells.  This would have 
decreased the likelihood of finding a difference in the extreme migration 
condition, however the absence of RhoC still completely abrogated the enhanced 
migration effect in 149crRhoC cells. 
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Chapter 4 
Nanoroughened Adhesion-based Capture of Circulating Tumor 
Cells with Heterogeneous Expression and Metastatic 
Characteristics 
 
This chapter has been accepted for publication in BMC Cancer. 
 
Chapter Summary 
After cancer cells successfully intravasate, they enter the circulation.  At this 
state in the metastatic series of sieves, they are called circulating tumor cells 
(CTCs) and are relatively easy to access for study via a simple blood draw.  
However, the challenge resides in their isolation as they are by far the rarest cell 
found in whole blood.  Since intravasation and other metastatic sieves are 
mechanical in nature, in Chapter 4 we explore the possibility of harnessing 
physical property differences between the cancer cells and normal blood cells as 
a means for their capture.  CTCs have shown prognostic relevance in many 
cancer types.  However, the majority of current CTC capture methods rely on 
positive selection techniques that require a priori knowledge about the surface 
protein expression of disseminated CTCs, which are known to be a dynamic 
population.  We developed a microfluidic CTC capture chip that incorporated a 
nanoroughened glass substrate for capturing CTCs from blood samples.  Our 
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CTC capture chip utilized the differential adhesion preference of cancer cells to 
nanoroughened etched glass surfaces as compared to normal blood cells and 
thus did not depend on the physical size or surface protein expression of CTCs.  
The microfluidic CTC capture chip was able to achieve a superior capture yield 
for both EpCAM+ and EpCAM- cancer cells in blood samples.  Additionally, the 
microfluidic CTC chip captured CTCs undergoing TGF--induced epithelial to 
mesenchymal transition with dynamically down-regulated EpCAM expression.  In 
a mouse model of human breast cancer using EpCAM positive and negative cell 
lines, the number of CTCs captured correlated positively with the size of the 
primary tumor and was independent of their EpCAM expression.  Furthermore, in 
a syngeneic mouse model of lung cancer using cell lines with differential 
metastasis capability, CTCs were captured from all mice with detectable primary 
tumors independent of the cell lines’ metastatic ability. 
 
Introduction 
While progress has been made on the prevention and treatment of primary 
cancers, metastases to distant sites remain a major clinical challenge and the 
main cause of death for the majority of cancer patients 1.  Thus attention has 
shifted toward a better understanding of the metastatic process in order to 
address the mortality of patients with metastatic lesions.  The spread of cancer 
systemically relies upon the critical step of the hematogenous spread of cancer 
cells 2.  These circulating tumor cells (CTCs) in the bloodstream are shed from 
primary and metastatic lesions and are believed to be key agents in the 
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metastatic process 2-4.  Therefore, capturing CTCs is not only important to 
understand the determinants of the metastatic fate of cancer cells, but also 
directly yields clinically relevant information as studies on CTCs have shown a 
general, but not complete, negative association between CTC counts and clinic 
outcomes 5-7.  The challenge being as a tumor progresses through the metastatic 
series of sieves, cancer cells are known to express diverse molecular 
phenotypes in a dynamic fashion, which complicates the isolation of CTCs for 
further study 6,8-13.  Moreover, other cells such as fibroblasts and non-cancerous 
epithelial cells are also shed into the circulation further complicating the 
identification of the true potentially metastatic cells. 
 
The most widely used methods for CTC capture have relied upon tumors’ cell of 
origin and utilized antibodies against tissue specific surface markers, notably 
epithelial cell adhesion molecule (EpCAM), which is expressed by epithelial cells 
14-21.  However, numerous studies have demonstrated that the EpCAM antibody-
based positive selection method is imperfect, as EpCAM expression on cancer 
cells varies not only from patient to patient but also within the same patient over 
time 6,8,9,11,12.  Furthermore, studies have demonstrated that epithelial-specific 
markers are selectively partially or completely down-regulated over the course of 
tumor dissemination through the epithelial-to-mesenchymal transition (EMT) 10,13.  
Other CTC capture methods utilize size-based selection, as cancer cells are 
believed to be generally larger than hematopoietic and other shed cells and thus 
amenable to filtration or centrifugation.  However, CTCs of various sizes, 
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including some smaller than leukocytes, have been reported recently 22-24.  The 
major challenge of CTC isolation is the extreme rarity of CTCs, even in patients 
with advanced cancer.  This is especially evident when using negative selection 
techniques which deplete the undesired leukocyte population using antibodies 
against CD45, a leukocyte cell surface marker.  Thus, because of the rarity of 
CTCs, it is difficult for negative selection techniques alone to achieve satisfactory 
yields for CTC capture 25,26. 
 
Along the complex and dynamic progression through the series of metastatic 
sieves there is however an important point of convergence.  The intravasation 
step into blood vessels by certain cancer cells within a tumor is a mechanically 
focused process by its very nature, and only those cells capable of behaving in a 
precise biomechanical way will successfully enter the bloodstream as live cells 27-
29.  The mechanical phenotype of a cancer cell results from the integration of 
multidimensional and heterogeneous factors such as cell intrinsic genetic 
expression and epigenetic regulation and cancer cell extrinsic signals from 
cytokines, growth factors, and extracellular matrix proteins as well as interactions 
involving non-cancerous immune and stromal cells 27,30.  Given these complex 
inputs into the cancer cell phenotype, we set out to develop a method for CTC 
capture that does not rely upon any one single facet of this complex set of 
determinants, such as surface marker expression, but instead relies upon an 
output that reflects the integration of the multitude of signaling pathways 
experienced by a spreading cancer cell. 
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To this end, we developed a method that captures CTCs based on their 
differential capability to selectively adhere to a nanoroughened glass surface as 
compared to normal blood cells.  In our prior work 31, we described that a 
nanorough glass substrate generated by reactive-ion etching (RIE) without any 
positive-selection antibodies exhibits significantly improved cancer cell capture 
efficiency owing to enhanced adherent interactions between the nanoscale 
topological features on the glass substrate and the nanoscale cellular adhesion 
apparatus.  In our prior work, this nanoroughened glass substrate was employed 
to recover cancer cells spiked in blood samples, in a fixed device setting, with 
capture efficiencies of over 90% for different cancer cell lines 31.  Expanding on 
this proof-of-concept work, we hypothesized that further improvements in CTC 
capture performance and blood sample throughput could be achieved by using a 
confining microfluidic environment around the nanoroughened glass substrate to 
promote cell-substrate interactions for highly efficient CTC capture. 
 
Herein we introduce our new microfluidic CTC capture platform and demonstrate 
its utility in recovering cancer cells with heterogeneous molecular properties and 
those obtained from two mouse models of cancer.  Our microfluidic CTC capture 
platform integrates two functional components: 1) a RIE-generated 
nanoroughened glass substrate with nanoscale topological structures to enhance 
adherent interactions between the glass substrate and cancer cells, and 2) an 
overlaid polydimethylsiloxane (PDMS) chip with a low profile microfluidic capture 
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chamber that promotes CTC-substrate contact frequency.  In this work we 
showed that the microfluidic CTC capture chip could capture > 80% of breast and 
lung cancer cells spiked in whole blood samples independent of the cell lines’ 
EpCAM expression.  The microfluidic CTC capture chip also captured equally 
well A549 lung cancer cells in their epithelial- or mesenchymal-like state before 
and after transforming growth factor beta (TGF--induced EMT.  To further 
demonstrate the clinical utility of the microfluidic CTC capture chip, we collected 
whole blood from mice with breast cancer orthotopic xenografts and 
demonstrated excellent label-free CTC capture efficiency by the microfluidic CTC 
capture chip.  More importantly, in a syngeneic mouse model of lung cancer 
utilizing cell lines with known metastatic and non-metastatic capabilities, CTCs 
were detected in all the mice with a detectable primary tumor independent of the 
metastatic propensity of the cell line implanted. This highlights the fact that not all 
CTCs are capable of forming and proliferating as metastases and our newly 
developed microfluidic CTC capture device is able to recover this less 
metastatically potent population as well. 
 
Results 
Capture of cancer cells independent of surface protein expression 
We have recently developed a simple yet precisely controlled method to 
generate random nanoroughness on glass surfaces using reactive ion etching 
(RIE) 32.  RIE-based nanoscale roughening of glass surfaces is consistent with a 
process of ion-enhanced chemical reaction and physical sputtering 33.  In our 
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previous work, we have shown that bare glass surfaces treated with RIE for 
different periods of time can acquire different levels of roughness (as 
characterized by the root-mean-square roughness Rq; Rq = 1 - 150 nm) with a 
nanoscale resolution (Fig. 4.S1) 32.  To validate the efficiency of RIE-generated 
nanorough glass surfaces (Fig. 4.1 a) for the capture of cancer cells with different 
surface protein expression, three breast cancer cell lines, MCF-7 (EpCAM-
positive, or EpCAM+), SUM-149 (EpCAM+), and MDA-MB-231 (EpCAM-negative, 
or EpCAM-) 34-36 spiked in minute amounts in culture medium (1,000 cells in 1 mL 
medium) as single cells were injected into the microfluidic CTC capture chip with 
either a smooth glass surface (Rq = 1 nm) or a nanoroughened glass surface (Rq 
= 150 nm) for 30 min.  Quantitative analysis revealed that the capture yield of 
cancer cells, defined as the ratio of the number of cancer cells captured on the 
glass surface to the total number of cells initially seeded, was 85.7%, 80.9%, and 
86.5% for MCF-7, SUM-149, and MDA-MB-231, respectively, for the nanorough 
glass surface with Rq = 150 nm (Fig. 4.1 b).  In distinct contrast, experiments 
using the smooth glass surface with Rq = 1 nm showed drastically lower capture 
yields for MCF-7, SUM-149, or MDA-MB-231 cells (6.7% for MCF-7, 8.0% for 
SUM-149, and 8.7% for MDA-MB-231) (Fig. 4.1 b).  We further performed cell 
capture assays using the EpCAM+ A549 lung cancer cell line 37 and observed a 
similarly significant enhancement of cancer cell capture yield by the 
nanoroughened glass surface (Fig. 4.1 b). Together, our results in Fig. 4.1 
suggest a very strong propensity for cancer cells to adhere to RIE-generated 
nanorough glass surfaces regardless of the cells’ EpCAM expression status, and 
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further support a superior efficiency of the label-free nanoroughened glass 
substrate for capturing CTCs. 
 
Capture of cancer cells before and after TGF--induced epithelial-mesenchymal 
transition 
Through the metastatic process, tumor cells are posited to undergo an EMT, 
which alters adhesive surface protein expression along with many other aspects 
of cellular behaviors 38,39.  During this EMT, in addition to acquiring a migratory 
and invasive phenotype, tumor cells express mesenchymal proteins and 
concomitantly lose epithelial markers including the expression of EpCAM 40.  To 
demonstrate specifically that the capture of cancer cells by the RIE-generated 
nanorough glass substrate was independent of a cancer cell’s epithelial or 
mesenchymal state, we used the A549 cell culture model of TGF--induced EMT 
and spiked known quantities of pre- and post-EMT A549 cells (n = 40 - 10,000) 
into 500 µL lysed human blood (Fig. 4.2 a).  After culture with TGF- for 72 hr, 
A549 cells express significantly reduced levels of EpCAM mRNA (Fig. 4.S2) 41.  
Yet despite these lung cancer cells’ dynamic EpCAM expression, high capture 
yields were achieved when seeding the cells for 1 hr in the microfluidic CTC 
capture chip with a nanoroughened glass surface (Rq = 150 nm) for both pre- and 
post-EMT A549 lung cancer cells, even at extremely low cancer cell 
concentrations (80 cells mL-1) (Fig. 4.2 b,c).  Strong linear correlations between 
the number of cancer cells captured vs. the number of cancer cells initially 
loaded (n = 40 - 900) were observed for both pre- and post-EMT A549 cells (Fig. 
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4.2 b).  Averaged across all cell concentrations assayed (80 - 20,000 cells mL-1), 
capture yields were 89.4% ± 5.3% for post-EMT A549 cells and 89.2% ± 2.2% for 
pre-EMT A549 cells (Fig. 4.2 c, Fig. 4.S2).  We further examined the effect of 
admixtures of pre- and post-EMT A549 cells on capture efficiency by varying the 
ratio of pre- and post-EMT A549 cells spiked in the same blood sample.  Here 
1,000 post-EMT A549 cells were mixed with 500 - 4,000 pre-EMT cells in 500 µL 
lysed blood to achieve a cell ratio from 2 : 1 to 1 : 4 (Fig. 4.2 d).  Cell capture 
assays using the microfluidic CTC capture chip for 1 hr revealed that capture 
yield was not significantly affected by the relative proportions of pre- or post-EMT 
A549 cells with differing EpCAM expression and remained constant over the 
entire range of cell ratios of pre- and post-EMT A549 cells (Fig. 4.2 d).  Together, 
our results in Fig. 4.2 support that the RIE-generated nanorough glass surfaces 
can achieve efficient capture of CTCs independently of the cancer cell’s epithelial 
or mesenchymal state or EpCAM expression, demonstrating the applicability of 
the microfluidic CTC capture device for the capture and enumeration of rare 
tumor cells from heterogeneous cell samples and throughout a tumor’s 
metastatic progression, even in the setting of a dynamic EMT process. 
 
Capture of CTCs from a human breast cancer orthotopic xenograft mouse model  
We next assayed the microfluidic CTC capture chip with a nanoroughened glass 
surface (Rq = 150 nm) using an orthotopic xenograft mouse model of breast 
cancer.  To generate tumor xenografts (Fig. 4.3 a), 1 × 106 MDA-MB-231 
(EpCAM-) or SUM-149 (EpCAM+) breast cancer cells were injected into the left 
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inguinal mammary fat pad of female Ncr nude mice 42.  When mice were 
euthanized to assess for tumor burden between 3 - 7 weeks of xenograft time, 
nearly the entire mouse blood volume (300 - 800 µL) was collected by cardiac 
puncture of the left ventricle from each mouse before assayed using the 
microfluidic CTC capture chip.  CTCs, as defined by cytokeratin+, CD45-, DAPI+ 
staining (Fig. 4.3 b), were successfully captured from 11 out of 12 mice bearing 
tumor xenografts of MDA-MB-231 cells and from all 5 mice with tumor xenografts 
of SUM-149 cells (Table 4.1).  Data pooled from both EpCAM+ and EpCAM- 
breast cancer mouse models showed that the number of CTCs captured by the 
microfluidic CTC capture chip ranged from 13 to 4,664 cells per 100 µL of blood 
and increased drastically over the 9-week period during tumor progression, 
correlating positively with an increase in tumor weight (Fig. 4.3 c-e). 
 
Capture of CTCs from metastatic and non-metastatic syngeneic mouse models 
of lung cancer 
We next sought to assay the microfluidic CTC capture chip using a syngeneic 
mouse model of lung cancer.  Two well-defined mouse lung cancer cell lines 
(344SQ and 393P) with different metastatic capabilities were subcutaneously 
implanted in a syngeneic host.  Even though 344SQ and 393P lung cancer cells 
have distinct metastatic potential, both cell lines are derived from the same 
transgenic mouse model of lung cancer (p53 null, mutant Kras) 43,44.  The 344SQ 
lung cancer cells form metastatic lesions from spontaneous and experimental 
metastatic assays (subcutaneous implantation and tail vein injection), whereas 
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the 393P cell line does not metastasize by either assay 43.  However, both cell 
lines are capable of undergoing EMT in response to TGF- with different kinetics 
and lose expression of epithelial markers 43,44.  
 
After 6 weeks of subcutaneous tumor growth, mice were sacrificed and whole 
blood was collected via cardiac puncture before being processed with the 
microfluidic CTC capture chip with a nanoroughened glass surface (Rq = 150 nm) 
(Fig. 4.S3).  Simultaneously, primary tumor volumes were measured and lungs 
were examined grossly for metastasis (Fig. 4.4 a).  The 344SQ primary tumors 
grew significantly larger and shed more CTCs than metastasis-incompetent 393P 
tumors (Fig. 4.4 c-f).  Using the microfluidic CTC capture chip, CTCs were 
detected in all 5 mice implanted with the metastatic 344SQ cell line (Fig. 4.4 d, 
Table 4.2).  Similar to results from the breast cancer xenograft model, the 
number of CTCs detected using the microfluidic CTC capture chip showed a 
positive correlation with primary tumor size (Fig. 4.4 g).  As expected, neither of 
the 2 mice implanted with the metastasis-incompetent 393P lung cancer cell line 
that formed palpable primary tumors (mice #6 and 7) had detectable metastatic 
lesions on their lungs (Fig. 4.4, Table 4.2).  Surprisingly, however, we detected 
the presence of CTCs in all the mice, including those mice with metastasis 
incompetent 393P implants, with palpable primary tumors (Fig. 4.4 d).  This 
observation clearly demonstrates that the presence of CTCs alone may not be 
indicative of the presence of metastatic disease. 
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Discussion 
In this work, we have successfully developed a microfluidic CTC capture chip 
utilizing an RIE-generated nanorough glass surface as the substrate for efficient 
capture of CTCs regardless of cell size or surface protein expression.  The 
microfluidic flow chamber incorporated on top of the nanorough glass surface 
promotes greater adhesive interactions of cancer cells with the nanorough glass 
substrate, thereby providing an effective strategy to achieve superior CTC 
capture efficiency.  Other efforts that have been undertaken to isolate CTCs have 
primarily depended on either physical size differences between cancer cells and 
hematocytes or on the surface protein expression of either cancer cells or 
leukocytes 14-24.  In contrast, our CTC capture strategy leverages the differential 
adhesion preference to the RIE-generated nanorough glass surfaces between 
cancer cells and normal blood cells 31.  Mechanical properties of cancer cells 
represent a point of convergence in the metastatic series of sieves whereby only 
those cells within a tumor behaving in a precise biomechanical manner will 
successfully intravasate into the bloodstream.  Since the mechanical phenotype 
of a cancer cell is the culmination of an array of heterogeneous factors both cell 
intrinsic and cell extrinsic 27,30, we posit that using a CTC capture system that is 
mechanically focused and adhesion-based will have greater success in detecting 
CTCs with different molecular signatures.  This fact was supported by this 
present study as our adhesion-based microfluidic CTC capture chip was capable 
of capturing heterogeneous CTC populations independent of their EpCAM 
expression status or phenotypic state along the epithelial-mesenchymal 
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continuum.  Specifically, with the microfluidic CTC capture device, we were able 
to achieve capture yields of > 80% for both EpCAM+ (MCF-7, SUM-149, A549) 
and EpCAM- (MDA-MB-231) cancer cell lines spiked in whole blood samples.  
Furthermore, the microfluidic CTC capture device attained high capture yields for 
both pre- and post-EMT lung cancer cells – and with equal affinity – in an in vitro 
model of induced EMT.  Unbiased efficient capture of heterogeneous populations 
of CTCs regardless their EpCAM expression status is important, as EpCAM 
expression in tumor cells varies between patient to patient and within a patient 
over time as it is rapidly down-regulated during EMT.  Similarly, many other 
surface markers on cancer cells are dynamically expressed over the course of 
tumor dissemination and metastatic progression 9-11,45,46.  Therefore, the precise 
surface marker expression of CTCs is a moving target during tumor progression, 
requiring capture methods targeting the whole CTC population to be independent 
of CTCs’ surface marker expression. 
 
Although there are several other microfluidic platforms capable of achieving high 
CTC capture efficiency, many of them depend on the use of positive selection 
agents (i.e. anti-EpCAM antibody or aptamer) 6,8,47,48.  These methods inherently 
require a priori assumption about the surface protein expression of CTCs that 
have been proven to be a dynamic and inconsistent population 6,8.  Some tumor 
cells may shed from the primary tumor and enter the bloodstream after 
undergoing the EMT process and losing their epithelial properties 39,49.  It has 
been proposed that the EMT process may additionally cause a series of other 
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CTC feature changes apart from the loss of epithelial properties, such as 
enhanced invasiveness and elevated resistance to apoptosis 50.  In agreement 
with this, a recent study has revealed dynamic changes of epithelial and 
mesenchymal compositions of CTCs with disease progression among patients 
with breast cancer 9.  Together, it is clear that some CTCs may experience 
phenotypic changes during tumor evolution and that the expression of EpCAM 
may be transient, so EpCAM expression based methods may potentially miss a 
substantial subset of CTCs 51,52.  Thus, any positive marker-based selection 
method can bias captured CTCs toward a population that is not representative of 
the CTCs in a patient 8,53.  The limited number of CTCs detected in patients even 
in late stages of metastases may well be a result of the use of CTC detection 
methods that heavily rely on EpCAM expression by CTCs 54-56. New methods, 
like the microfluidic CTC capture chip using the label-free nanoroughened glass 
substrate, are critically needed to capture the entirety of heterogeneous CTC 
populations.  In this work we have shown that by focusing on a biomechanical 
property dependent on a multitude of cellular signals, we can capture CTCs in 
different morphologic states and irrespective of EpCAM expression, thus our 
adhesion-based microfluidic CTC capture is marker and molecular independent. 
 
To advance the clinical relevance of our microfluidic CTC capture chip further, we 
studied two in vivo models of breast and lung cancer.  In orthotopic xenografts of 
EpCAM+ and EpCAM- breast cancer cell lines, clear correlations between tumor 
size and CTC number were observed for both MDA-MB-231 and SUM-149 
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xenografts, supporting the independence of our CTC capture methodology from 
cell surface marker expression.  Our adhesion-based method for capturing 
heterogeneous CTC populations was further demonstrated by the use of a 
syngeneic lung cancer mouse model with differential metastatic capabilities.  In 
this model, a positive correlation between primary tumor size and CTC number 
was observed.  Interestingly, CTCs were also detected by our microfluidic CTC 
capture chip in 2 mice implanted with the non-metastatic 393P cell line.  These 
mice did not grow overt lung metastases as did all the mice in the metastatic 
344SQ cell line cohort.  Thus, a population of CTCs incapable of forming 
metastases was detected by the microfluidic CTC capture chip, supporting that 
cellular signals and biological processes that allow for individual cell invasion and 
intravasation are not identical to those governing the seeding of fruitful 
metastases.  It is important to understand the differences in the nature of these 
CTCs to determine their true significance in patient prognosis and in the clinical 
management of cancer, and our microfluidic CTC capture chip allows for both 
populations’ study with its unbiased capture method based on the selective 
adhesion of cancer cells. 
 
Materials and Methods 
Cell culture 
MCF-7 cells were maintained in high-glucose DMEM (Invitrogen); MDA-MB-231, 
344SQ, and 393P cells in RPMI-1640 (Invitrogen); SUM-149 cells in Ham’s F-12 
w/L-glutamine (Fisher Scientific); and A549 cells in DMEM/F12 (Invitrogen).  
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MCF-7, MDA-MB-231, and SUM-149 media contained 0.5 μg mL-1 Fungizone, 5 
μg mL-1 Gentamicin, 100 units mL-1 penicillin, and 100 μg mL-1 streptomycin (all 
Invitrogen).  Additionally, SUM-149 cells were supplemented with 5 μg mL-1 
Insulin and 1 μg mL-1 Hydrocortisone (both Sigma-Aldrich).  A549, 344SQ, and 
393P were supplemented with penicillin and streptomycin as above 43,44.  All 
media contained 10% fetal bovine serum (Atlanta Biological) except SUM-149 
media which had 5%.  SUM-149 cells were maintained at 37ºC with 10% CO2 
and all other cell lines at 37ºC with 5% CO2.  Fresh 0.25% trypsin-EDTA in 
phosphate buffered saline (PBS) was used to re-suspend cells. To induce the 
EMT, A549 cells were cultured with TGF- at 5 ng mL-1 in serum free media for 
72 hr. TGF- is a potent inducer of EMT 57-60. 
 
Chip fabrication 
The microfluidic chip includes three components: a PDMS microfluidic chamber, 
an RIE-etched nanorough glass substrate, and a polyacrylate gadget to 
sandwich the chamber and substrate together.  The microfluidic chamber was 
generated by replica molding using a Si mold fabricated using microfabrication.  
The detailed protocol for fabrication of the microfluidic CTC capture chip is 
described in the Supporting Materials Additional File.  
 
Human blood specimens 
Human blood specimens from healthy donors were collected in EDTA-containing 
vacutainers and were processed and assayed within 6 hr of collection.  RBC 
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Lysis Buffer (eBioscience) was added to whole blood at a 10:1 v/v ratio.  After 
incubation for 10 min at room temperature, the sample was diluted with 20 - 30 
mL PBS to stop the lysing reaction and then centrifuged at 300 g for 10 min.  
After discarding the supernatant, the cell pellet was re-suspended in an 
equivalent volume of growth medium before use in CTC capture assays. 
 
Mouse models of cancer 
Care of animals and experimental procedures were according to the University of 
Michigan University Committee on Use and Care of Animals (UCUCA) approved 
protocols #PRO5314 and #PRO4116.  To generate breast cancer xenografts, 1 × 
106 MDA-MB-231 or SUM-149 cells were injected orthotopically into the left 
inguinal mammary fat pad of each female Ncr nude mouse (Taconic).  The cells 
were suspended in 50 μL PBS and 50 μL Matrigel (Becton Dickinson).  For the 
lung cancer studies, 1 × 106 cells of two mouse lung cancer cell lines (metastatic 
344SQ and non-metastatic 393P) with differential metastatic capability 43,44 were 
subcutaneously implanted on either side of the dorsal flank in C57BL/6 mice 
(Taconic).  Tumor growth was monitored weekly by caliper measurement with 
ellipsoid volumes calculated using ½ x length × width × height.  Before 
euthanizing the mice, blood samples (0.3 - 0.8 mL) were collected via cardiac 
puncture under anesthesia to quantify CTCs. 
 
CTC capture from in vitro spiked blood samples 
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Prior to CTC capture assays, cancer cells were first labeled with CellTracker 
Green (Invitrogen) before mixed with Δ9-DiI-stained (Invitrogen) leukocytes in 
lysed blood.  The total cancer cell number in the blood sample was first 
quantified using a hemocytometer before the spiked sample was diluted using 
lysed whole blood to achieve the desired final CTC concentration.  For the 
capture of pre- and post-EMT A549 cells in admixture, pre- and post-EMT A549 
cells were first labeled with CellTracker Green (Invitrogen) and CellTracker Blue 
(Invitrogen), respectively, before mixed in cell culture medium. 
 
The CTC capture chip was assembled and connected to a custom-built pressure 
control setup.  The PDMS microfluidic chamber was washed with PBS for 5 min 
before 1.0 mL of spiked blood sample was loaded at a flow rate of 200 µL min-1 
and incubated for 30 min - 1 hr at 37 °C with 5% CO2.  After the CTCs adhered, 
the chamber was washed with PBS then loaded with 4% paraformaldehyde 
(PFA; Electron Microscopy Sciences) in PBS for 20 min to fix captured CTCs.  
The nanorough glass substrate was then detached from the PDMS chamber and 
rinsed with PBS to remove floating cells.  Adherent cells immobilized on the 
nanorough glass substrate were then imaged directly using a fluorescence 
microscope (Nikon Eclipse Ti-S, Nikon) equipped with an electron multiplying 
charge-coupled device (EMCCD) camera (Photometrics).  To quantify CTC 
capture yield, the entire glass surface area was scanned on a motorized stage 
(ProScan III, Prior Scientific).  Image processing software ImageJ (National 
Institutes of Health) was used to determine the number of CTCs.  
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CTC capture from in vivo mouse models 
Capture of CTCs from mouse blood samples was performed using a procedure 
similar to the one employed for spiked blood samples.  To visualize and quantify 
CTCs captured on the nanorough glass substrate, immunostaining was 
performed after the glass substrate was detached from the microfluidic chamber.  
After the PBS rinse as above, adherent cells were permeabilized with 0.25% 
Triton X-100 (Roche Applied Science) in PBS for 10 min.  Fixed cells were 
incubated with 10% goat serum (Invitrogen) for 1 hr before another 1 hr 
incubation with primary antibodies to cytokeratin (FITC; BD Biosciences) and 
mouse CD45 (PE) and DAPI to identify cancer cells, leukocytes, and cell nuclei, 
respectively.  CTCs were identified by: positive staining of anti-cytokeratin and 
DAPI; negative staining of anti-CD45; and appropriate morphometric 
characteristics including cell size, shape, and nuclear size.  The researcher 
counting CTCs was blinded to the mouse group and tumor characteristics. 
 
Statistical analysis 
Student's two-sample, unpaired t-tests were calculated using GraphPad Prism 
software with P-values < 0.05 considered statistically significant. 
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Figure 4.1.  Nanotopography-based microfluidic chip for CTC capture.  (a) 
Photo of the microfluidic CTC capture chip (left) and SEM images (right) showing 
the nanorough glass surface (top right, Rq = 150 nm) and a cancer cell adhered 
to the surface (bottom right).  (b) Bar graph showing 30 min capture yield for 
breast cancer cells (MCF-7, MBA-MB-231, and SUM-149) and lung cancer cells 
(A549) using the capture chip with smooth (Rq = 1 nm) and nanorough (Rq = 150 
nm) glass surfaces as indicated.  For each cell type, 1,000 cells were spiked in 1 
mL lysed human blood.  EpCAM expression of each cell line is denoted below 
the graph.  Error bars, s.e.m. (n = 4).  **, p < 0.01. 
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Figure 4.2.  Capture of pre- and post-EMT lung cancer cells using the 
nanotopography-based microfluidic CTC capture chip.  (a) Representative 
staining images showing pre- (top) and post-EMT (bottom) A549 cells captured 
on nanorough glass surfaces (Rq = 150 nm) 1 hr after cell seeding.  10,000 pre- 
and post-EMT A549 cells labeled with CellTracker Green were spiked in 500 µL 
lysed blood that was pre-stained with DiI to label peripheral blood mononuclear 
cells (PBMCs).  (b,c) Regression analysis of 1 hr capture efficiency for pre- and 
post-EMT A549 cells (n = 40 - 900 spiked in 500 µL lysed blood) using the 
microfluidic CTC capture chip.  The number of A549 cells captured (b) and the 
capture yield (c) is plotted as a function of the total number of A549 cells spiked 
in blood samples.  (d) Ratio of pre- and post-EMT A549 cells captured 1 hr after 
cell seeding as a function of their ratio when spiked in blood samples.  1,000 
post-EMT A549 cells were mixed with 500 - 4,000 pre-EMT cells in 500 µL lysed 
blood to achieve ratios from 2 : 1 to 1 : 4.  Solid lines in b & d represent linear 
fitting.  Error bars, s.e.m. (n > 4). 
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Figure 4.3.  CTCs captured using the microfluidic CTC capture chip from 
mice with breast cancer orthotopic xenografts.  (a) Photos of MDA-MB-231 
xenografts, 1 cm scale bar.  (b) Representative staining images showing CTCs 
captured on nanorough glass surfaces from mice with MDA-MB-231 tumor 
xenografts.  Cells were co-stained for nuclei (DAPI; blue), cytokeratin (green), 
and CD45 (red).  (c-e) Temporal changes in CTC number and tumor weight 
during tumor progression. Tumor weight (c) from mice with MDA-MB-231 and 
SUM-149 tumor xenografts as a function of xenograft time.  Scatter plot (d) of 
CTC number per 100 µL blood vs. tumor weight.  Bar plot (e) showing number of 
CTCs captured by the microfluidic CTC chip as a function of xenograft time.  For 
each CTC capture assay, 300 - 800 µL blood samples were obtained via cardiac 
puncture.  Error bars, s.e.m. 
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Figure 4.4.  Capture of CTCs from metastatic and non-metastatic syngeneic 
mouse models of lung cancer.  (a) Photos of lung metastases from 344SQ 
(top) and 393P (bottom) implants.  Mouse 344SQ lung cancer cells are highly 
metastatic, while mouse 393P lung cancer cells are metastasis-incompetent.  (b) 
Representative staining images showing CTCs captured on nanorough glass 
surfaces from mice implanted with 344SQ cells.  Cells were co-stained for nuclei 
(DAPI; blue), cytokeratin (green), and CD45 (red).  (c-g) Analysis of CTC number 
and tumor volume for mice with 344SQ and 393P tumor allografts.  Bar plots 
show tumor volume (c) and CTC number per 100 µL blood (d) for individual mice.  
Bar plots showing average tumor volume (e) and average CTC number per 100 
µL blood (f) of all mice.  Scatter plot (g) of CTC number per 100 µL blood vs. 
tumor volume for mice with 344SQ and 393P tumor allografts.  Mice were 
subcutaneously implanted with tumor allografts of 344SQ and 393P lung cancer 
cells.  For each CTC capture assay, 350 - 600 µL blood samples were obtained 
via cardiac puncture.  Error bars, s.e.m.  *, p < 0.05. 
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Group Sample 
Xenograft 
Time 
End tumor 
weight (g) 
Collected 
blood 
volume (µL) 
Captured 
CTCs 
(CTCs/100 
µL) 
MDA-MB-
231 
#1 
3 weeks 
0.05 800 16 
#2 0.08 800 498 
#3 
5 weeks 
0.20 800 29 
#4 0.17 800 13 
#5 0.30 800 772 
#6 0.10  800 468 
#7 0.12  500 478 
#8 
7 weeks 
0.60 800 1348 
#9 0.30 800 259 
#10 0.32 800 261 
#11 
9 weeks 
0.20 800 0 
#12 0.60 800 4664 
SUM-149 
#13 
5 weeks 
0.22  300  675 
#14 0.20 800  306 
#15 0.24  700  1366 
#16 
7 weeks 
0.30  500  579 
#17 0.40  700 4408 
 
Table 4.1. Capture of CTCs from mice with orthotopic breast cancer 
xenografts.  
 
MDA-MB-231 or SUM-149 xenografts of 1 × 106 cells were grown before blood 
collection and enumeration of CTCs. 
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Group Sample 
End tumor 
volume 
(mm3) 
Collected blood 
volume (µL) 
Captured CTCs 
(CTCs/100 µL) 
Metastasis-
Prone 
(344SQ) 
#1 179 500 84 
#2 144 500 28 
#3 1470 350 336 
#4 503.5 500 84 
#5 988 500 1148 
Metastasis-
Incompetent 
(393P) 
#6 15.8 400 28 
#7 40 350 112 
#8 No tumor 500 0 
#9 No tumor 600 0 
 
Table 4.2: Capture of CTCs from metastatic and non-metastatic syngeneic 
mouse models of lung cancer. 
 
The metastasis-prone 344SQ or metastasis-incompetent 393P lung cancer cell 
lines were subcutaneously implanted into mice that were sacrificed 6 weeks after 
implantation with blood collected for circulating tumor cell quantification. 
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Supplemental Materials, Methods, and Figures 
Fabrication of CTC capture chip 
The CTC capture chip includes three components: a PDMS microfluidic 
chamber, a patterned nanorough glass substrate, and a polyacrylate gadget 
sandwiching the PDMS chamber and the patterned nanorough glass substrate. 
The glass substrate has dimensions of 50 mm × 76 mm and an effective 
nanoroughed region of 44 mm × 56 mm. The PDMS microfluidic chamber (height 
400 µm, width 44 mm, length 56 mm) was produced by soft-lithography using a 
replicate on a silicon mold. Briefly, a silicon master for the microfluidic chamber 
was fabricated using photolithography and deep reactive ion etching (DRIE; STS 
Deep Silicon Etcher, Surface Technology Systems). The silicon master was then 
silanized with (tridecafluoro-1,1,2,2,-tetrahydrooctyl)-1-trichlorosilane vapor 
(United Chemical Technologies) for 4 hr under vacuum to facilitate subsequent 
release of the PDMS microfluidic chamber from the silicon master. PDMS 
prepolymer (Sylgard 184, Dow-Corning) was then prepared by thoroughly mixing 
the monomer with the curing agent (at a w/w ratio of 10:1), poured onto the 
silicon master and cured at 110 ºC for 1 hr. The fully cured PDMS chamber was 
peeled off from the silicon mold and the excess PDMS was trimmed using a 
razor blade and two through-holes were punched at the inlet and outlet for the 
tubing connections. 
 
For the patterned nanorough glass substrates, a photoresist was first spin-coated 
on glass wafers (Borofloat 33, Plan Optik) and patterned using photolithography. 
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The glass wafer was then processed with RIE (LAM 9400, Lam Research) for 
different periods of time to generate nanoscale surface roughness (ranging from 
1 nm to 150 nm) on the open regions of the glass wafer, where the photoresist 
had previously been developed and dissolved. The RIE process condition was 
selected as: SF6 (8 sccm), C4F8 (50 sccm), He (50 sccm), Ar (50 sccm), chamber 
pressure (1.33 Pa), bias voltage (100 V), and radio frequency power (500 W), 
with the resulting glass etch rate as about 50 nm min-1. After the RIE process, the 
photoresist was striped using solvents, and the glass wafer was cleaned using 
distilled water. The glass wafers were then cut into the designated size (50 mm × 
76 mm) using an ADT7100 dicing saw (Advanced Dicing Technologies Ltd.).  
 
To assemble the chip, a device holder composed of two polyacrylate plates was 
machined to sandwich the PDMS microfluidic chamber and the nanorough glass 
substrate using screws at the four corners and along the edges of the 
polyacrylate plates. Two through-holes were drilled on the top polyacrylate plate 
to align with the inlet and outlet holes of the PDMS microfluidic channel, thus 
allowing a convenient tubing connection to the microfluidic chamber. The 
complete assembly using the polyacrylate plates to hold the PDMS microfluidic 
chamber could withstand a pressure of about 50 psi without leaking. 
 
SEM Specimen Preparation 
Cell samples were washed three times with 50 mM Na-cacodylate buffer (pH 7.3; 
Sigma-Aldrich), fixed for 1 hr with 2% glutaraldehyde (Electron Microscopy 
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Sciences, Hatfield, PA) in 50 mM Na-cacodylate buffer, and dehydrated in a 
graded series of ethanol concentrations through 100% over a period of 1.5 hr. 
Dehydration in 100% ethanol was performed three times. Afterwards, dehydrated 
substrates were dried with liquid CO2 using a super critical point dryer (Samdri
®-
PVT-3D, Tousimis, Rockville, MD). Samples were mounted on stubs, sputtered 
with gold palladium, observed and photographed under a Hitachi SU8000 Ultra-
High Resolution SEM machine (Hitachi High Technologies America, Inc., 
Pleasanton, CA). 
 
Surface Characterization Using Atomic Force Microscope 
Nanoroughness of the glass surfaces was measured at room temperature with 
the Veeco NanoMan Atomic Force Microscope (AFM, Digital Instruments Inc., 
Santa Barbara, CA) using non-contact, tapping mode and standard Si tapping 
mode AFM tips with a scan rate of 1 Hz. The resulting map of the local surface 
height was represented using AFM topographs. The nanoroughness of each 
glass sample was characterized by the root mean square (RMS) roughness Rq of 
the local surface height over the scanned areas collected using the AFM 
topographs. 
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Figure 4.S1. Intrinsic nanotopological sensing for CTC capture. (a) 
Schematic of nanotopography generated by RIE on glass surfaces. (b) SEM 
images of glass surfaces with their RMS nanoroughness (Rq) indicated. (c) 
Phase-contrast micrograph showing MDA-MB-231 cells selectively adhering to 
patterned nanorough letters (UM; Rq = 70 nm) on the glass surface 24 hr after 
cell seeding. 
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Figure 4.S2. Capture of pre-EMT and post-EMT lung cancer cells spiked in 
cell culture medium or lysed mouse blood. (a) Representative fluorescence 
images and zoom-in fluorescence and phase imgages showing known quantities 
(10,000) of pre-EMT and post-EMT cancer cells as indicated spiked in cell 
culture medium captured on nanorough glass surfaces (Rq = 150 nm) 1 hr after 
cell seeding. Target cancer cells were labeled with CellTracker Green before 
capture. (b) Capture yields of pre-EMT and post-EMT cancer cells in cell culture 
medium on nanorough glass surfaces (Rq = 150 nm) 1 hr after cell seeding. (c) 
Capture yields of pre-EMT and post-EMT cancer cells in lysed blood on 
nanorough glass surfaces (Rq = 150 nm) 1 hr after cell seeding. (d) Time-course 
of A549 EpCAM mRNA expression during TGF- -induced EMT as assessed by 
microarray analysis using an Affymetrix U133 plus chip. Fold change shown 
relative to unstimulated cells. Error bars, s.e.m. (n > 4). 
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Figure 4.S3. Representative merged immunofluorescence and phase 
images of captured CTCs from mice with 344SQ lung tumor allografts. Cells 
were co-stained for nuclei (DAPI; blue), cytokeratin (green), and CD45 (red). 
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Chapter 5 
Functional and Biophysical Phenotyping of Inflammatory 
Breast Cancer Stem Cells 
 
Chapter Summary 
At each step in the metastatic series of sieves, cancer cells are required to 
behave in a precise mechanical manner if they are to successfully traverse to the 
next stage.  Therefore, we hypothesized there could be a defining overarching 
biomechanical phenotype of these most aggressive cells that form metastasis.  A 
distinct subpopulation of the cells that can effectively move through each 
metastatic sieve is composed of cancer stem cells (CSCs).  CSCs, as defined 
through specific marker expression methods, have been shown to initiate 
tumorigenesis, have the capacity to self-renew, and initiate cancer metastasis in 
many cancer types.  Although identification of CSCs through marker expression 
helps separate and define the CSC compartment, it does not directly provide 
information on how or why this cancer cell subpopulation is more tumorigenic 
and capable of bypassing the restrictive metastatic sieves.  In this study, we 
comprehensively profiled the functional as well as biophysical characteristics of 
inflammatory breast cancer (IBC) CSCs at the single-cell level using multiple 
microengineered tools and traditional in vitro studies to delineate the live cell 
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phenotypic characteristics of the model of the most metastatic breast cancer 
subtype.  IBC is the most aggressive and lethal form of breast cancer with two-
thirds of patients presenting with axillary lymph node involvement and up to one-
third of patients having distant metastases at initial diagnosis. Characterizing the 
functional behaviors of IBC CSCs such as cell migration, growth, adhesion, 
invasion, self-renewal, and differentiation is a direct approach to describe and 
understand IBC CSCs based upon their intrinsic properties, thus paving the way 
to determine therapeutic approaches to this most lethal subpopulation within IBC.  
Distinct biophysical properties of IBC CSCs such as cell deformability, adhesion 
strength, and traction force provide physical insights into why IBC has an 
enhanced propensity to metastasize compared to other breast cancers.  Our 
multiparametric cellular phenotyping of functional and biophysical characteristics 
of IBC CSCs yields a new understanding of IBC’s metastatic properties and how 
they might develop and be targeted for therapeutic interventions. 
 
Introduction 
Increasing evidence indicates that cancer cells with stem cell-like properties, 
termed “cancer stem cells” (CSCs), have the potential for self-renewal, 
differentiation, and tumorigenicity and play a major role in cancer recurrence and 
metastasis (Fig. 5.1 A)1-3.  CSCs have been shown to initiate tumorigenesis in 
numerous cancer types4-6, and recent studies have begun to define a role for 
CSCs in cancer metastasis as well7-10.  CSCs have been characterized on the 
basis of their expression of particular surface markers11,12 - such as CD133 and 
 
 
132 
 
CD44 - and also on the basis of cell adhesion molecules13, cytoprotective 
enzymes (e.g. aldehyde dehydrogenase, ALDH)14, and drug-efflux pumps (e.g. 
ABC transporters)15.  CSCs, defined as the high ALDH-expressing 
subpopulation, have been shown to play a role in inflammatory and aggressive 
breast cancers10.  Inflammatory breast cancer (IBC) is the most lethal form of 
breast cancer with 20 - 30% of patients presenting with metastasis at initial 
diagnosis16,17.  Although RhoC GTPase and anaplastic lymphoma kinase (ALK) 
are implicated in the IBC phenotype, the underlying detailed mechanisms that 
allow IBC to be so aggressively metastatic from its inception are still under study, 
some of which have been explored in Chapter 3.  In order to advance the field, 
an understanding of the physical attributes of CSCs that underlie their ability to 
execute the multiple events of metastases is important and has not been 
previously undertaken.  
 
Here we analyzed both the intrinsic functional capabilities of IBC’s CSC 
compartment as well as these cells’ inherent biophysical properties that make 
them capable of early metastasis, essentially from the tumor’s inception. During 
metastatic progression, cancer cells encounter complex biophysical 
environments consisting of different degrees of extracellular matrix (ECM) cross-
linking18, a differing ECM topology19-21, mechanical heterogeneity within the 
ECM20,22,23, as well as being exposed to shear flow and interstitial pressure24-26.  
In response, metastatic cancer cells must acquire unique biophysical 
characteristics in order to navigate through this dynamic microenvironment to 
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reach and proliferate in distant sites.  As CSCs are believed to play critical roles 
in metastasis, it is highly possible that CSCs too will develop biophysical 
properties - such as increased deformability and decreased adhesion strength - 
necessary to traverse this environment and be capable, for example, of 
repopulating tumor masses following treatment. 
 
Cell deformability (i.e. compliance under an applied load) has been postulated to 
play key roles in cancer cell invasiveness24,27-30.  Cytoskeletal changes have 
been suggested to underlie mechanical differences observed in invasive cancer 
cells, consistent with a process of selection for cells that are able to squeeze into 
vessels by traversing walls (intravasate)24,31,32.  Many studies have demonstrated 
a significantly higher degree of cell deformability for both cancer cell lines and 
primary tumors when compared to normal epithelial cells27-29.  In the case of 
breast and ovarian cancers, the subpopulation of cancer cells with increased cell 
deformability has been shown to have a more malignant phenotype compared to 
stiffer cells27,33.  Cell traction force is another key mechanical factor that has 
previously been shown to mediate cell functions34-37 (e.g. migration, adhesion, 
and proliferation) as well as mechanotransduction.  Therefore, cell traction forces 
may also be involved in cancer progression. 
 
Previous studies have convincingly established the usefulness of biophysical 
characteristics for identifying more aggressive cancer cells in a label-free manner 
that is independent of current immunohistological methods24,27,31,32,38,39.  Given 
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that IBC is the most aggressive and metastatic breast cancer, we sought to 
utilize quantitative techniques to characterize the IBC CSC compartment using a 
panel of assays to specifically profile the functional as well as biophysical 
characteristics of CSCs at the single-cell level.  Such comprehensive, 
multiparametric phenotypic profiling of CSCs can provide useful insights into the 
qualities of IBC CSCs that increase their aggressiveness and propensity for 
tumorigenesis and metastasis as well as allow for studies of novel therapeutic 
interventions targeting CSCs functions. 
 
Results 
Functional phenotyping of IBC CSCs 
High activity of ALDH within tumors has been associated with a poor prognosis in 
many cancers including breast10,12,40,41, lung42,43, liver44, colon14,45, pancreatic46, 
ovarian47, head and neck48, and prostate49 cancer.  ALDH is a superfamily of 
detoxifying enzymes responsible for metabolizing a wide variety of intracellular 
aldehydes and plays an important role in multiple biological activities, including 
drug resistance, cell differentiation, and oxidative metabolism50-52.  ALDH 
expression has been used as a predictive marker of CSCs for breast 
cancer12,40,41,53 – including IBC10 – and ALDH expression has proven to be more 
predictive than other established markers such as CD44+ / CD24- for 
identification of breast CSCs, as it has been shown that ALDH can identify cells 
with a greater resistance to chemotherapy54,55.  
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In this study, breast CSCs with high ALDH enzymatic activity were isolated from 
an IBC cell line, SUM149, using an ALDEFLOUR assay (see Methods)40.  
SUM149 cells were stained for ALDH using the ALDEFLOUR reagent and sorted 
by flow cytometry. ALDEFLUOR treated cells quenched with the ALDH inhibitor 
diethylaminobenzaldehyde (DEAB) were used to set the ALDEFLUOR-positive 
FACS gate, containing less than 0.1% of DEAB-treated cells (Fig. 5.1 B).  
SUM149 cells above this 0.1% fluorescence threshold were sorted as ALDH-
positive (ALDH+).  ALDH negative (ALDH-) cells were sorted as the bottom 
percentage of cells that corresponded to the ALDH+ percentage (i.e. if 3.5% of 
cells were ALDH+, then the bottom 3.5% of cells were gated for the ALDH- 
population). 
 
We performed comprehensive profiling to study functional phenotypes of ALDH+ 
IBC CSCs.  First, the ratio of ALDH+ CSCs in the SUM149 cell line was 
quantified across multiple sortings to establish reliability (> 20).  The proportion of 
ALDH+ cells in the SUM149 cell line was between 1 - 7%, with an average of 
3.93% ± 1.84%, similar to what has been reported previously10.  Interestingly, the 
ALDH+ CSC population maintained a dynamic equilibrium in the SUM149 cell 
line.  In a purified ALDH+ population, the percentage of ALDH+ cells gradually 
decreased from 100% to the normal level (3 - 5%) for SUM149 cells over 3-5 
days (data not shown), presumably by cell differentiation.  Thus, the ALDH+ 
compartment was able to recapitulate the heterogeneity of the parent cell 
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population by maintaining an almost constant percentage of ALDH+ CSCs, 
consistent with previously reported results10,56,57. 
 
To study the tumorigenic and metastatic potential of ALDH+ IBC CSCs, in vitro 
invasion, migration, and proliferation assays were conducted.   In vitro invasion 
assays were performed using the Biocoat Matrigel Invasion Chamber (see 
Methods) to examine the ability of cancer cells to invade through a Matrigel 
membrane under a serum gradient, mimicking the basement membrane invasion 
process in cancer metastasis.  As shown in Fig. 5.1 C and D, ALDH+ IBC CSCs 
were more invasive compared to the ALDH- population and the unsorted 
SUM149 control. 
 
To examine cell motility, the Cellomics Cell Motility kit was utilized to measure 
the migration area of ALDH+ and ALDH- cells.  Each sorted cell type (ALDH+ 
and ALDH-) was plated in equal densities in 3 -5 wells of a 96-well plate that had 
previously been coated with blue fluorescent microbeads.  After 24 hr of 
incubation, the area a cell migrated is represented by the negative space in the 
microbead carpet that has been pushed away or phagocytosed by the cell.  This 
cell motility assay demonstrated a significantly higher motility for ALDH+ than 
ALDH- cells (Fig. 5.1 E,F), suggesting a more aggressive and motile phenotype 
for ALDH+ IBC CSCs. 
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To evaluate the growth rates of ALDH+ and ALDH- cells, these populations were 
quantified and compared with unsorted SUM149 controls using MTT assays (see 
Methods).  Cell populations of flow-sorted ALDH+ and ALDH- cells and unsorted 
SUM149 controls were measured at 24 hr, 36 hr, 72 hr, and 96 hr post sorting.  
As shown in Fig. 5.1 G and H, ALDH+ cells had a slower growth rate and 
significantly longer cell doubling time compared to ALDH- cells and unsorted 
control cells.  This slower growth rate for ALDH+ cells suggests that the IBC 
CSCs can maintain a semi-quiescent or slowly-cycling state, similar to the 
behavior of many adult stem cell types. 
 
Cell deformability measurements for IBC CSCs 
Our invasion assays demonstrated that ALDH+ cells had a greater capability to 
migrate through confined physical spaces, a process that necessitates significant 
cell shape and cytoskeleton changes.  Thus, we hypothesized that there would 
be a concomitant difference in cell deformability between ALDH+ and ALDH- 
cells.  Furthermore, at a key metastatic sieve, cell deformability has been 
postulated to play a key role in invasion through the basement membrane31,32.  
To explore potential differences in cell deformability between the ALDH+ IBC 
CSCs and ALDH- subpopulations, we utilized a microfluidics-based deformability 
microcytometer especially designed for highly-sensitive, high-throughput and 
label-free quantification of cell deformability at the single-cell level. 
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The microfluidic deformability microcytometer was made of poly-dimethylsiloxane 
(PDMS) and contained an array of identical funnel-shaped, long confining 
microchannels that served to automatically direct and trap individual live cancer 
cells within each channel (Fig. 5.2 A & Fig. 5.S1).  The microchannel walls were 
pre-coated with Pluronic-127, a hydrophilic non-ionic surfactant, so that friction 
between the cell and the channel wall would be negligible.  Within the 
deformability microcytometer, differential hydrodynamic pressure acting on 
individual cancer cells gradually pushes the cell down the funnel and, ultimately, 
the motion of the cell stops and the cell is trapped due to confining space of the 
funnel-shaped channel.  For inert microfluidic channels where cell trapping is 
dictated by steric interactions between cancer cells and the channel wall, the 
penetration length (L) of an individual cancer cell into the channel is completely 
determined by its cell volume and cell deformability (Fig. 5.2 A,B).  Thus, the cell 
deformability of each cancer cell can be calculated (see Methods) based upon 
known or measured parameters including pressure, cell volume, and the 
penetration length L (or the distance d between the position where the cell 
started to deform and the final trapped position in the channel). 
 
We quantified the cell deformability of both ALDH+ and ALDH- SUM149 cells 
using the deformability microcytometer, with results showing that under the same 
differential hydrodynamic pressure across the confining microchannels, the 
average penetration length L of ALDH+ IBC CSCs was significantly greater than 
that of ALDH- cells, while the cell diameters of both populations were comparable 
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(Fig. 5.2 C,D).  This suggested a greater deformability of ALDH+ IBC CSCs than 
ALDH- cells.  We further performed correlative studies using single cell data for 
cell deformability and cell diameter.  Our analysis in Fig. 5.2 E showed no strong 
correlation between cell deformability and cell diameter for either ALDH+ or 
ALDH- cells, suggesting that cell deformability is an intrinsic biophysical property 
regardless of cell size.  Interestingly, deformability of ALDH+ cells was distributed 
across a relatively higher range than ALDH- cells  (Fig. 5.2 E,F), pointing to a 
potential inherent propensity and ability of ALDH+ IBC CSCs to more readily 
undergo the necessary cytoskeletal rearrangement to intravasate across the 
basement membrane during invasion. 
 
In addition to measurements for CSCs, we also compared the cell deformability 
of another non-inflammatory and less aggressive breast cancer cell line (MCF-7) 
with the normal-like breast epithelial cell line (MCF-10A).  Our results showed 
that MCF-7 cells exhibited greater cell deformability than MCF-10A cells (Fig. 
5.S1 C,D).  Together, our data show that the small population of IBC CSCs 
possesses a greater degree of cell deformability than normal breast cancer cells. 
 
Cell adhesion strength characterization for IBC CSCs 
We conducted adhesion assays for SUM149 breast cancer cells to evaluate their 
ability to make stable physical contact with surfaces (Fig. 5.3 A,B).  Three groups 
of SUM149 cancer cells - sorted ALDH+ cells, ALDH- cells, and an unsorted 
control – were seeded at the same density as single cells in polystyrene 48-well 
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cell culture plates.  Three hours after cell seeding, floating cells were removed, 
and adherent cancer cells were stained with Calcein AM for visualization.  
Fluorescence images of stained cancer cells in the entire sample area were 
taken for quantification of the adhesion rate, defined as the ratio of the number of 
cells adhered to the surface to the total number of cells initially seeded per 
sample. 
 
Quantitative analysis revealed that ALDH+ cells had a much lower adhesion rate 
compared to both the ALDH- population and unsorted control (Fig. 5.3 B).  On 
average, the adhesion rate after 3 hr of cell seeding was 25.6% for ALDH+ cells, 
while for ALDH- cells and unsorted control cells the adhesion rates were 60.6% 
and 52.0%, respectively. 
 
Our results in Fig. 5.3 A and B demonstrating a significant difference in the 
adhesion properties of ALDH+ and ALDH- cancer cells suggested the possibility 
that adhesion strength of cancer cells might similarly be correlated with ALDH 
expression as was cell deformability.  To examine specifically the possibility of 
the IBC CSC compartment consisting of intrinsically less adherent cells, we 
developed a microfluidic cell adhesion assay for direct measurements of the 
adhesion strength of cancer cells (Fig. 5.3 C; see Methods).  A low density of 
ALDH+ or ALDH- IBC cells was seeded uniformly inside the microfluidic channel 
for 12 hr before they were exposed to constant directional fluid shear (0.1 - 320 
dyne cm-2) for 3 min.  We quantified the fraction of cancer cells remaining 
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adherent in the microfluidic channel after exposure to this sustained 3-min 
directional fluid shear.  Our data demonstrated that indeed, the ALDH+ IBC 
CSCs that adhered to the microfluidic channel were only capable of withstanding 
much lower fluidic shear stresses than the ALDH- cells (Fig. 5.3 D,E).  The 
adhesion strength of cancer cells, defined as the fluidic shear stress at which 
50% of cancer cells initially adherent on the microfluidic channel detach after 
exposed to shear, was significantly lower for ALDH+ IBC CSCs than ALDH- cells 
(Fig. 5.3 F). 
 
Together, our results in Fig. 5.3 demonstrated that adhesive properties could be 
quantitatively delineated and correlated with the ALDH-defined IBC CSC 
population in the SUM149 cell line.  In summary, ALDH+ IBC cells had a 
decreased ability to adhere to a substrate and overall decreased adhesion 
strength. 
 
Cell traction force measurements for IBC CSCs 
The difference seen in cell adhesion properties between ALDH+ IBC CSCs and 
ALDH- cells implicated an involvement of actin cytoskeleton (CSK) and integrin-
mediated focal adhesions that tether the actin CSK to the extracellular matrix.  To 
investigate this hypothesis, we utilized an array of PDMS microposts as 
subcellular live-cell force sensors to quantify intracellular CSK contractile forces 
(Fig. 5.4 and Fig. 5.S2)58-60.  This PDMS micropost array consists of hexagonally 
spaced, vertical, elastomeric posts fabricated using replica molding with PDMS 
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from microfabricated silicon masters (Fig. 5.4 A and Fig. 5.S2 A-D).  After 
adhesive proteins are coated on the post tips using microcontact printing (Fig. 
5.S2; see Methods), cells are able to adhere, spread out, and exert contractile 
forces that deflect the underlying posts (Fig. 5.4 A-D and Fig. 5.S2 C).  Each 
post, therefore, functions as a cantilever and force sensor, capable of measuring 
local cellular traction force exerted at the post tip (Fig. 5.S2 E-G)58-60. 
 
We performed quantitative analysis of cell morphology and CSK contractility of 
SUM149 cells with the PDMS micropost array (Fig. 5.4 E,F).  Our results 
revealed that the total cell traction force was significantly less for ALDH+ cells 
compared to ALDH- ones (Fig. 5.4 G).  Previous studies have demonstrated that 
cell traction force generation can be confounded by a cell’s footprint area36,37,58.  
To exclude the possibility that the decreased cell traction force for ALDH+ CSCs 
was simply caused by a variance in cellular area, we quantified cell spread area 
for SUM149 cells.  Our results in Fig. 5.4 H showed no significant difference in 
cell spread area between ALDH+ and ALDH- cells.  To further investigate the 
role of cell spread area in the generation of traction forces, we analyzed the total 
traction force of each cell normalized by its spread area (traction force per cell 
area), with results showing that the average traction force per cell area was lower 
for ALDH+ IBC CSCs compared to ALDH- SUM149 cells (Fig. 5.4 I).  Hence, 
these results indicate that the smaller traction forces exerted by ALDH+ IBC 
CSCs vs. ALDH- cells are not linked to differences in cell spread area, but to 
other inherent cellular differences between the two populations.  Consistent with 
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previous reports though36,37,58, within the same group of cells (ALDH+ or ALDH-) 
the correlative plot (Fig. 5.4 J) of single-cell data of total traction force and cell 
spread area did show a strong linear correlation of increasing traction force with 
cell spread area.  However, the slope of the linear correlation between the 
traction force and cell spread area was substantially less for ALDH+ cells than for 
ALDH- cells (0.13 nN µm-2 vs. 0.07 nN µm-2), again indicating distinct biophysical 
properties of ALDH+ and ALDH- cells.  Our traction force study in conjunction 
with the adhesion strength results indicate that ALDH+ and ALDH- cells have 
differential biophysical properties with the ALDH+ IBC CSCs being less adherent 
and exerting less contractile force.  This may help explain the metastatic potential 
difference between the ALDH+ and ALDH- populations.  Cells that are prone to 
forming strong connections with their surrounding ECM (ALDH- cells) may be 
less likely to successfully migrate away from the primary tumor61.   
 
Discussion 
Cancer stem cells have been proven to initiate tumorigenesis and are the primary 
population of cells responsible for cancer metastasis in numerous cancer types4-
10.  Within IBC, the ALDH+ population has been shown to represent the 
tumorigenic and metastatic subpopulation10, but detailed studies characterizing 
the IBC CSC’s mechanical properties were lacking.  ALDH expression is also 
negatively correlated with survival outcome10, thus we postulated that the ALDH+ 
CSCs of IBC would exhibit distinct biomechanical properties that would help 
explain their extremely aggressive metastatic behavior.  In our studies, we first 
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examined the migratory and invasive phenotypes of the ALDH+ population in an 
IBC cell line, SUM149.  Utilizing in vitro cell motility and Matrigel invasion assays, 
we demonstrated a more aggressive phenotype for IBC CSCs, which covered a 
larger migration area and were more successful in invading through a basement 
membrane mimic.  Furthermore, the ALDH+ population could recapitulate the 
parental cell line heterogeneity and was more slowly cycling than the ALDH- 
population.  Both of these characteristics support the fact that the ALDH+ 
population comprises, or is contained within, the IBC CSC compartment.  
Although helpful, these studies only allowed identification of the appropriate 
group of cells in which to explore metastatic aggressiveness that is potentially 
derived from cellular mechanical properties.  In order to more specifically 
ascertain and potentially explain the mechanical basis for the aggressive 
behavior of IBC CSC’s, we undertook novel experiments and engineered devices 
targeted at quantitatively defining cells’ mechanical properties. 
 
This biophysical characterization of ALDH+ IBC CSCs revealed distinct 
biophysical properties that might mechanistically explain the functional 
differences seen between the IBC CSC and non-CSC population.  These 
biophysical properties included a greater cell deformability, weaker adhesion 
strength, and less cellular traction force.  This unique profile of biophysical 
characteristics associated with ALDH+ IBC CSCs could help explain how CSCs 
are better adapted than non-CSCs to successfully navigate through their 
dynamic microenvironment in the metastatic series of sieves. 
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In the first metastatic sieve encountered, decreased adhesion of IBC CSCs, as 
demonstrated by their lower measured adhesion strength, might indicate why 
these cells are able to migrate away from the primary tumor.  The strongly 
adherent ALDH- cells might not be able to overcome their attachment, which is 
further supported by ALDH- cells’ reduced migration capacity in our in vitro 
studies.  Additionally, IBC CSCs, a highly metastatic cell population, showed 
significantly lower traction forces compared to their non-CSC counterparts, 
suggesting inherent differences in cell force generation correlated with 
aggressiveness.  In the next sieves of the metastatic program, migrating cancer 
cells must invade through the basement membrane and squeeze through 
endothelial cell tight junctions during intravasation and extravasation.  As 
measured in our assays, the greater capacity for deformation of ALDH+ cells 
suggests significant plasticity towards cytoskeletal changes or reorganization and 
underlying mechanical differences in IBC CSCs.  This may account in part for 
their invasive capability to more successfully transit through a confining 
biophysical microenvironment.  Cell deformability may thus be used as a label-
free biophysical marker for identification and understanding of other CSCs in 
future studies. 
 
Together, our study of IBC CSC’s biophysical properties paints a picture where 
these cells are mechanically adapted to migrate and invade for successful 
completion of the metastatic series of sieves.  At initial diagnosis, 60-80% of IBC 
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patients present with axillary lymph node involvement and 20-30% already have 
distant metastases16,17.  Why IBC is so much more aggressive and metastatic 
than other breast cancers though is not definitively known.  Previous studies 
have identified ALDH+ IBCs as key mediators of tumorigenesis and metastasis, 
and they are negatively correlated with survival10; however, the how and why 
have been left unstudied.  Therefore, in this work we comprehensively profiled 
the functional as well as biophysical characteristics of IBC CSCs at the single-cell 
level using multiple microengineered tools.  Such multiparametric cellular 
phenotypic profiling of CSCs can provide critical insight into the characteristics of 
these cells and their biomechanical adaptation for cancer metastasis, opening 
the door for the standardization of studies to potentially prognosticate the 
probability of metastatic growth and/or of therapies that target a tumor’s unique 
biophysical signature associated with IBC CSCs. 
  
Materials and Methods 
Fabrication of PDMS microfluidic devices for cell deformability and adhesion 
strength measurements 
Poly-dimethylsiloxane (PDMS) microfluidic devices for cell adhesion strength and 
deformability measurements were fabricated using soft lithography and replica 
molding.  Briefly, a silicon master for microfluidic channels was fabricated using 
photolithography and deep reactive ion etching (DRIE; STS Deep Silicon Etcher, 
Surface Technology Systems, Newport, UK).  The silicon master was then 
silanized with (tridecafluoro-1,1,2,2,-tetrahydrooctyl)-1-trichlorosilane vapor 
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(United Chemical Technologies, Bristol, PA) for 4 hr under vacuum to facilitate 
subsequent release of the PDMS microfluidic channel from the silicon master.  
PDMS prepolymer (Sylgard 184, Dow-Corning, Midland, MI) was then prepared 
by thoroughly mixing PDMS monomer with curing agent (with the w / w ratio of 
10:1), poured onto the silicon master and cured at 110ºC for 30 min.  The fully 
cured PDMS top layer was then peeled off from the silicon mold, and excess 
PDMS was trimmed using a razor blade.    Through-holes were then punched in 
the PDMS top layer using a Harris Uni-Core Punch (GE Healthcare Whatman, 
Piscataway, NJ) to generate microfluidic inlet and outlet holes.  The PDMS top 
layer was then bound to a coverslip substrate using an oxygen plasma-assisted 
bonding process (Plasma Prep II, West Chester, PA).   
 
Fabrication and surface functionalization of PDMS micropost array 
The PDMS micropost array was fabricated using DRIE and replica molding, as 
previously described58.  The silicon micropost array master was first fabricated 
using photolithography and DRIE.  The PDMS micropost array was then 
generated through a ‘double casting’ process (Fig. 5.S2 D).  Briefly, the silicon 
master was first silanized with (tridecafluoro-1,1,2,2,-tetrahydrooctyl)-1-
trichlorosilane vapor for 4 hr under vacuum to facilitate subsequent release of the 
negative PDMS mold from the silicon master.  PDMS prepolymer was then 
prepared, poured onto the silicon master, and cured at 110ºC for 20 min.  The 
fully cured negative PDMS mold was peeled off from the silicon mold, before 
activated with an oxygen plasma for 1 min and silanized with (tridecafluoro-
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1,1,2,2,-tetrahydrooctyl)-1-trichlorosilane vapor for 24 hr.  To generate the final 
PDMS micropost array, 1:10 ratio PDMS prepolymer was poured over the 
negative PDMS mold and degassed under vacuum for 10 min.  A 25 cm × 25 cm 
cover glass, which served as the substrate for the PDMS micropost array, was 
then placed on top of the negative PDMS mold.  After curing at 110ºC for 40 hr, 
the PDMS micropost array was peeled off from the negative mold to release the 
final PDMS micropost array.  When peeling induced collapse of the PDMS 
microposts, we regenerated freestanding PDMS microposts by sonication in 
100% ethanol for 30 sec followed by dry-release with liquid CO2 using a critical 
point dryer.  The PDMS micropost array used in this study had a post diameter of 
1.83 µm, a height of 7.1 µm, and a post center-to-center distance of 4 µm. 
 
Microcontact printing was used to functionalize the PDMS microposts with ECM 
proteins to promote cell attachment (Fig. 5.S2 D).  Briefly, a flat 1:30 PDMS 
stamp was prepared and inked with collagen (BD Biosciences, San Jose, CA) at 
a saturating concentration of 50 mg mL-1 in distilled water for 1 hr at room 
temperature.  The PDMS stamp was then thoroughly rinsed with distilled water 
and blown dry with nitrogen gas.  In parallel, the PDMS micropost array was 
treated with ultraviolet (UV) ozone (UV-ozone cleaner; Jelight, Irvine, CA) for 7 
min to ionize the PDMS surface and thus facilitate transfer of ECM molecules 
from the stamp to the PDMS micropost tops.  The collagen-coated PDMS stamp 
was then gently placed in conformal contact with the PDMS micropost array for 
30 sec to complete the protein transfer process.  To utilize the PDMS micropost 
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array for live-cell traction force measurements, we stained the PDMS micropost 
with 1,1′-dioleyl-3,3,3′,3′-tetramethylindocarbocyanine methanesulfonate (Δ9-DiI; 
Invitrogen, Grand Island, NY).  Pluronic F127 NF dissolved in PBS (0.2%, w/v; 
BASF, Ludwigshafen, Germany) was then adsorbed to the PDMS surface for 1 
hr at room temperature to prevent protein adsorption to non-functionalized 
portions of the PDMS micropost array. 
 
Cell culture and reagents 
SUM149 cells were cultured in growth medium (Ham’s F-12 with L-glutamine, 
Fisher Scientific, Hanover Park, IL) supplemented with 5% fetal bovine serum 
(Atlanta Biological, Flowery Branch, GA), 0.5 μg mL-1 Fungizone (Invitrogen), 5 
μg mL-1 Gentamicin (Invitrogen), 5 μg mL-1 insulin (Sigma-Aldrich, St. Louis, MO), 
1 μg mL-1 Hydrocortisone (Sigma-Aldrich), 50 units mL-1 penicillin, and 50 μg mL-
1 streptomycin.  Cells were maintained at 37ºC with 10% CO2 and 100% 
humidity.  Fresh 0.025% trypsin-EDTA in phosphate buffered saline (PBS) was 
used to re-suspend cells.  
 
ALDEFLUOR assay 
The ALDEFLUOR assay was performed using the ALDEFLOUR Kit (Stemcell 
Technologies, Vancouver, Canada) according to the manufacturer’s 
instructions40. Briefly, ALDEFLUOR treated cells quenched with ALDH inhibitor 
diethylaminobenzaldehyde (DEAB) were used to set the ALDEFLUOR-positive 
FACS gate, which we defined as a gate containing less than 0.1% of DEAB-
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treated cells.  Cells treated with ALDEFLUOR alone were then sorted by FACS 
and used for downstream experiments.  SUM149 cells above this fluorescence 
threshold were sorted as ALDH+ and the bottom matching percentage was 
sorted as ALDH-.   
 
Invasion assay 
In vitro invasion was assayed using the Biocoat Matrigel invasion chamber (BD 
Biosciences, San Jose, CA).  Cells were plated in triplicate in the top portion of 
the invasion chamber in serum-free medium with 5% serum growth medium in 
the bottom chamber to induce invasion through the Matrigel membrane.  After 24 
hr of incubation, non-invading cells were removed from the top chamber with a 
cotton swab, and invading cells were fixed with formaldehyde and stained with 
1% crystal violet.  Matrigel membranes were then removed and de-stained in 
10% acetic acid, and an VersaMax optical density reading (Molecular Devices, 
Sunnyvale, CA) of the acetic acid was taken at 590 nm.  In some experiments, 
Matrigel membranes stained with crystal violet were imaged with invaded cells 
manually counted. 
 
Cell motility assay 
The Cellomics Cell Motility kit (Thermo Scientific, Waltham, MA) was used to 
determine cell motility.  According to the manufacturer’s protocol, single cell 
suspensions were plated in three wells of a 96-well plate that had previously 
been coated with blue fluorescent microbeads.  After 24 hr of incubation, the 
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area a cell migrated was represented by the negative space in the microbead 
carpet that was pushed away or phagocytosed by the cell.  Cells were then fixed, 
and the migration tracks were imaged using fluorescence microscopy with an 
Olympus DP26 single chip color CCD camera and an Olympus IX-51 inverted 
microscope (Olympus, Center Valley, PA).  To quantify cell motility, the whole 
sample surface area was imaged and the image processing software ImageJ 
(National Institutes of Health, Bethesda, MD) was then used to determine the 
migration track area of each cell.   
 
Cell proliferation assay 
Cell proliferation rates were quantified using an MTT Cell Proliferation Assay Kit 
(Life technologies, Grand Island, NY).  Cells were sorted by FACS and plated in 
triplicate onto 96-well plates.  MTT staining and a subsequent optical density 
reading (Molecular Devices VersaMax) at 590 nm were carried out at 24 hr, 36 
hr, 72 hr, and 96 hr post sorting.  
 
Cell deformability measurements 
The cell deformability was measured using a PDMS-based microfluidic 
deformability microcytometer developed in our lab (See Supplemental Methods 
for device fabrication method).  The deformability microcytometer contains an 
array of funnel-shaped long confining microchannels that trap individual live 
cancer cells in each channel for single cell deformability measurement.  Each 
channel has a length of 300 µm, a height of 30 µm, a width at the wide end 
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(entry) of 30 µm and a width at the narrow end of 4 µm.  The channel wall is pre-
coated with Pluronic-127 (Sigma) for 30 min such that friction between the cell 
and the channel wall can be neglected.  Single cancer cells in suspension are 
first loaded into the channel using a pressure pump (ELVESYS, Paris, French) 
under low pressure (0.1-0.5 kPa).  The differential pressure acting on cancer 
cells will gradually push the cells down the funnel, and ultimately the motion of 
cancer cells will stop due to the confining channel and the cells will be trapped in 
place.  After the cell trapping, the loading pressure is gradually increased in steps 
(0.5 kPa for each step) to push the cell further into the channel.  The trapped 
cells will have different deformation under different pressure.  For inert 
microfluidic channels where cell trapping is dictated by steric interactions of 
cancer cells with the confining channel, the penetration length (L) of individual 
cancer cells into the confining channel will be purely determined by cell size and 
deformability.  Thereby, the single cell deformability can be calculated based on 
model equation Deformability = 16.9×d× (A×ΔP)-1, where ΔP is the change of the 
flow pressure, d is the penetrating length under the pressure change, and A is 
the projective area of the cell.  Cell volume V is calculated as V = (4×A×π-1)-1/2.  
During the assay, deformed cells were monitored with the Carl Zeiss Axio 
Observer Z1 microscope using a 10× objective (0.3 NA; EC Plan NEOFLUAR®; 
Carl Zeiss MicroImaging).  Phase-contrast images were recorded.  The 
penetration length (L) and the longitudinal and lateral diameters (Dlong and Dlat ) of 
each cell for each pressure were quantified from the recorded microscope 
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images using ImageJ (National Institutes of Health, Bethesda, MD) to calculate 
the projective area of the cell A ≈ 0.25π×Dlong×Dlat. 
 
Quantification of cell adhesion rate 
Cells were first seeded as single cells in polystyrene 48-well cell culture plates.  
The total loading cell number in each sample was first determined using a 
hemocytometer, and the desired cell concentration was then prepared by serially 
diluting the original cell suspension with fresh culture medium.  After incubation 
at 10% CO2 and 37ºC for 3 hr, samples were rinsed gently with PBS to remove 
floating cells.  Adherent cells were then labeled with Calcein AM (Invitrogen), 
before imaged using fluorescence microscopy (Nikon Eclipse Ti-S, Nikon, 
Melville, NY).  Specifically, to quantify cell adhesion rate, the whole surface area 
of sample was scanned on a motorized stage (ProScan III, Prior Scientific, 
Rockland, MA).  The images were stitched into a composite and ImageJ was 
used to determine the number of cells attached to the culture plate surface.   
 
Cell adhesion strength measurements 
Cell adhesion strength was quantified as previously described62.  Briefly, cells in 
growth medium were first injected into the microfluidic channel by pipette, and 
the cells were allowed to adhere to the bottom glass surface at 37ºC with 10% 
CO2 and 100% humidity for 12 hr.  An optimized cell loading density (1 × 10
6 
cells mL-1) was used to ensure a uniform seeding of single cells in the 
microfluidic channel.  After cells attached to the bottom glass surface, the 
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microfluidic channel was connected to a syringe pump and a constant flow of 
PBS was injected into the channel to exert directional fluid shear stress on cells.  
To remove floating cells before cell adhesion strength measurements, PBS was 
flowed into the channel with a very low flow rate (10 µL min-1 for 1 min, then 30 
µL min-1 for 1 min).  The flow rate was then gradually increased from 100 µL min-
1 to 2 mL min-1 step by step.  At each step, the flow rate was maintained constant 
for 3 min to exert a constant directional fluid shear stress on cells.  During the 
assay, detachment of cells was monitored with a Carl Zeiss Axio Observer Z1 
microscope using a 10× objective (0.3 NA; EC Plan NEOFLUAR®; Carl Zeiss 
MicroImaging, Thornwood, NY).  Phase-contract images were recorded at 15 sec 
intervals for a total period of 3 min.  Numbers of adherent cells on the glass 
surface before and after each step were quantified from the recorded microscope 
images using ImageJ.  The fluidic shear stress (τ0) exerted on cells was 
calculated using the equation τ0 = (6µQ) / (WH
2), where µ was the viscosity of 
culture medium (~10-3 Pa s), Q was the flow rate, and W and H were the 
microfluidic channel width and height, respectively.  The PDMS microfluidic 
channel used for cell adhesion strength measurements had a channel width W of 
2 mm, a channel total length L of 6 mm, and a channel height H of 80 µm.  
Adhesion strength of cells was defined as the fluidic shear stress at which 50% of 
cells initially attached on glass surfaces would detach after exposed to 3-min fluid 
shear.  
 
Quantification of cell traction force 
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Cell traction forces were quantified as previously described58,59.  In brief, phase-
contrast images of live cells and fluorescence images of Δ9-DiI stained PDMS 
microposts underlying the cells were taken at the focal plane passing through the 
top surface of the posts with a 40× objective on the Zeiss Observer Z1 
microscope attached with the AxioCam camera.  The microscope was enclosed 
in the Carl Zeiss XL S1 environmental chamber to maintain the experimental 
environment at 37°C and 10% CO2.  Images were then analyzed with a custom-
developed MATLAB program to calculate the deflection δ of the post centroid 
from its ideal position determined by the free and undeflected posts, which was 
then converted to the horizontal traction force f using the expression f = Kδ, 
where K was the nominal spring constant of the PDMS micropost calculated from 
the Euler-Bernoulli beam theory as K = 3πED4 / (64H3).  In this equation, E was 
the elastic Young’s modulus of PDMS and D and H were post diameter and 
height, respectively.  
 
Statistics 
p-value was calculated using the student t-test function in Excel (Microsoft, 
Seattle, WA).   
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Figure 5.1. Functional phenotyping of IBC CSCs.  (A) Concept of cancer stem 
cells.  (B) Representative ALDEFLUOR analysis for SUM149 cells by FACS.  
Negative control samples (left) pre-treated with DEAB inhibitor were used to 
ensure identification of ALDH+ and ALDH- cells (right).  (C&D) Representative 
images (C) and quantitative data (D) from in vitro invasion assays performed for 
ALDH+ and ALDH- SUM149 cells using the Biocoat Matrigel Invasion Chambers.  
In C, invading cells were fixed with formaldehyde before stained with 1% crystal 
violet.  (E&F) Distribution (E) and average (F) migration track area for single 
ALDH+ and ALDH- SUM149 cells measured by the Cellomics Cell Motility kit.  
(G&H) Cell population doubling time (G) and normalized cell population as a 
function of culture time (H) determined using the MTT Cell Proliferation Assay Kit.  
For D, F, G, and H, error bars represent ± standard error of the mean (s.e.m.; n = 
4).  p-values were calculated using the student's t-test;  ns (p > 0.05), * (p < 0.05), 
and ** (p < 0.01). 
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Figure 5.2. Cell deformability measurements for IBC CSCs.  (A) Schematic of 
microfluidic deformability microcytometer for single cell deformability 
measurements.  (B&C) Representative images (B) and quantitative data (C) 
showing differential penetrating distances for ALDH+ and ALDH- SUM149 cells 
in the deformability microcytometer under different pressures as indicated.  (D) 
Average cell diameter of ALDH+ and ALDH- SUM149 cells.  (E) Cell 
deformability plotted as a function of cell diameter.  Each data point represents 
an individual cell.  (F) Average cell deformability of ALDH+ and ALDH- SUM149 
cells.  For C, D, and F, error bars represent ± s.e.m (n > 100).  p-values were 
calculated using the student t-test;  ns (p > 0.05) and ** (p < 0.01). 
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Figure 5.3. Cell adhesion strength characterization.  (A&B) Representative 
fluorescence images (A) and quantified adhesion rate (B) of ALDH+, ALDH-, and 
unsorted SUM149 cells adhering to polystyrene 48-well cell culture plates 3 hr 
after cell seeding.  Cells were stained with Calcein AM for visualization and 
enumeration.  (C) Schematic of a microfluidic channel for quantification of cell 
adhesion strength.  Insert shows adherent cancer cells in the channel under 
sustained directional fluid shear.  (D) Representative brightfield images showing 
temporal sequences of ALDH+ and ALDH- SUM149 cells detaching from the 
microfluidic channel under increased fluid shear stress.  (E) Fraction of ALDH+ 
and ALDH- SUM149 cells remaining adherent in the microfluidic channel after 3-
min exposures to sustained directional fluid shear.  Low densities of cancer cells 
were seeded into microfluidic channels and cultured for 12 hr before PBS was 
flowed continuously along the channel to exert fluid shear stress on cells.  Solid 
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lines represent logistic curve fitting.  (F) Adhesion strength of ALDH+ and ALDH- 
SUM149 cells.  For B, E, and F, error bars represent ± s.e.m. (n = 4).    p-values 
were calculated using the student t-test;  ns (p > 0.05) and ** (p < 0.01). 
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Figure 5.4. Quantification of cell traction force.  (A-D) Representative SEM 
(A-C) and immunofluorescence (D) images showing single SUM149 cells 
adherent on the PDMS micropost array.  In D, the single SUM149 cell was 
stained with fluorophore-labeled phalloidin for visualization of actin filaments 
(green).  The underlying PDMS posts were labeled with DiI for visualization.  
(E&F) Phase (E) and colorimetric (F) maps showing subcellular traction forces 
exerted by single ALDH+ (top) and ALDH- (bottom) SUM 149 cells on the PDMS 
microposts.  (G-J) Quantitative analysis of cell morphology and traction force.  G-
I plot total traction force per cell (G), total cell spread area (H), and traction force 
per cell area (I) for single ALDH+ and ALDH- cells.  Data represents the means ± 
s.e.m (n > 15).  p-values were calculated using the student t-test;  ns (p > 0.05) 
and ** (p < 0.01).  (J) Total traction force per cell as a function of cell spread 
area.  Each data point represents an individual cell.  Data trends in J are plotted 
using linear least square fitting (black lines), with slope values ± s.e.m indicated. 
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Supplemental Figures 
 
Figure 5.S1.  MCF10A and MCF7 deformability measurement. (A) Photo 
showing the microfluidic deformability microcytometer for single cell deformability 
measurements.  (B) Brightfield image showing structure of the deformability 
microcytometer.  (C) Representative brightfield images showing breast cells 
(MCF-10A) and breast cancer cells (MCF-7) trapped in the deformability 
microcytometer under differential pressure across the tapped channels.  (D) 
Normalized cell deformability of MCF-10A and MCF-7 cells.  Error bars represent 
± s.e.m. (n > 20).  p-value was calculated using the student t-test.  ** (p < 0.01). 
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Figure 5.S2.  Fabrication and characterization of PDMS micropost arrays.  
(A) Representative photograph of the silicon micropost array master.  (B) SEM 
image of microfabricated hexagonally arranged silicon micropost array master 
with post geometrical factors indicated.  (C) Schematic of using PDMS 
microposts as force sensors for subcellular traction force measurements.  (D) 
Fabrication of PDMS micropost arrays involves standard photolithography and 
deep reactive-ion etching (DRIE) for the silicon micropost array master in a 
cleanroom environment, and then replica molding with PDMS to generate the 
final PDMS micropost array.  (E) Finite-element method (FEM) analysis of 
micropost bending in response to a horizontal traction force F of 20 nN.  Values 
of Von Mises stress, σv , are plotted (σv = 0.707·[(σ1 - σ2)
2 + (σ2 - σ3)
2 + (σ1 - 
σ3)
2]1/2, where σ1, σ2, and σ3 are the principle stresses in orthogonal directions).  
(F) Dependence of nominal spring constant K of PDMS micropost on micropost 
height L, as computed from FEM (bars), and from the Euler-Bernoulli beam 
theory (dark yellow curve).  K is determined as K = dF / dδ (δ0).  (G) Micropost 
deflection δ as a function of F for PDMS microposts of different heights, as 
calculated by FEM analysis (L = 0.97 μm (red), L = 6.1 μm (blue), and L = 12.9 
μm (green)).  
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Chapter 6 
Conclusions and Future Directions 
 
The metastatic series of sieves represents the complement of biological 
challenges a tumor cell must overcome in order to metastasize.  Not every cell in 
a cancer is intrinsically able to navigate the metastatic process.  Less than 0.01% 
of a cancer’s heterogeneous population can successfully initiate a distant site of 
tumor growth, and understanding what gives these rare cells this capability – be 
they genes, extrinsic cytokines, or a biomechanical phenotype – will ultimately 
provide insight into how to target the process responsible for more than 90% of 
cancer deaths.  In this work I advanced our present knowledge of the metastatic 
process by marrying microfluidic techniques with four fundament questions of the 
metastatic series of sieves. 
 
What are genetic molecular drivers that allow certain cancer cells to 
metastasize? 
In Chapter 2, we showed that the highly chemotactic subpopulation of MDA-MB-
231 breast cancer cells selected through the migration assay maintained this 
migratory phenotype after harvesting and reintroduction to the migration assay. 
Furthermore, the chemotactic cells expressed significantly greater amounts of 
the MAPK isoform p38γ and the RhoC GTPase, both critical modulators of 
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mesenchymal motility.  Our lymphatic capillary mimetic device can be used to 
directly visualize one of the critical steps of the metastatic series of sieves in 
order to reveal further insights into what molecular underpinnings allow certain 
cancer cells within a heterogeneous tumor to intravasate into capillaries and 
subsequently metastasize.  Thus, the present platform provides the capability to 
correlate the migration phenotype of the highly chemotactic cells with a molecular 
signature of gene expression within this subpopulation. 
 
The most logical next step to elevate the significance of this work would be to 
isolate patient tumor cells from a biopsy and screen them for chemotactic 
subpopulations.  Our device has proven capable with the loading of just a few 
hundred cells and technologies exist that could run a panel of genetic assays on 
the limited output of only tens of chemotactic cells.  The limitation of the present 
study was its reliance on derived cell lines.  If the device can be proven to sort 
patient samples, then it would be useful as a tool for discovery of new molecular 
drivers of metastasis in addition to being a diagnostic tool driving treatment 
decisions.  Different anti-metastatic therapies will be developed to target different 
mechanisms and oncologists will need a function-based assay to determine 
which is active in a given patient to rationalize precision therapy. 
 
What are environmental cues to tumor cells that trigger metastasis? 
In Chapter 3, we demonstrated that inflammatory breast cancer – a rare and very 
aggressive subset of breast cancer nearly metastatic from its inception – is 
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hyper-responsive to macrophage-conditioned media, which stimulates an 
extreme migratory phenotype.  We found that interleukins -6, -8, and -10 within 
the macrophage media are sufficient to induce this effect individually and that a 
Ras-homology GTPase is necessary for the extreme migration.  Rather than 
acting as the chemoattractants themselves, it appears that the macrophage-
conditioned media serves to “prime” the IBC cells to have a magnified migration 
response by increasing the expression of RhoC. 
 
It remains an open question and studies are ongoing in our lab as to whether the 
specific cytokines identified in vitro will have a metastasis-promoting effect in 
mouse models.  There are no transgenic mouse models of inflammatory breast 
cancer and so we are left with studying the process in immunocompromised 
animals.  Preliminarily, mice implanted with macrophages only, inflammatory 
breast cancer cells only, or both together all grew masses therefore confounding 
any interpretation of the source of human DNA in the mouse lungs as determined 
by PCR.  This results from the limitation of using cell line derived macrophages 
rather than macrophages isolated and stimulated from healthy donors or, better 
still, macrophages isolated from the tumor stroma of IBC patients.  Further 
experiments will make use of specifically tagged cancer cells and patient-derived 
macrophages.  Another limitation of this work was the relatively small magnitude 
of the enhanced migration effect seen with single-agent cytokine stimulation.  
Despite this, for patients with metastatic inflammatory breast cancer on the last 
lines of treatment options, opening a clinical trial for anti-interleukin-6 therapies 
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already in use against rheumatoid arthritis might be an option to see if inhibiting 
the microenvironmental cues might alter the course of this aggressive breast 
cancer. 
 
Can we harness physical property differences to isolate cancer cells in 
patients once they do metastasize? 
In Chapter 4, we developed a microfluidic CTC capture chip that incorporated a 
nanoroughened glass substrate for capturing CTCs from blood samples.  Our 
CTC capture chip utilized the differential adhesion preference of cancer cells to 
nanoroughened etched glass surfaces as compared to normal blood cells and 
thus did not depend on the physical size or surface protein expression of CTCs.  
Most significantly, in a syngeneic mouse model of lung cancer using cell lines 
with differential metastasis capability, CTCs were captured from all mice with 
detectable primary tumors independent of the cell lines’ metastatic ability. 
 
Thus, a population of CTCs incapable of forming metastases was detected by 
the microfluidic CTC capture chip, supporting that cellular signals and biological 
processes that allow for individual cell invasion and intravasation are not identical 
to those governing the seeding of fruitful metastases.  It remains to be proven if 
these same properties will reliably detect patient CTCs and not just those derived 
from cell lines and xenografts.  However, if they can be detected, future important 
research will be to understand the differences in the nature of non-metastasis 
forming CTCs from those that form metastasis to determine their true 
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significance in patient prognosis and in the clinical management of cancer.  This 
is now possible as our microfluidic CTC capture chip allows for both populations’ 
study with its unbiased capture method based on the selective adhesion of 
cancer cells. 
 
Is there an overall mechanical phenotype of the most aggressive tumor 
cells that are successful in metastasis? 
In Chapter 5, we comprehensively profiled the functional and, more importantly, 
biophysical characteristics of IBC CSCs at the single-cell level using multiple 
microengineered tools and traditional in vitro studies to delineate the live cell 
phenotypic characteristics of the model of the most metastatic breast cancer 
subtype.  This biomechanical characterization of ALDH+ IBC CSCs revealed 
distinct physical properties that might mechanistically explain the functional 
differences seen between the IBC CSC and non-CSC population.  These 
biophysical properties included a greater cell deformability, weaker adhesion 
strength, and less cellular traction force.  This unique profile of mechanical 
characteristics associated with ALDH+ IBC CSCs could help explain how CSCs 
are better adapted than non-CSCs to successfully navigate through their 
dynamic microenvironment in the metastatic series of sieves.  Our 
multiparametric cellular phenotyping of functional and biophysical characteristics 
of IBC CSCs yields a new understanding of IBC’s metastatic properties and how 
they might develop and be targeted for therapeutic interventions.  While the 
present work is limited to an in vitro model and will need validation, future work to 
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alter these cells’ mechanical characteristics and profile their metastatic ability 
could pave the way for an entirely new class of anti-cancer and anti-metastatic 
therapies targeted to modify the physical parameters of cells. 
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Appendix 
Chronic Mastitis in Egypt and Morocco: Differentiating Between 
Idiopathic Granulomatous Mastitis and IgG4-related Disease 
 
The work presented in the Appendix has been accepted for publication in The 
Breast Journal. 
 
Appendix Summary 
Idiopathic granulomatous mastitis (IGM) is a benign, frequently severe chronic 
inflammatory lesion of the breast.  Its etiology remains unknown and reported 
cases vary in their presentation and histologic findings with an optimal treatment 
algorithm yet to be described owing mainly to the disease’s heterogeneity.  IgG4-
related disease (IgG4-RD) is a newly recognized systemic fibroinflammatory 
condition characterized by a dense lymphoplasmacytic infiltrate with many IgG4-
positive plasma cells, storiform fibrosis, and obliterative phlebitis.  
Immunosuppressive therapy is considered to be an effective first-line therapy for 
IgG4-RD.  We sought to clarify and classify chronic mastitis according to the 
histologic findings of IgG4-RD mastitis with respect to IGM and to develop a 
robust diagnostic framework to help select patients for optimal treatment 
strategies.  Using the largest collection to date (43 cases from Egypt and 
Morocco), we show that despite sharing many features, IGM and IgG4-RD 
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mastitis are separate diseases.  To diagnostically separate the diseases, we 
created a classification schema – termed the Michigan Classification – based 
upon our large series of cases, the consensus statement on IgG4-RD, and the 
histologic description of IGM in the literature.  Using our classification, we 
discerned 17 cases of IgG4-RD and 8 cases of IGM among the 43 chronic 
mastitis cases, with 18 indeterminate cases.  Thus our Michigan Classification 
can form the basis of rational stratification of chronic mastitis patients between 
these two clinically and histopathologically heterogeneous diseases. 
 
Introduction 
Idiopathic granulomatous mastitis (IGM) is a non-neoplastic, chronic 
inflammatory lesion of the breast that mimics carcinoma both clinically and 
radiologically 1-5.  IGM affects mostly parous women of child-bearing age, but has 
been reported in the age range of 11-80 years 2,6.  Patients most commonly 
present with an enlarging, firm, and tender breast lump with erythema and 
occasionally nipple retraction and/or axillary lymphadenopathy 3,4,7,8.  With these 
concerning clinical characteristics and non-specific imaging findings frequently 
resembling inflammatory breast cancer, the diagnosis is often made by core 
needle biopsy 1-4,6,7,9.  Histologically, IGM appears as non-caseating granulomas, 
frequently centered on the breast lobules, with epithelioid histiocytes and 
multinucleated giant cells and varying numbers of plasma cells, lymphocytes, 
neutrophils, and eosinophils 8,10.  IGM remains a diagnosis of exclusion, 
however, as there are multiple processes that may cause granulomatous 
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inflammation of the breast 8.  An optimal treatment algorithm remains elusive 
owing mainly to the lack of a complete etiological classification.  Therapeutic 
choices comprise observation, immunosuppressive therapy, wide local excision, 
mastectomy, or combined therapies; however, these strategies have varied 
success and recurrences are common 2,6,7,9,11. 
 
IgG4-related disease (IgG4-RD) is a newly recognized fibroinflammatory 
condition affecting various organs 12-14.  It is characterized by a dense 
lymphoplasmacytic infiltrate with many IgG4-positive plasma cells, storiform 
fibrosis, obliterative phlebitis, and often elevated serum IgG4 concentration 12-17.  
Reportedly uncommon are the presence of well-formed granulomas and a 
marked neutrophilic infiltration 12,13,18.  IgG4-RD is now known to at least partly 
explain a broad range of medical conditions previously believed to be unique 
diseases 12,15,17.  While no randomized clinical trials have been conducted, 
glucocorticoid treatment is the standard first-line therapy 12,15. 
 
In contrast to the abundance of cases in other organs, there have been up to 
now only 9 reported cases of IgG4-RD occurring in the breast 19-23.  Among these 
cases of IgG4-RD mastitis, there is a great heterogeneity in the clinical and 
histopathological findings and apparent overlap with IGM characteristics.  
Consistent with this observation, IgG4-RD is known to have variations in 
histologic appearance depending on the specific organ involved 12-14,17,18.  
Furthermore, IGM itself is known to have a heterogeneous appearance and lacks 
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a consensus on an optimal treatment protocol 2,3,6,9,11. Thus, we sought to clarify 
and classify chronic mastitis according to the histologic findings of IgG4-RD 
mastitis with respect to IGM from a large retrospective collection of cases from 
Egypt and Morocco, in order to better characterize and distinguish the subset of 
chronic mastitis patients with IgG4-RD who would benefit from 
immunosuppressive therapy. 
 
Results 
Diagnosis of IgG4-Related Disease and Idiopathic Granulomatous Mastitis 
Table 1 summarizes the histopathologic findings and IgG4 and IgG quantification 
of the cases.  In total, 17 cases of IgG4-RD mastitis were identified along with 8 
cases of IGM and 18 indeterminate chronic mastitis cases.  In our schema, which 
we term the Michigan Classification, to be classified as most likely IgG4-RD 
mastitis, a sample must have met at least 4 of 5 positive criteria and 2 of 3 
negative criteria.  The positive criteria were adapted from and are consistent with 
the IgG4-RD consensus statement and the negative criteria were newly 
developed by our group to propose a classification schema that would 
encompass the heterogeneity of the findings in our large sample while in 
agreement with the consensus statement and the general histologic 
characteristics of IGM described previously 10,13.  The positive criteria were: 
dense lymphoplasmacytic infiltrate, storiform fibrosis, obliterative phlebitis, >10 
IgG4+ cells/hpf, and >40% IgG4:IgG ratio.  The negative criteria were: epithelioid 
histiocytes, well-formed granulomas, and giant cells.  Consistent with the 
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histological description of IGM 10, cases were classified as IGM if they 
demonstrated: epithelioid histiocytes, vague or well-formed granulomas, and 
giant cells.  The diagnostic criteria for IGM and our newly developed criteria for 
IgG4-RD mastitis are outlined in Table 2.  The IGM category was assigned 
irrespective of the number of IgG4-positive plasma cells or IgG4:IgG ratio or the 
presence of other histologic characteristics of IgG4-RD.  Although a prominent 
neutrophilic infiltration has generally been reported as relatively rare with IgG4-
RD, this is known to vary by organ 12,13.  Neutrophils were not therefore 
considered in our diagnostic criteria for breast IgG4-RD because they did not 
appear to be a distinguishing characteristic between IgG4-RD mastitis and IGM 
in our large sample. 
 
Pathologic Findings 
Both IgG4-RD mastitis (Figure 1A) and IGM (Figure 1B) cases overwhelmingly 
had a dense lymphoplasmacytic infiltrate and only the indeterminate cases 
tended to have a mixed infiltrate.  The presence of storiform fibrosis, however, 
was a more specific differentiator between the two diseases as it was present in 
17 of 17 IgG4-RD mastitis cases (Figure 1C) and absent in the 5 of 8 IGM cases 
(Figure 1D) (P<0.001).  Obliterative phlebitis was not a differentiating criterion 
and was seen in 11 of 17 IgG4-RD cases (Figure 1E) and present in 3 of 8 IGM 
cases (P=0.39).  The presence of epithelioid histiocytes was the most common 
IGM feature overlapping with the IgG4-RD cases, being present in 5 of the 17 
IgG4-RD cases.  There were no well-formed granulomas in the IgG4-RD mastitis 
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cases and giant cells were present in 3 cases.  Representative images of IGM 
epithelioid histiocytes, granulomas, and giant cells can be seen in Figures 2A-D. 
 
IgG4 Quantification 
The average number of IgG4 cells per high power field and the IgG4:IgG ratio for 
each of the IgG4-RD mastitis, IGM, and indeterminate cases are plotted in 
Figures 3A-B.  There were statistically significantly more IgG4+/hpf in the IgG4-
RD cases than in the indeterminate cases (P<0.01), but not compared to the IGM 
cases (P=0.061).  However, the average ratio of the IgG4-RD mastitis cases 
(49%) was significantly higher than the average ratio for both the IGM cases 
(26%, P<0.001) and indeterminate cases (20%, P<0.001).  As has been reported 
previously 13,14,16,17, an IgG4:IgG ratio of  >40% proved quite specific as a 
diagnostic criterion with 14 of 17 IgG4-RD cases meeting the threshold, in 
contrast to only 2 of 8 IGM cases (P<0.01).  Representative images of IgG4 and 
IgG dual-staining of IgG4-RD mastitis and IGM cases are shown in Figures 4 A-B 
and C-D, respectively. 
 
Discussion 
Our report describes the largest chronic mastitis series to date comprising of 43 
cases from Egypt and Morocco and seeks to develop a robust framework to 
begin to differentiate and to understand the possible pathogenetic basis of this 
complex set of diseases.  In light of previous work in this field, we first sought to 
understand IGM in the context of the more recently recognized IgG4-RD.  Of 
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these 43 chronic mastitis cases, 17 (40%) were determined to be IgG4-RD 
mastitis, 8 were IGM, and 18 were indeterminate cases of mastitis.  Ogura et al 20 
first posited that IGM could be separated into IgG4-related and non-IgG4-related 
cases, but our analysis supports the conclusion that the two appear more likely to 
be distinct disease entities.  While the two cases of IGM Ogura et al 20 reported 
on did have significant numbers of IgG4 positive cells, an IgG4:IgG ratio was not 
calculated, which has proven to be the most specific indicator for IgG4-RD in our 
study and others 13.  In our present study, when classified solely based upon the 
presence of epithelioid histiocytes, giant cells, and vague or well-formed 
granulomas, it is apparent that some of the IGM cases (see cases 18 and 22 
Table 1) do share many features typical for IgG4-RD mastitis.  Therefore, the 
distinction between the two diseases likely only became apparent with our larger 
sample size. 
 
Furthermore, we were able to ascertain which histologic features are the most 
specific for differentiating between IgG4-RD mastitis and IGM by classifying IGM 
cases without regard to their IgG4-RD features.  Therefore, by our schema, it 
was determined the most common and least specific IgG4-RD features seen in 
IGM were a dense lymphoplasmacytic infiltrate (7/8 cases) and large numbers of 
IgG4-positive plasma cells (5/8 cases).  In contrast, the dual criteria of storiform 
fibrosis coupled with an IgG4:IgG ratio >40% is reasonably specific for IgG4-RD 
mastitis with 14/17 cases meeting both criteria.  Additionally, since we did not 
specify which of the positive or negative criteria must be met to diagnose IgG4-
 
 
180 
 
RD mastitis, we can determine the most frequently absent IgG4-RD feature and 
most frequently present IGM feature.  This is helpful in further clarifying the 
distinction between borderline cases.  Obliterative phlebitis was the feature most 
often absent from IgG4-RD mastitis cases and epithelioid histiocytes the most 
common IGM characteristic seen in IgG4-RD mastitis.  Therefore, the presence 
of giant cells or well-formed granulomas is quite specific within the breast for IGM 
when differentiating between it and IgG4-RD mastitis.  Conversely, the absence 
of obliterative phlebitis should not preclude a diagnosis of IgG4-RD mastitis. 
 
The average number of IgG4-positive plasma cells per high power field is lower 
for some of our reported IgG4-RD mastitis cases (12-29 cells/hpf for 7 of the 17 
cases) than for cases reported in the literature 18,19.  We point to two likely 
explanations for this apparent deviation.  First, our samples were biopsy samples 
known to have fewer IgG4+/hpf than surgical specimens 18 and, in fact, the 
consensus criteria lowers the requirement from 30 to 10 IgG4+/hpf for biopsy 
samples 13.  All of our IgG4-RD mastitis cases met this lower threshold.  Second, 
we had an observable area of 0.139 mm2 compared to 0.196 mm2 reported by 
Cheuk et al 19 and mentioned by the consensus statement 13.  While this area 
difference would not affect the IgG4:IgG ratio, it would be expected to affect the 
absolute number of positive cells.  If the absolute counts for our IgG4-RD cases 
were multiplied by a 1.2x area scaling factor, then 13 of the 17 cases would have 
greater than 30 IgG4+ cells/hpf – even as biopsy and not surgical specimens.  
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Ultimately though, it is the IgG4:IgG ratio that is a better and more specific 
diagnostic criterion for IgG4-RD. 
 
In summary, we report on the largest chronic mastitis series to date comprising of 
43 cases from Egypt and Morcco, of which 17 (40%) were IgG4-RD of the breast, 
8 were IGM, and 18 indeterminate cases of mastitis.  This also represents the 
largest collection of IgG4-RD of the breast – nearly doubling the number of 
previously reported cases 19-23.  Among our samples, storiform fibrosis, an 
IgG4:IgG ratio >40%, and the absence of well-formed granulomas and giant cells 
is a highly specific 4-variable panel for IgG4-RD mastitis.  IGM on the other hand 
is characterized by many giant cells and epithelioid histiocytes and one should 
not be misled by the occasional high number of IgG4-positive plasma cells or 
increased IgG4:IgG ratio.  Thus our Michigan Classification requiring the 
presence of 4 of 5 positive criteria and absence of 2 of 3 negative criteria 
suggests a rational stratification basis between these two clinically and 
histopathologically heterogeneous diseases. 
 
Materials and Methods 
Study Population 
We performed a retrospective hospital-based study and identified 43 cases of 
chronic mastitis of unknown etiology from 5 hospitals in Morocco (L’hopital Ibn 
Rochd, Hassan II University and L’Hopital Ibn Toufail) and Egypt (Cairo 
University Medical School, Mansoura University Oncology Center, and the Tanta 
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Cancer Center) 5.  The average age of the patients was 36.9 years (SD 9.1, 
range 17-60).  Cases were defined as any female patient with histopathological 
diagnosis of chronic mastitis of unknown etiology based upon an excisional 
biopsy and seen at the study hospitals from 2008-2011.  All patients initially 
presented with a breast mass and routine clinical workup (e.g. acid-fast staining 
and appropriate cultures) was performed to rule out other common mass-forming 
and granulomatous-forming lesions of infectious and other etiologies.  The only 
exclusion criterion was previous diagnosis of malignancy 5.  Further 
epidemiological and clinical characteristics (including lactation history and parity) 
of the study population are reported in detail in Oltean et al 5.  The study 
underwent ethics board review and approval at all the institutions named above 
and at the University of Michigan. 
 
Pathology Review and Dual Staining Protocol 
Blinded to the IgG4 quantification, two authors (C.K. and S.G.A.) analyzed one 
haematoxylin and eosin (H&E) slide from each case sectioned from the same 
paraffin-embedded tissue cassette as were the immunostained slides.  The 
parameters assessed were: a dense lymphoplasmacytic infiltrate, storiform 
fibrosis, obliterative phlebitis, epithelioid histiocytes, granulomas, giant cells, and 
neutrophils.  Immunohistochemistry staining was performed as described 
previously 24.  Specific to this study, slides were incubated for 1.5 hours at room 
temperature with an antibody cocktail containing rabbit anti-IgG (Cell Marque, 
Cat# 269A-15) diluted 1:5400 and mouse anti-IgG4 (Cell Marque, Cat# 367M-15) 
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diluted 1:900 and detected with Mach 2 Double Stain 2, (Biocare Medical) for 10 
minutes at room temperature. 
 
Imaging and counting protocol 
H&E images were captured using an Olympus BX41TF microscope with an 
Olympus UD03 CCD at 100x and 400x magnification.  After immunostaining, 
digital images were captured by an Olympus DP26 CCD using an Olympus IX-51 
microscope.  The 200x immunostain digital images’ field of view was 0.139 mm2 
in area.  This was 20% smaller in area than the hpf reported by Cheuk et al 19.  
The three areas of the most intense inflammation were imaged and then IgG4 
and IgG positive cells were quantified in each of the three images using ImageJ 
and averaged.  The IgG4:IgG ratio was calculated as: IgG4/(IgG4+IgG). 
 
Statistics 
OriginPro 9.1 was used to calculate statistical differences using either Fisher’s 
exact test or a t-test of unequal variances.  
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Figure A.1 – IgG4-RD and IGM comparison 
Representative H&E images of IgG4-RD (a, c, and e) and IGM (b and d).  A 
dense lymphoplasmacytic infiltrate is seen in IgG4-RD mastitis (a) and IGM (b), 
x400.  (c) Storiform fibrosis in IgG4-RD mastitis, x100, x400.  (d) Non-storiform 
fibrosis in IGM, x100, x400.  (e) Obliterative phlebitis in IgG4-RD mastitis, x100, 
x400. 
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Figure A.2 – IGM histopathology 
(a and b) Epithelioid histiocytes, x400.  (c and d) Well-formed granulomas and 
giant cells, x400. 
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Figure A.3 – Quantification of IgG4 and IgG immunostaining 
(a) Plot of the average number of IgG4+ plasma cells per high power field.  The 
average IgG4/hpf was significantly higher for the IgG4-RD cases than the 
indeterminate cases (P<0.01).  (b) Plot of the IgG4:IgG plasma cell ratio.  The 
IgG4:IgG ratio is significantly greater in the IgG4-RD cases as compared to the 
IGM and indeterminate cases (each P<0.001).  Solid lines represent means, 
dashed lines the diagnostic cutoffs. 
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Figure A.4 – IgG4 and IgG immunostaining 
Images of dual-stained (IgG4+ brown, IgG+ red) IgG4-RD mastitis cases (a and 
b) and IGM cases (c and d), x200. 
  
 
 
188 
 
 
Table A.1 – Histopathology of Chronic Mastitis 
The histopathologic characteristics and IgG4 and IgG immunostaining 
quantification of the IgG4-RD, IGM, and indeterminate cases. 
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IgG4-Related Disease Mastitis 
  
Positive Criteria (4 of 5 present): 
Negative Criteria (2 of 3 
absent): 
1. Dense lymphoplasmacytic 
infiltrate 1. Epithelioid histiocytes 
2. Storiform fibrosis 2. Well-formed granulomas 
3. Obliterative phlebitis 3. Giant cells 
4. >10 IgG4 cells/hpf   
5. >40% IgG4:IgG ratio   
  
  Idiopathic Granulomatous Mastitis 
  
Positive Criteria (3 of 3 present): Negative Criteria: 
1. Epithelioid histiocytes none 
2. Vague or well-formed 
granulomas   
3. Giant cells   
 
Table A.2 – Diagnostic criteria for IgG4-RD mastitis and IGM 
The positive and negative criteria we developed to distinguish IgG4-RD mastitis 
from IGM. 
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